

Reseptregisteret
2008–2012

The Norwegian
Prescription Database
2008–2012



Reseptregisteret 2008–2012

The Norwegian Prescription Database 2008–2012

Christian Berg
Øystein Karlstad
Milada Mahic
Ingvild Odsbu

Rapport 2013:2
Nasjonalt folkehelseinstitutt /
The Norwegian Institute of Public Health

Tittel/Title:
Reseptregisteret 2008–2012

The Norwegian Prescription
Database 2008–2012

Redaktør/Editor:
Christian Berg

Forfattere/Authors:
Øystein Karlstad
Milada Mahic
Ingvild Odsbu

Publisert av / Published by:
Nasjonalt folkehelseinstitutt
Postboks 4404 Nydalen
NO-0403
Norway

Tel: + 47 21 07 70 00
E-mail: folkehelseinstituttet@fhi.no
www.fhi.no

Design/Layout
Houston911

Acknowledgement:
Julie D.W. Johansen (English version)

Forsideillustrasjon / Front page illustration:
iStockPhoto

Trykk/Print:
www.wj.no

Opplag / Number printed:
300

Bestilling/Order:
publikasjon@fhi.no
Fax: +47-21 07 81 05
Tel: +47-21 07 82 00

ISSN: 1890-9647
ISBN: 978-82-8082-551-3 trykt utgave/printed version
ISBN: 978-82-8082-552-0 elektronisk utgave/electronic version

Tidligere utgave / Previous edition:
2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007
2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008
2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian Prescription Database 2005–2009. Topic: Addictive drugs
2011: Legemiddelstatistikk 2011:2: Reseptregisteret 2006–2010 / The Norwegian Prescription Database 2006–2010
2012: Legemiddelstatistikk 2012:2: Reseptregisteret 2007–2011 / The Norwegian Prescription Database 2007–2011



Forord

Bruken av legemidler i befolkningen er økende. En viktig målsetting for norsk legemiddelpolitikk er rasjonell legemiddelbruk. En forutsetning for arbeidet med å optimalisere legemiddelbruken i befolkningen er kunnskap om hvilke legemidler som brukes, hvem som bruker legemidlene og hvordan de brukes. For å få bedre kunnskap på dette området, vedtok Stortinget i desember 2002 å etablere et nasjonalt reseptbasert legemiddelregister (Reseptregisteret). Oppgaven med å etablere registeret ble gitt til Folkehelseinstituttet som fra 1. januar 2004 har mottatt månedlige opplysninger fra alle apotek om utlevering av legemidler til pasienter, leger og institusjoner.

Denne rapporten er sjette utgave av den årlige statistikken fra Reseptregisteret. Generell informasjon om Reseptregisteret, legemiddelstatistikk, klassifikasjon av legemidler og målemetoder finnes i rapportens del 1. Del 2 inneholder noen nøkkeltall fra Reseptregisteret og et omfattende tabellverk med opplysninger om antall individer som har fått utlevert legemidler etter resept fra apotekene i Norge i siste femårsperiode (2008–2012). Opplysningene er fordelt på enkeltlegemidler og legemiddelgrupper. ATC (Anatomisk Terapeutisk Kjemisk) -klassifikasjon er benyttet i tabellene. For 2012 er informasjon om alders- og kjønnsfordeling og kostnader inkludert i tabellene. ATC-/DDD-versjon gjeldende fra januar 2013 er benyttet i rapporten, se også www.whocc.no

Reseptregisteret har også en nettside der man kan finne kompletterende informasjon. Nettstedet er: www.norpd.no (engelsk versjon) eller www.reseptregisteret.no (norsk versjon). Det er også mulig å søke om utlevering av data fra Reseptregisteret til forskning eller til andre formål som er i henhold til formålet for Reseptregisteret. Mer informasjon om dette finnes i bokens del 2 og på nettsiden til Folkehelseinstituttet (www.fhi.no).

Avdeling for legemiddelepidemiologi
Folkehelseinstituttet
Mai 2013

Preface

The use of drugs in the population is increasing. An important goal of the health policies regarding pharmaceuticals in Norway is rational drug use. In order to improve drug use, knowledge about which drugs are used, how they are used and who uses them is vital. In December 2002, the Parliament decided to establish a national prescription database in Norway (NorPD). The task of building up the register was given to the Norwegian Institute of Public Health (NIPH). Since 1st January 2004, the institute has received monthly data on prescriptions from all Norwegian pharmacies.

This report is the sixth edition of the annual statistics from NorPD. General information about NorPD, drug statistics, classification of drug and measurement methods is included in part 1 of the report. Part 2 contains some key figures from NorPD and the main tables with information about the number of individuals who had prescriptions dispensed from pharmacies in Norway during the latest five years period (2008–2012). The information includes particular drug substances as well as drug groups. ATC (Anatomical Therapeutic Chemical) classification is used in the tables. For 2012, information about age, gender and costs are included in the tables. The ATC/DDD version of January 2013 has been used in the report, see also www.whocc.no

NorPD also has a website where you can find complementary information. The website is: www.norpd.no (English version) or www.reseptregisteret.no (Norwegian version). It is also possible to apply for data from NorPD for research or for other purposes which are according to the objectives of NorPD. More information about this can be found in part 2 of the report, and at the website of the Norwegian Institute of Public Health (www.fhi.no).

Department of Pharmacoepidemiology
Norwegian Institute of Public Health
May 2013

Innhold

Forord	6
1. Generelt om Reseptregisteret og legemiddelstatistikk	11
1.1 Reseptregisteret (NorPD).....	11
1.2 Nordiske reseptregistre	14
1.3 Grossistbasert legemiddelstatistikk	15
1.4 Anatomisk Terapeutisk Kjemisk (ATC)-klassifisering.....	15
1.5 Definert Døgndose (DDD).....	16
1.6 WHO Collaborating Centre for Drug Statistics Methodology.....	17
2. Reseptregisteret 2008–2012	19
2.1 Utvalgte nøkkeltall fra Reseptregisteret.....	19
2.2 Reseptkategorier og refusjon av utgifter til legemidler	23
2.3 Beskrivelse av hovedtabellene	27
2.4 ATC main groups	31
2.5 ATC group A – Alimentary tract and metabolism	32
2.6 ATC group B – Blood and bloodforming organs	43
2.7 ATC group C – Cardiovascular system	46
2.8 ATC group D – Dermatologicals.....	53
2.9 ATC group G – Genito urinary system and sex hormones	59
2.10 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins	64
2.11 ATC group J – Antiinfectives for systemic use.....	67
2.12 ATC group L – Antineoplastic and immunomodulating agents	73
2.13 ATC group M – Musculo-skeletal system	76
2.14 ATC group N – Nervous system	80
2.15 ATC group P – Antiparasitic products, insecticides and repellents	89
2.16 ATC group R – Respiratory system	91
2.17 ATC group S – Sensory organs	95
2.18 ATC group V – Various	99
Noen forkortelser og definisjoner	100
Folkemengde i Norge 2008–2012 (per 1. juli)	101
Folkemengde etter alder i 2012 (per 1. juli).....	101
Liste over publikasjoner basert på data fra Reseptregisteret per mars 2013.....	102

Contents

Preface	7
1. General information about the Norwegian Prescription Database and drug statistics	11
1.1 About the NorPD.....	11
1.2 Prescription statistic in the other Nordic countries.....	14
1.3 The Norwegian Drug Wholesales Statistics	15
1.4 The Anatomical Therapeutic Chemical (ATC) classification system	15
1.5 The Defined Daily Dose (DDD)	16
1.6 The WHO Collaborating Centre for Drug Statistics Methodology	17
2. The Norwegian Prescription Database (NorPD) 2008–2012	19
2.1 Selected key figures from NorPD.....	19
2.2 Prescription categories and reimbursement of medicinal expenses	23
2.3 Description of the main tables	27
2.4 ATC main groups	31
2.5 ATC group A – Alimentary tract and metabolism	32
2.6 ATC group B – Blood and bloodforming organs	43
2.7 ATC group C – Cardiovascular system	46
2.8 ATC group D – Dermatologicals.....	53
2.9 ATC group G – Genito urinary system and sex hormones	59
2.10 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins	64
2.11 ATC group J – Antiinfectives for systemic use.....	67
2.12 ATC group L – Antineoplastic and immunomodulating agents	73
2.13 ATC group M – Musculo-skeletal system	76
2.14 ATC group N – Nervous system	80
2.15 ATC group P – Antiparasitic products, insecticides and repellents	89
2.16 ATC group R – Respiratory system	91
2.17 ATC group S – Sensory organs	95
2.18 ATC group V – Various	99
Some abbreviations and definitions	100
Population in Norway 2008–2012 (as of 1st July)	101
Population by age in 2012 (as of 1st July).....	101
List of publications based on data from the Norwegian Prescription Database (NorPD) as of March 2013	102

1. Generelt om Reseptregisteret og legemiddelstatistikk

1.1 Reseptregisteret (NorPD)

Datainnsamling og variabler i Reseptregisteret

Ny apoteklov trådte i kraft 1. mars 2001, og ifølge den nye loven ble apotek forpliktet til å videresende reseptdata til en ny nasjonal legemiddeldatabase. I oktober 2003 ble ny detaljert forskrift for Reseptregisteret (hjemlet i Helseregisterloven) vedtatt av Kongen i Statsråd (1). Formålet med Reseptregisteret (jf forskriftens § 1-3) er å samle inn og behandle data om legemiddelbruk hos mennesker og dyr for å:

1. kartlegge forbruket i landet og belyse endringer over tid
2. fremme og gi grunnlag for forskning og utredning for å kunne belyse positive og negative effekter av legemiddelbruk
3. gi myndighetene et statistisk grunnlag for kvalitetssikring av legemiddelbruk og overordnet tilsyn, styring og planlegging
4. gi legemiddelrekvisiter et grunnlag for internkontroll og kvalitetsforbedring

Forskriftens formål bestemmer hva Reseptregisteret kan brukes til. Forskriften bestemmer også hva slags data som kan samles inn fra apotek og administrative registre.

1. General information about the Norwegian Prescription Database and drug statistics

1.1 About the NorPD

Data collection and variables in NorPD

New legislation in the Norwegian pharmacy sector came into force on March 1st 2001. According to the new act, pharmacies were obliged to forward prescription data to a new national drug database. In October 2003, new, detailed regulations for the NorPD were approved (1). The objectives of the NorPD, as defined in authoritative regulations, are to collect and prepare data on drug use in individuals and animals in order to:

1. describe drug use patterns, highlighting changes over time
2. promote and form a basis for research and review of the safety and effectiveness of drug use
3. serve as a management tool for the authorities in order to assure prescribing quality in addition to general surveillance, control and planning
4. give the prescribing doctors a basis for internal control, as part of an audit method to improve the quality of prescribing practices

All NorPD data use must be in accordance with these objectives. The regulation also determines what kind of data can be collected from the pharmacies and administrative registers.

Reseptregisteret inneholder følgende variabler:

Pasient

Personidentifikasjon (kryptert), fødselsmåned /-år, døds måned/- år, kjønn, bosted (kommune og fylke)

Forskriver

Personidentifikasjon (kryptert), fødselsår, kjønn, yrke, spesialitet

Legemiddel

Nordisk varenummer (merkenavn, styrke, legemiddelform, pakningsstørrelse), antall pakninger, ATC-kode, antall definerte døgndoser (DDD), reseptkategori, kode for refusjon (fra mars 2008: ICD10, ICPC koder og enkelte koder definert av Legemiddelverket, fullstendig implementert fra mars 2009), bruksområde og forskrevet dose (fritekst), utleveringsdato, pris (apotekets utsalgspris)

Apotek

Apoteknavn, konsesjonsnummer, kommune og fylke

Det nordiske varenummeret er en unik identifikasjon for hver pakning av et legemiddel og muliggjør kobling til andre registre som gir detaljert informasjon om legemidlene. Indikasjon for forskrivning ble de første årene ikke registrert i databasen, kun overordnede refusjonskoder som for enkelte legemidler fungerte som grov diagnosekode. Fra mars 2008 ble forskriver pålagt å angi mer spesifikke diagnosekoder på blåresepter som erstatning for de gamle sykdomspunktene. Det skal benyttes enten International Classification of Diseases versjon 10 (ICD-10) eller International Classification of Primary Care (ICPC). I tillegg har Legemiddelverket på enkelte områder definert egne koder. Ordningen er fullstendig implementert fra mars 2009.

Fra 1. januar 2004 har Folkehelseinstituttet mottatt månedlig informasjon om reseptutleveringer fra alle apotek i Norge (2). I alle apotek er det tilrettelagt for automatisk innsending av rapport til Reseptregisteret til fast tidspunkt hver måned, slik at apotekene kan oppfylle sin rapporteringsplikt uten vesentlig ekstra arbeid. Reseptregisteret inneholder informasjon om alle legemidler som er forskrevet og utlevert til enkeltpasienter utenom sykehus og institusjoner. Legemidler forskrevet på godkjeningsfritak er også inkludert, men legemidler som selges reseptfritt er ikke registrert i Reseptregisteret. Hvis reseptfrie legemidler er forskrevet på resept vil de imidlertid bli registrert i databasen.

De viktigste dataene i Reseptregisteret er basert på resepter forskrevet til enkeltpersoner, men også forskrivning av legemidler fra veterinærer til dyr og forskrivning til egen praksis registreres i Reseptregisteret. Når det gjelder pasienter som er innlagt i sykehus eller sykehjem, samler registeret kun inn

The NorPD contains the following variables:

Patient

Person-identifier (encrypted), month/year of birth, month/year of death, gender, place of residence (municipality & county)

Prescriber

Person-identifier (encrypted), year of birth, gender, profession, speciality

Drug

Nordic article number (unique product identifier stating brand name, strength, pharmaceutical form and pack size), number of packs, ATC code, number of Defined Daily Doses (DDD), prescription category, reimbursement code (from March 2008: ICD10, ICPC codes or codes defined by the Norwegian Medicines Agency, completely implemented from March 2009), intended use and prescribed dose (free-text according to pharmacy label), dispensing date, price (pharmacy retail price)

Pharmacy

Name, licence number, municipality and county

The Nordic article number is the important link to other registries providing detailed information about the drugs. The indication for prescribing was in the first years not recorded in the database, only the code of reimbursement which in some cases, acted as a proxy of diagnosis. From March 2008, prescribers had to use either the International Classification of Diseases version 10 (ICD10), or the International Classification of Primary Care Codes (ICPC) or special codes assigned by the Norwegian Medicines Agency as the code of reimbursement on the prescriptions. This was fully implemented from March 2009.

Since 1st January 2004, the NIPH has received monthly data on prescriptions from all Norwegian pharmacies (2). Monthly electronically reports are automatically generated in all pharmacies, thus avoiding extra work for the pharmacy. NorPD contains information about all drugs prescribed (reimbursed or not) and dispensed at pharmacies to individual patients living outside institutions, i.e. ambulant care. Unlicensed drugs are also included, but drugs sold over-the-counter (OTC) are not recorded in NorPD. However, if the OTC drugs are prescribed by a physician and dispensed, then they will be recorded in the database.

The main data in NorPD are based on prescriptions to individual humans, but also prescribed drugs by veterinarians to animals and prescribing to a physician's own practice are collected in NorPD. For patients in nursing homes and hospitals, the register collects figures on drug use at the level of the institution or the department, i.e. on an aggregate level.




Figure 1.1: Data flow, the Norwegian Prescription Database (NorPD)

aggregerte data på institusjons- eller avdelingsnivå basert på informasjon som apotekene registrerer når de leverer legemidler til institusjoner.

Datasikkerhet

Som illustrert i figur 1.1 blir registreringer av utleverte legemidler fra apotek elektronisk og automatisk overført til Statistisk sentralbyrå (SSB) før de kommer til FHI og inkluderes i Reseptregisteret. SSB fungerer som en såkalt tiltrodd tredjepart og er en del av datasikkerheten for å ivareta konfidensialitet og informasjonssikkerhet for all personlig informasjon. SSB har tilgang til pasientens personnummer og forskrivers helsepersonellnummer, og erstatter begge med et pseudonym. SSB kan ikke lese noen annen informasjon fra reseptene, fordi denne informasjonen er kryptert før SSB mottar dataene. Når SSB sender data er fødselsnummer og forskrivers helsepersonellnummer fjernet, og FHI kan dekode helseopplysningene som fremgår av resepten igjen. Prinsippet for pseudonymisering er at ingen, heller ikke den som tildeler og forvalter pseudonymer, skal kunne ha samtidig tilgang til både pseudonym, helseopplysninger og personens identitet. Begrepet "Pseudonymiserte helsedata" er definert i Helseregisterloven: "Personlig helsedata som identitet er kryptert, eller på annen måte skjult, men likevel individuell, slik at det er mulig å følge hver person gjennom helsesystemet uten at vedkommendes identitet blir avslørt" (3). Dette betyr at identiteten til pasienter og forskrivere har blitt kryptert i henhold til norsk lovgivning, men likevel er individuell, slik at det er mulig å følge enkeltpersoner over tid, og gjøre registerkoblingsstudier.

Kvalitetssikring

For kvalitetssikring blir et antall søk gjennomført månedlig eller halvårlig for å identifisere mulige feil eller uoverensstemmelser. FHI gjør ulike rutinemessige

Data protection

As illustrated in figure 1.1 the pharmacy records of dispensed drugs are electronically and automatically transferred through Statistics Norway before they arrive at NIPH and are included in NorPD. Statistics Norway acts as a so-called "trusted third party centre" and is a part of the data protection to ensure confidentiality of personal information. Statistics Norway only has access to the patient personal identification number and the prescriber's health personnel number and replaces both with a pseudonymised identifier. Statistics Norway cannot read any other prescription data because this information is encrypted before Statistics Norway receives the data. When Statistics Norway sends the data including the pseudonymised identifiers to the NIPH, the NIPH is allowed to decrypt the prescription information again. The term "Pseudonymous health data" is defined in the Personal Health Data Filing System Act (in Norwegian: Helseregisterloven): "personal health data in which the identity has been encrypted or otherwise concealed, but nonetheless individualized so that it is possible to follow each person through the health system without his identity being revealed" (3). This means that the identity of patients and prescribers has been encrypted according to Norwegian legislation, but nonetheless individualized, so that it is possible to follow individuals over time and perform record-linkage studies. Data linkage is based on the unique identification number system which is available in all the Nordic countries.

Quality checks

For quality assurance, a number of queries are carried out monthly or half-yearly to identify possible errors or inconsistencies. NIPH performs different routine checks on the data before they are transferred to the NorPD. In the NorPD, the Nordic article number is linked to the national register of medicinal products with validated

kontroller på data før de overføres til Reseptregisterets database. I Reseptregisteret er det nordiske varenummeret knyttet til det nasjonale vareregisteret for legemidler med gyldige ATC-koder og DDD-verdier (4). Dette registeret oppdateres månedlig. FHI sjekker også om dataleveranser fra hvert apotek er av rimelig størrelse. Det totale antallet reseptbelagte poster, totalt antall pasienter og forskrivere blir sjekket hver måned. Statistikk for apotekene blir rutinemessig kjørt. Denne rutinen vil identifisere uvanlige variasjoner i størrelsen på dataleveranser fra måned til måned, og fange opp manglende leveranser av spesielle typer data, eller hvis en datalevering fra ett apotek er tom i en måned på grunn av tekniske feil på apoteket eller hos tiltrodd tredjepart (SSB). Fødselsnummeret kontrolleres hos SSB mot Folkeregisteret. Når fødselsnummeret er ugyldig eller mangler, lager SSB et spesielt pseudonym. Disse personene er ikke mulig å følge over tid, og heller ikke mulig å koble til andre datakilder, men det rapporterte antall ordinasjoner og DDD knyttet til disse personene kan likevel inkluderes i totalstatistikken.

1.2 Nordiske reseptregistre

På slutten av 1980-tallet, tok apotek i de nordiske landene gradvis i bruk elektroniske systemer ved ekspedering av resepter. Dette gjorde det mulig å samle inn reseptdata fra apotek på en enklere og mer effektiv måte. Selv om helsevesenet ikke er organisert likt i de nordiske landene, har alle fem land et helsevesen med universell dekning for helseutgifter. Alle borgere, uavhengig av sosioøkonomisk status, har ubegrenset tilgang til helsetjenester, inkludert delvis eller fullstendig refusjon av kjøpte legemidler. Nasjonale reseptdatabaser, som er basert på data fra ekspederte og utleverte legemidler fra apotek til individer utenfor sykehus/sykehjem, har vært tilgjengelig siden 1994 i Finland og Danmark, siden 2004 i Norge, siden 2005 i Sverige og siden 2006 på Island. Databasene dekker til sammen 25 millioner innbyggere (Danmark: 5,6 millioner, Finland: 5,4 millioner; Island: 0,3 millioner; Norge: 5,1 millioner og Sverige: 9,6 millioner). Det er mulig å koble disse dataene til ulike helseutfall og andre data basert på det unike fødselsnummeret/-koden som alle innbyggere i disse landene har. Databasene er en viktig ressurs for å kunne gjennomføre longitudinelle og registerkoblede studier med helseundersøkelser og andre registre. Databasene representerer også et godt kunnskapsgrunnlag for nasjonale beslutninger innen legemiddelbruk. En artikkel fra 2010 gir en oversikt over datainnsamlingsprosedyrer og innhold i de nordiske landenes reseptregistre (5).

ATC codes and DDD values (4). This register is updated monthly. NIPH also checks if the data deliveries from each pharmacy are of a reasonable size. The total number of prescription records and the total number of patients and prescribers are checked every month. Statistics for the pharmacies are checked by routine. Unusual variations in size of data files from month to month are identified and any missing data is caught, such as missing special data type deliveries or empty data files caused by technical error at the pharmacy or at the trusted third party. The Personal Identification Number is checked in Statistics Norway against the Central Population Registry. If the Personal Identification Number is invalid or missing, Statistics Norway creates a special pseudonym, but it is not possible to track these individuals or link them to other data sources. However, the reported total number of ordinations and DDDs can be included in the total statistics.

1.2 Prescription statistic in the other Nordic countries

During the late 1980s, pharmacies in the Nordic countries gradually computerized their records of dispensed prescriptions which made it possible to collect data efficiently. Although healthcare systems are not organized identically in the Nordic countries, all five countries have a tax-supported public health service with universal coverage. All citizens, independent of socioeconomic status, have unrestricted access to health services, including partial or complete reimbursement of purchased medicines. National prescription databases, containing data on drugs dispensed at pharmacies (exposure data) to individuals receiving ambulatory care, have been available since 1994 in Finland and Denmark, since 2004 in Norway, since 2005 in Sweden and since 2006 in Iceland. The databases together cover 25 million inhabitants (Denmark: 5.6 million; Finland: 5.4 million; Iceland: 0.3 million; Norway: 5.1 million; and Sweden: 9.6 million) and have the potential to link these data to different health outcomes and other data based on the unique personal identity code which all residents in these countries have. The databases serve as a resource for conducting longitudinal and record-linkage studies with health surveys and other registries. They also offer a sound evidence base for national decision-making in the field of drug utilization. An article from 2010 provides an overview of the data collection procedures and content of the Nordic countries' prescription databases (5). In addition, the article discusses their unique potential for cross-national record linkage and for analytical pharmacoepidemiological studies.

1.3 Grossistbasert legemiddelstatistikk

Statistikk basert på totalt salg av legemidler fra grossist til apotek, sykehus/sykehjem har vært tilgjengelig i Norge siden 1970-tallet. Grossistbasert legemiddelstatistikk omfatter alt salg av legemidler fra grossist til apotek, sykehus/sykehjem, dagligvaredetaljister og andre med tillatelse til å omsette legemidler. Legemidler til dyr og mennesker, både reseptfrie og reseptbelagte, er inkludert i statistikken. Statistikken gir en oversikt over utviklingen i legemiddelomsetningen over tid, både totalt og på fylkesnivå. Statistikken inneholder imidlertid ikke opplysninger om den enkelte legemiddelbruker.

Legemiddelforbruket i Norge – årlig publikasjon

Årlig publiseres data fra den Grossistbaserte legemiddelstatistikken i publikasjonen Legemiddelforbruket i Norge. Hver utgave omfatter 5-årsoversikter over totalsalget av reseptfrie og reseptbelagte legemidler i Norge (6). Boken er tilgjengelig på nettsiden www.legemiddelforbruk.no. Nærmere informasjon vedrørende utlevering av data fra den grossistbaserte legemiddelstatistikken finnes på Folkehelseinstituttets nettside www.fhi.no.

1.4 Anatomisk Terapeutisk Kjemisk (ATC)-klassifisering

Alle legemidler som er registrert i Norge er gruppert etter ATC-systemet. I ATC-systemet inndeles legemidlene i grupper på 5 nivåer: På 1. nivå fordeles legemidlene på 14 anatomiske hovedgrupper. Det neste nivået (2. nivå) er en terapeutisk eller farmakologisk undergruppe. 3. nivå og 4. nivå er terapeutiske, farmakologiske eller kjemiske undergrupper, mens 5. nivå representerer den kjemiske substansen.

ATC-koden

En fullstendig klassifisering av legemiddelsubstansen spironolakton (vanndrivende middel) med ATC-koden C03DA01 kan illustrere oppbyggingen av ATC-systemet:

C	Hjerte og kretsløp (1. nivå, anatomisk hovedgruppe)
C03	Diuretika (2. nivå, terapeutisk undergruppe)
C03D	Kaliumsparende midler (3. nivå, farmakologisk undergruppe)
C03DA	Aldosteronantagonister (4. nivå, farmakologisk undergruppe)
C03DA01	Spironolakton (5. nivå, kjemisk substans)

1.3 The Norwegian Drug Wholesales Statistics

Statistics based on total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes has been available in Norway since the 1970s. The Norwegian Drug Wholesales Statistics database includes total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes and non-pharmacy outlets and others with permission to sell medicines. Total sales of prescription and non-prescription human and veterinary medicines are included in the statistics. The statistics give an overview of developments in drug consumption over time, both at county and country level. The statistics, however, contain no information about the individual drug user.

Drug Consumption in Norway – published annually

Data from the Norwegian Drug Wholesales Statistics Database have been published annually in *Drug Consumption in Norway* (6) since 1977. Each issue includes total sales data for 5 year periods for both prescription- and non-prescription drugs in Norway. The book is available from the website www.drugconsumption.no. Further information on the Norwegian Drug Wholesales Statistics database, including how to apply for data, can be found at the Norwegian Institute of Public Health's website www.fhi.no.

1.4 The Anatomical Therapeutic Chemical (ATC) classification system

In the ATC system the drug substances are classified into groups at 5 different levels. The drugs are divided into fourteen main groups (1st level), with pharmacological/therapeutic sub-groups (2nd levels). The 3rd and 4th levels are chemical/pharmacological/therapeutic sub-groups and the 5th level is the chemical substance.

The ATC code

A complete classification of the drug spironolactone (diuretic) with the ATC code C03DA01 illustrates the structure of the ATC system:

C	Cardiovascular system (1st level, anatomical main group)
C03	Diuretics (2nd level, therapeutic sub-group)
C03D	Potassium-sparing agents (3rd level, pharmacological sub-group)
C03DA	Aldosterone antagonists (4th level, pharmacological sub-group)
C03DA01	Spironolactone (5th level, chemical substance)

Alle spironolakton preparater (Aldactone® og Spirix®) gis i dette systemet koden C03DA01.

Ved hjelp av dette klassifikasjonssystemet kan man lage statistikker over legemiddelforbruk gruppert på fem ulike nivåer, fra tall som viser totalforbruket av alle preparater klassifisert f.eks. under hovedgruppe C – *Hjerte og kretsløp* (1. nivå), tall for de ulike undergruppene (2., 3. og 4. nivå) og ned til tall som viser forbruket av det enkelte virkestoff.

ATC-kode for hvert enkelt preparat er angitt i *apotekenes vareregister*, og i preparatomtalene (SPC) som er publisert i *Felleskatalogen*. Ved å bruke "Anatomisk terapeutisk kjemisk legemiddelregister" (Felleskatalogens gule del), vil man få en oversikt over hvilke produktnavn hver enkelt ATC-kode omfatter.

1.5 Definert Døgn dose (DDD)

I enkelte tabeller i del 2 i boken er volum av legemiddelforbruk angitt i antall DDD. Ved å benytte definerte døgn doser (DDD) som måleenhet, får man bedre mulighet for sammenligninger mellom alternative legemidler uavhengig av prisforskjeller. Vurdering av volum av legemiddelforbruket gjennom lengre tidsperioder, nasjonalt og internasjonalt, blir enklere og bedre ved bruk av definerte døgn doser. Måleenheten DDD er definert som *den antatt gjennomsnittlige døgn dose brukt ved preparatets hovedindikasjon hos voksne*.

Døgn dosene fastsettes på bakgrunn av en vurdering av bruken internasjonalt, selv om de nasjonale terapitradisjonene kan variere fra et land til et annet (f.eks. bruksområde og doseringsanbefalinger). Den definerte døgn dose (DDD) bør derfor betraktes som en teknisk måleverdi.

Legemidler som benyttes ved forskjellige indikasjoner kan by på spesielle problemer som det må tas hensyn til ved vurdering av døgn dosestatistikk. Dosen ved hovedindikasjonen benyttes normalt ved fastsettelse av DDD. Med unntak for noen få spesielle barnepreparater benyttes doseringer for voksne. Ofte vil DDD for ulike administrasjonsformer være like med unntak av der biotilgjengeligheten er svært forskjellig. For preparater der man benytter en støtdose og en vedlikeholdsdose, vil døgn dosen være basert på vedlikeholdsdosen. Hvis mulig er DDD angitt i mengde aktiv substans. Er det umulig, som f.eks. ved kombinasjonspreparater og enkelte flytende preparater, angis DDD som antall enkeltdoser (antall tabletter, kapsler, milliliter osv.).

All medicinal products containing plain spironolactone (Aldactone® and Spirix®) are thus assigned the code C03DA01.

The ATC classification system makes it possible to compile drug consumption statistics on 5 different levels, i.e., figures showing total consumption of all preparations classified in main group C – *Cardiovascular system* (1st level), figures for the various subgroups (2nd, 3rd and 4th levels), and down to figures showing consumption of each active ingredient.

The ATC code for all pharmaceuticals on the Norwegian market can be retrieved from *the pharmacy medicinal product register* and in the monographs of the national drug catalogue "*Felleskatalogen*". The yellow section of the latter, entitled *The Anatomical Therapeutic Chemical Medicines Register*, lists all medicinal products belonging to each of the ATC 5th level codes.

1.5 The Defined Daily Dose (DDD)

In some tables in part 2 in this book the sales volume of drug consumption is given in number of DDDs. Using DDDs as the unit of measurement allows better comparison between alternative medications, regardless of price differences. The evaluation of drug consumption volumes over time, nationally and internationally, is simplified and improved by the use of DDDs. A DDD is defined as *the assumed average maintenance dose per day for a drug used on its main indication in adults*.

The DDDs are determined on the basis of evaluation of international use of the substance in question, bearing in mind that national therapy traditions (indications, dosages) often differ greatly. Each DDD should therefore be regarded as a technical measuring unit.

Drugs used for more than one indication may cause particular problems which are important to consider when evaluating statistics based on DDDs. With the exception of a very few specially formulated pediatric preparations, adult dosages are used. The DDD for a substance will often be one and the same, irrespective of the route of administration. However, drugs with different bioavailabilities depending on their administration route will have more than one DDD, each of them linked to a specific dosage form. For medications where a booster dose is followed by a smaller maintenance dosage, the maintenance dose will form the basis for determining the DDD. Whenever possible, the DDD is indicated as the quantity of active substance.

DDD representer ikke nødvendigvis den mest forskrevne eller brukte dose, noe som må tas i betraktning når tallene vurderes. Det vil derfor ofte være vanskelig å beregne antall brukere ved kun å bruke DDD som måleenhet. Dette gjelder særlig der doseringsanbefalingene kan variere mye etter bruksområde. Salgstallene kan angis i DDD/1000 innbyggere/døgn og beregnes på følgende måte:

$$\frac{\text{Samlet forbruk i antall DDD} \times 1000}{365 \times \text{antall innbyggere}}$$

Dette tallet vil gi et estimat av andelen av befolkningen i promille som får en bestemt medikamentell behandling. Et estimert salg av et legemiddel på 10 DDD/1000 innbyggere/døgn indikerer at 10 av 1000 personer (dvs. 1 % av befolkningen) daglig kan bruke dette legemidlet. Dette estimatet blir imidlertid kun riktig dersom det er samsvar mellom DDD og dosen som faktisk brukes.

1.6 WHO Collaborating Centre for Drug Statistics Methodology

ATC/DDD systemet administreres og videreutvikles av WHO Collaborating Centre for Drug Statistics Methodology. Dette senteret er en del av Avdeling for legemiddelepideologi ved Nasjonalt folkehelseinstitutt. Nærmere beskrivelse av systemet finnes i publikasjonen *Guidelines for ATC classification and DDD assignment* (7). ATC Index with DDDs, som inneholder en liste over alle fastsatte DDD, kan bestilles fra WHO senteret (8). Begge publikasjonene finnes i engelsk og spansk versjon. Senterets webside har følgende adresse: www.whocc.no. ATC og DDD endringer som er vedtatt blir publisert årlig og gjort gjeldende ved årsskiftet. ATC/DDD versjon gjeldende fra januar 2013 er benyttet i rapporten. Publikasjonene kan bestilles fra WHO Collaborating Centre for Drug Statistics Methodology.

Referanser/References:

1. Forskrift om innsamling og behandling av helseopplysninger i reseptbasert legemiddelregister (Reseptregisteret). 20-10-2003.
2. Strøm H. Reseptbasert legemiddelregister: et viktig verktøy for å oppnå detaljert legemiddelstatistikk. *Nor J Epidemiol.* 2004;14(1):53-55.
3. Helseregisterloven [Personal Health Data Filing System Act]. Lov av 18.mai 2001
4. Rønning M, Litlekare I, Addis A et al. Recommendations for national registers of medicinal products with validated ATC codes and DDD values. *Italian J Public Health* 2006;3(1):30-35.
5. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. *Basic Clin Pharmacol Toxicol* 2010;106(2):86-94.
6. Sakshaug S (Ed). *Drug Consumption in Norway 2008–2012*. [Legemiddelforbruket i Norge 2008–2012] Oslo: Norwegian Institute of Public Health, 2013.
7. WHO Collaborating Centre for Drug Statistics Methodology, *Guidelines for ATC classification and DDD assignment* 2013. Oslo, 2012.
8. WHO Collaborating Centre for Drug Statistics Methodology, *ATC classification index with DDDs* 2013. Oslo 2012.

When this is impossible, as is the case with combination preparations and some liquid preparations, the DDD is indicated as the number of single doses (number of tablets, capsules, millilitres etc.). The DDDs are not necessarily the most frequently prescribed or used doses. This must be considered when evaluating the data. Accordingly it will often be difficult to estimate the number of users by using the DDD as the measuring unit. The sales can be given as the number of DDDs/1000 inhabitants/day, calculated as follows:

$$\frac{\text{Total consumption measured in number of DDDs} \times 1000}{365 \times \text{number of inhabitants}}$$

This figure offers an estimation of what proportion of the population that may receive a certain drug treatment. An estimated drug consumption of 10 DDDs/1000 inhabitants/day corresponds to a daily use of this drug by 1% of the population. This estimate is, however, only valid if there is good correlation between the DDD and the actual consumed dose.

1.6 The WHO Collaborating Centre for Drug Statistics Methodology

The WHO Collaborating Centre for Drug Statistics Methodology is responsible for the administration and development of the ATC/DDD system. The Centre is located at the Department of Pharmacoepidemiology at the NIPH. Further information about the ATC/DDD system is given in the publication *Guidelines for ATC classification and DDD assignment* (7). The ATC Index with DDDs which includes a list of all assigned DDDs can be ordered from the Centre (8). Both publications are available in English and Spanish. The website for the Centre is www.whocc.no. ATC and DDD changes are published annually and are made official by the end of the year. ATC/DDD version from January 2013 has been used in the book. The ATC/DDD publications can be ordered from the WHO Collaborating Centre for Drug Statistics Methodology.

2. Reseptregisteret 2008–2012

2.1 Utvalgte nøkkeltall fra Reseptregisteret

Reseptregisteret inneholder opplysninger fra alle landets apotek om utlevering av legemidler på resept, til forskrivers egen praksis og til institusjoner. I 2012 ble rundt 95 % av legemidlene i Reseptregisteret (målt i DDD) utlevert til enkeltpersoner. Leveransene til institusjoner (sykehus og sykehjem) utgjorde 4,2 % av det totale antall DDD og ca. 0,3 % av totalt antall DDD ble utlevert til bruk i forskrivers egen praksis. Salg av reseptfrie legemidler er ikke inkludert i Reseptregisteret. Reseptfritt salg utgjorde i 2012 15 % av totalt salg av legemidler i Norge målt i DDD (Kilde: Grossistbasert legemiddelstatistikk, Folkehelseinstituttet).

2. The Norwegian Prescription Database (NorPD) 2008–2012

2.1 Selected key figures from NorPD

NorPD contains information from all Norwegian pharmacies of prescriptions to individuals, to a prescriber's own practice and to institutions. In 2012, about 95% of DDDs in NorPD were dispensed to individuals in ambulatory care. Deliveries to institutions (hospitals and nursing homes) amounted to 4.2% of the DDDs and about 0.3% of the DDDs were dispensed for use in the physician's practice. Sales of OTC medicines are not included in NorPD. OTC sales constitute 15% of total sales of pharmaceuticals in Norway in 2012, measured in DDDs (source: Norwegian Drug Wholesale Statistics, Norwegian Institute of Public Health).

Table 2.1.a: Number of individuals and one-year prevalence (%) of the population who had at least one prescription dispensed in Norway 2008–2012

	Women n (%)	Men n (%)	Both genders n (%)
2008	1 800 541 (75,3)	1 470 215 (61,8)	3 270 756 (68,6)
2009	1 839 960 (76,1)	1 523 065 (63,2)	3 363 025 (69,6)
2010	1 842 575 (75,4)	1 510 186 (61,8)	3 352 761 (68,6)
2011	1 879 445 (76,0)	1 551 598 (62,6)	3 431 043 (69,3)
2012	1 887 735 (75,5)	1 560 303 (62,0)	3 448 038 (68,7)




Figure 2.1: One-year prevalence (%) of the population who had at least one prescription dispensed in 2012 in Norway according to age and gender

Reseptregisteret ble opprettet 1. januar 2004 og i perioden 2004–2012 har mer enn 5 millioner individer blitt inkludert i NorPD med minst ett legemiddel utlevert på resept fra apotek. Antall legemiddelutleveringer etter resept til pasienter i samme periode er 327 millioner.

I 2012 fikk 68,7 % av den norske befolkningen utlevert minst ett legemiddel på resept, 75,5 % av kvinnene og 62 % av mennene (tabell 2.1.a). Krav om at pasientens fødselsnummer skal påføres resepten ble innført 1. oktober 2003. I 2004, det første driftsåret for NorPD, var andelen av resepter med ugyldig eller manglende 11-sifret fødselsnummer 3,7 %. I årene 2006–2007 lå denne andelen på rundt 2 %, og i 2008 og 2009 har den ligget på i underkant av 1,4 %. I 2010–2012 var andelen uten gyldig fødselsnummer under 1 % (0,76 % i 2012).

Ettårsprevalensen for å få utlevert legemiddel etter resept i 2012 var lavest for begge kjønn i aldersgruppen 10–14 år (figur 2.1). Rundt 90 % av individene i alderen 70 år og eldre fikk utlevert medisiner etter resept. Hvis vi ekskluderer kvinner som kun fikk utlevert hormonelle prevensjonsmidler (ATC-kode G03A), blir prevalensen av legemiddelbruk redusert med ca. 10–15 prosentpoeng hos kvinner i alderen 15–29 år, men fortsatt var andelen av legemiddelbrukere blant kvinner over 15 år høyere enn blant menn.

Since January 2004 more than 5 million individuals have been included in NorPD with at least one prescription medication dispensed from a pharmacy. The number of prescriptions dispensed to patients in the same period (2004–2012) is 327 million.

In 2012, 68.7% of the Norwegian population had at least one prescription dispensed, 75.5% of women and 62% of men (table 2.1.a). In 2004, the first operational year of NorPD, the proportion of prescriptions having invalid or missing personal identification number was 3.7%. In the period 2005–2007, the proportion was around 2%. The proportion of prescriptions with an invalid personal identification number has declined further to just below 1.4 % in 2008 and 2009. In 2010–2012 the proportion was less than 1% (0.76% in 2012).

The age-specific one year prevalence for having a drug dispensed in 2012 was lowest in both genders at about 10–14 years of age (figure 2.1). About 90 % of individuals aged 70 years and older received prescription medications. Excluding women who received only hormonal contraception for systemic use (ATC code G03A), the prevalence of drug use was reduced by about 10–15 percentage points in women aged 15–29, although the proportion of drug users among women over 15 years of age was still higher than in men.

Table 2.1.b: One-year prevalence (%) of the population who had at least one prescription dispensed in Norway in 2012 according to the main ATC groups

ATC	Women %	Men %	Both genders %
A	17,9	13,4	15,7
B	12,2	12,3	12,3
C	20,8	19,8	20,3
D	13,7	11,4	12,5
G	24,6	5,8	15,1
H	11,1	5,4	8,2
J	31,3	21,6	26,5
L	1,9	1,6	1,7
M	21,4	15,9	18,6
N	30,8	21,1	25,9
P	2,4	1,4	1,9
R	27,7	21,5	24,6
S	13,9	10,5	12,2
V	0,4	0,4	0,4

Tabell 2.1.b viser ettårsprevalens for hele befolkningen som har fått utlevert minst ett legemiddel etter resept innen hver av de 14 ATC-hovedgruppene, totalt og fordelt på kvinner og menn. De tre legemiddelgruppene som er mest brukt blant begge kjønn er midler mot infeksjoner til systemisk bruk (ATC-gruppe J), legemidler med virkning på nervesystemet (ATC-gruppe N) og legemidler som brukes for sykdommer i luftveiene (ATC-gruppe R).

Tabell 2.1.c viser en oversikt over legemidler med flest brukere i Norge i 2012. De legemidlene (definert som ATC 5. nivåer) som brukes av flest personer er smertestillende midler (diclofenac og kombinasjonen kodein/paracetamol). Fenoxymetylpenicillin (antibiotikum) har ligget som nummer to på listen de fire siste årene. Paracetamol (smertestillende) er i 2012 nummer fem på listen som i 2011, etter å ha ligget på henholdsvis 8. og 7. plass i 2009 og 2010. Paracetamol brukes også av mange reseptfritt og denne bruken telles ikke i Reseptregisteret. For øvrig inneholder listen i hovedsak de samme legemidlene som tidligere år, men med noen endringer i rekkefølgen.

Table 2.1.b shows the one-year prevalence of the entire population, and among men and women, who received at least one prescription in each of the main ATC groups. The three drug groups most used in both men and women are anti-infectives (ATC group J), drugs affecting the nervous system (ATC group N) and drugs used for respiratory diseases (ATC group R).

Table 2.1.c lists the medicines with most users in Norway in 2012. The medicines (defined as ATC 5th levels) used by most individuals are analgesics (diclofenac, and the combination of codeine / paracetamol). Phenoxymethylpenicillin (antibacterial) has for the last four years been number two on the list. Paracetamol (analgesic) is number five on the list in 2012 as in 2011 compared to number 7 and 8 in the two previous years. Paracetamol is also used by many individuals without prescription and this use is not covered by NorPD. In general the list comprises mainly the same medicines as previous years, but with some changes in the sequence.

Table 2.1.c: Drugs with the highest number of users in Norway 2012

	ATC code	Active ingredient	Use	Number of individuals	Proportion (%) of the population
1	M01AB05	diclofenac ¹⁾	NSAID/analgesic	459 930	9,2
2	J01CE02	phenoxymethylpenicillin	Antibacterial	454 241	9,1
3	N02AA59	codeine and paracetamol	Analgesic	385 788	7,7
4	B01AC06	acetylsalicylic acid	Antithrombotic	379 545	7,6
5	N02BE01	paracetamol ¹⁾	Analgesic	361 057	7,2
6	C10AA01	simvastatin	Cholesterol-lowering	314 102	6,3
7	N05CF01	zopiclone	Hypnotic	305 873	6,1
8	R06AE07	cetirizine ¹⁾	Anti-allergic	281 965	5,6
9	R05DA01	ethylmorphine	Cough suppressant	270 238	5,4
10	C07AB02	metoprolol	Antihypertensive/cardiac disease	266 560	5,3
11	M01AE01	ibuprofen ¹⁾	NSAID/analgesic	224 496	4,5
12	R03AC02	salbutamol	Asthma/COPD	214 777	4,3
13	S01AA01	chloramphenicol	Antibacterial eye drops	194 863	3,9
14	J01CA08	pivmecillinam	Antibacterial	192 857	3,8
15	H03AA01	levothyroxine sodium	Thyroxine supplement	186 948	3,7
16	H02AB06	prednisolone	Antiinflammatory/corticosteroid	167 261	3,3
17	C10AA05	atorvastatin	Cholesterol-lowering	166 438	3,3
18	J01AA02	doxycycline	Antibacterial	164 097	3,3
19	N02AX02	tramadol	Analgesic	154 739	3,1
20	J01FA01	erythromycin	Antibacterial	151 708	3,0
21	R01AD09	mometasone	Anti-allergic nose spray	150 680	3,0
22	A02BC02	pantoprazole	Reflux oesofagitis	148 151	3,0
23	J01CA04	amoxicillin	Antibacterial	136 437	2,7
24	A02BC05	esomeprazole	Reflux oesofagitis	134 694	2,7
25	N05BA04	oxazepam	Anxiolytic	134 081	2,7
26	R05CB01	acetylcysteine ¹⁾	Mucolytic	128 248	2,6
27	C08CA01	amlodipine	Antihypertensive/cardiac disease	125 710	2,5
28	N05BA01	diazepam	Anxiolytic	125 552	2,5
29	G03AA07	levonorgestrel and estrogen	Hormonal contraception	112 987	2,3
30	N06AB10	escitalopram	Antidepressant	109 164	2,2

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.2 Reseptkategorier og refusjon av utgifter til legemidler

Reseptregisteret inneholder opplysninger om antall individer som fikk utlevert minst ett legemiddel innenfor de ulike reseptkategorier. Reseptkategorier har følgende hovedinndeling:

- Hvit resept
- Blå resept
- Helseforetaksresept

Følgende er ikke inkludert i tabellene som presenteres i dette kapittelet (tabell 2.2.a–2.2.d): Bidragsordningen hjemlet i Lov om folketrygd (folketrygdloven) § 5.22 hvor bidrag kan ytes til dekning av utgifter til helsetjenester når utgiftene ikke ellers dekkes etter andre lover, og støtte til legemidler for vernepliktige og jernbanepersonell.

Hvite resepter

Resepter hvor pasienten betaler hele kostnaden for legemidlet selv.

Blå resept

Resepter som rekvireres i henhold til Blåreseptforskriften (FOR-2007-06-28-814), der staten betaler deler av kostnaden for legemidlet. I tabellene 2.2.a–2.2.d er Blåreseptordningene slått sammen (§§ 2, 3a, 3b, 4).

Refusjon etter § 2

Legemidler som er ført opp på refusjonslista tilknyttet § 2 refunderes pliktmessig når brukt ved de diagnoser (angitt med ICPC eller ICD diagnosekoder) spesifisert i refusjonslista. Legemiddelverket avgjør hvilke legemidler som skal føres opp i refusjonslista, og hvilke diagnosekoder/vilkår legemidlet skal underlegges ved rekvirering på blå resept.

Refusjon etter §§ 3a og 3b

HELFO kan fatte vedtak om refusjon av utgifter til legemidler som ikke er ført opp i refusjonslista tilknyttet § 2, forutsatt at bruken av legemidlene er dekket av en diagnosekode i refusjonslista (§3a). Vedtak fattes for hver enkelt pasient på grunnlag av søknad fra behandlende legen. For andre kostbare legemidler mot kroniske sykdommer som ikke er nevnt i refusjonslista, kan HELFO unntaksvis fatte vedtak om refusjon for hver enkelt pasient på grunnlag av legens søknad (§3b). Reseptregisteret gir ikke en komplett oversikt over refusjon etter §§ 3a og 3b.

Refusjon etter § 4

Legemidler som benyttes ved allmennfarlige smittsomme sykdommer, refunderes etter § 4 etter en nærmere angitt sykdomsliste. Det ytes stønad til utgifter til legemidler mot infeksjoner, immunstimulerende legemidler og vaksiner. Denne støtten ytes til alle som

2.2 Prescription categories and reimbursement of medicinal expenses

NorPD contains information about the number of individuals having at least one drug dispensed in the various prescription categories. Prescription categories are divided into:

- Non-reimbursable prescriptions
- Reimbursement prescriptions
- Health Trust prescriptions (HELFO)

The following is not included: Contribution according to National Insurance Act § 5.22 in which a contribution may be granted to cover the cost of healthcare when expenses are not otherwise covered by other laws and medicinal support during military service and railway personnel.

Non-reimbursable prescriptions

These are prescriptions paid in full by the patient.

Reimbursement prescriptions ("Blue Prescription")

The costs under the various reimbursement schemes are combined in the tables (§§ 2, 3a, 3b, 4).

Reimbursement according to § 2

Drugs listed on the reimbursement list § 2 will always be reimbursed when prescribed for the diagnoses (indicated by the ICPC and ICD codes) specified in the reimbursement list. The Norwegian Medicines Agency decides which medicines are included in the list and which diagnostic codes/conditions should be subject to reimbursement prescribing.

Reimbursement according to §§ 3a and 3b

HELFO can decide to reimburse drugs that are not listed in the reimbursement list attached to § 2, provided that use of the drug is covered by a diagnostic code in the reimbursement list (§ 3a). Decisions are made for the individual patient based on an application from the treating physician. For other expensive drugs for chronic diseases not mentioned in the reimbursement list, in special cases HELFO may grant reimbursement for an individual patient based on the physician's application (§ 3b). NorPD will not contain a complete listing of reimbursement according to §§ 3a and 3b.

Reimbursement according to § 4

Drugs used for communicable diseases are reimbursed according to § 4 according to a specified disease list. The reimbursement is granted for anti-infective, immunostimulants and vaccines.

bor i Norge, uavhengig av medlemskap i folketrygden. Legen har mulighet til å rekvirere flere av legemidlene i denne paragrafen til seg selv for å bevare pasientenes anonymitet. Slike resepter vil følgelig ikke kunne følges på individnivå i Reseptregisteret.

Informasjon om egenbetaling (egenandel og eventuell tilleggsbetaling ved reservasjon mot generisk bytte) er ikke tilgjengelig i Reseptregisteret.

Helseforetaksresept

De regionale helseforetakene er gitt et særskilt finansieringsansvar for enkelte kostbare legemidler. Dette gjelder blant annet immunmodulerende legemidler til behandling av revmatiske lidelser (TNF α -hemmerne), multipel sklerose og kreft. Bare legemidler som er ekspedert på resept til individer er tatt med i tabellen.

This support is provided to all who live in Norway, regardless of citizenship. The physician may prescribe these drugs for use in their own practice without giving the person-identifier of the patient. Such prescriptions will not be available on an individual level in the NorPD.

Information regarding self-payment is not available in NorPD.

Health Trust Prescription

The regional health trusts provide a dedicated funding for certain expensive drugs. These include immune-modulating drugs for the treatment of rheumatic disorders (TNF α inhibitors), multiple sclerosis and cancer. Only drugs that are dispensed by prescription to individuals are included in the table.

Table 2.2.a Sales of drugs by prescription categories, overview 2012

	Number of individuals	Proportion (%) of the population	Number of DDDs	Sales in 1000 NOK
Non-reimbursable prescriptions	2 981 914	59.4	577 069 899	2 626 442
Reimbursement prescriptions	2 157 984	43.0	1 580 232 738	9 287 941
Health Trust prescriptions	16 157	0.3	4 855 611	1 324 416

Table 2.2.b: Sales of reimbursed drugs (§§ 2, 3a, 3b, 4) by ATC main groups 2012

ATC main groups	Number of individuals	Proportion (%) of the population	Number of DDDs	Sales in 1000 NOK
A Alimentary tract and metabolism	438 210	8,7	172 980 440	1 220 214
B Blood and blood forming organs	270 133	5,4	80 483 698	627 739
C Cardiovascular system	956 239	19,1	713 202 626	1 654 963
D Dermatologicals	238 808	4,8	321 626	119 178
G Genito urinary system and sex hormones	110 797	2,2	34 975 064	257 906
H Systemic hormonal preparations, excl. sex hormones and insulins	324 631	6,5	61 462 526	395 167
J Antiinfectives for systemic use	111 676	2,2	9 957 974	522 215
L Antineoplastic and immunomodulating agents	73 345	1,5	21 715 565	1 058 646
M Musculo-skeletal system	257 881	5,1	50 834 223	173 199
N Nervous system	573 651	11,4	179 932 273	1 666 617
P Antiparasitic products, insecticides and repellents	6 269	0,1	731 611	4 387
R Respiratory system	744 583	14,8	220 784 711	1 301 169
S Sensory organs	255 204	5,1	32 595 772	214 253
V Various	13 746	0,3	254 628	72 288

Table 2.2.c: Reimbursed drugs (§§ 2, 3a, 3b, 4) with the highest number of users 2012

	ATC code	Active ingredient	Use	Number of individuals	Proportion (%) of the population	Number of DDDs	Sales in 1000 NOK
1	C10AA01	simvastatin	Cholesterol-lowering	313 103	6,2	99 400 846	129 130
2	C07AB02	metoprolol	Antihypertensive/cardiac disease	264 162	5,3	43 508 529	123 950
3	R06AE07	cetirizine	Anti-allergic	243 541	4,9	48 692 864	53 417
4	H03AA01	levothyroxine sodium	Thyroxine supplement	186 198	3,7	40 114 945	52 880
5	R03AC02	salbutamol	Asthma/COPD	180 559	3,6	18 351 550	72 661
6	C10AA05	atorvastatin	Cholesterol-lowering	166 142	3,3	92 592 021	125 796
7	C08CA01	amlodipine	Antihypertensive/cardiac disease	125 291	2,5	56 276 070	53 744
8	R01AD09	mometasone	Anti-allergic nose spray	111 161	2,2	13 170 989	44 523
9	N02BE01	paracetamol	Analgesic	109 242	2,2	11 843 818	28 977
10	N06AB10	escitalopram	Antidepressant	107 960	2,2	34 106 171	72 884
11	A10BA02	metformin	Diabetes	102 568	2,0	25 479 833	50 069
12	H02AB06	prednisolone	Antiinflammatory/corticosteroid	95 046	1,9	14 655 632	22 627
13	B01AA03	warfarin	Antithrombotic	94 265	1,9	20 591 537	77 074
14	R03AK06	salmeterol and fluticasone	Asthma/COPD	94 059	1,9	21 102 898	320 594
15	A02BC05	esomeprazole	Reflux oesofagitis	91 280	1,8	27 171 625	172 126
16	A02BC02	pantoprazole	Reflux oesofagitis	90 514	1,8	18 902 029	33 880
17	C03CA01	furosemide	Antihypertensive/cardiac disease	86 356	1,7	22 768 039	19 057
18	R06AX27	desloratadine	Anti-allergic	85 400	1,7	13 537 214	29 141
19	R03AK07	formoterol and budesonide	Asthma/COPD	83 189	1,7	15 145 805	234 047
20	C09CA06	candesartan	Antihypertensive/cardiac disease	80 524	1,6	38 441 649	127 454
21	S01GX02	levocabastine	Anti-allergic eye drops	68 857	1,4	*	17 705
22	C09DA01	losartan and diuretics	Antihypertensive/cardiac disease	67 367	1,3	22 127 157	49 875
23	R06AX13	loratadine	Anti-allergic	66 638	1,3	12 941 314	17 066
24	R01AD12	fluticasone furoate	Anti-allergic nose spray	64 799	1,3	4 994 760	17 107
25	C09CA01	losartan	Antihypertensive/cardiac disease	61 334	1,2	22 680 081	38 051
26	C09AA05	ramipril	Antihypertensive/cardiac disease	60 891	1,2	49 127 515	24 797
27	R03BA05	fluticasone	Asthma/COPD	57 647	1,1	5 064 435	41 273
28	D07AB02	hydrocortisone butyrate	Inflammatory skin disorders/eczema/psoriasis	56 872	1,1	*	9 292
29	M01AB05	diclofenac	NSAID/analgesic	55 438	1,1	6 671 960	13 576
30	D07AC13	mometasone	Inflammatory skin disorders/eczema/psoriasis	55 368	1,1	*	13 246

* No DDD assigned for this ATC 5th level

Table 2.2.d: Reimbursed drugs (§§ 2, 3a, 3b, 4) with highest sales in NOK 2012

	ATC code	Active ingredient	Use	Number of individuals	Proportion (%) of the population	Number of DDDs	Sales in 1000 NOK
1	R03AK06	salmeterol and fluticasone	Asthma/COPD	94 059	1,9	21 102 898	320 594
2	R03AK07	formoterol and budesonide	Asthma/COPD	83 189	1,7	15 145 805	234 047
3	A02BC05	esomeprazole	Reflux oesofagitis	91 280	1,8	27 171 625	172 126
4	B02BD02	coagulation factor VIII	Bleeding disorder	166	0,0	43 029	149 706
5	H01AC01	somatropin	Growth hormone deficiency	1 808	0,0	771 811	146 499
6	R03BB04	tiotropium bromide	COPD	39 417	0,8	10 634 025	144 918
7	N06BA04	methylphenidate	ADHD	26 856	0,5	11 565 508	130 766
8	C10AA01	simvastatin	Cholesterol-lowering	313 103	6,2	99 400 846	129 130
9	C09CA06	candesartan	Antihypertensive/cardiac disease	80 524	1,6	38 441 649	127 454
10	C10AA05	atorvastatin	Cholesterol-lowering	166 142	3,3	92 592 021	125 796
11	C07AB02	metoprolol	Antihypertensive/cardiac disease	264 162	5,3	43 508 529	123 950
12	A10AC01	insulin human	Diabetes	31 937	0,6	11 533 710	103 116
13	C09DA06	candesartan and diuretics	Antihypertensive/cardiac disease	54 194	1,1	17 395 322	102 085
14	R03DC03	montelukast	Asthma	37 844	0,8	8 572 758	101 696
15	L01XE01	imatinib	Cancer	465	0,0	53 058	100 948
16	A10AB05	insulin aspart	Diabetes	26 980	0,5	8 661 322	86 129
17	L02BX03	abiraterone	Cancer	470	0,0	74 640	85 404
18	N02CC01	sumatriptan	Migraine	43 327	0,9	2 677 574	85 010
19	N03AX09	lamotrigine	Epilepsy/bipolar disorders	25 963	0,5	6 580 915	83 259
20	A07EC02	mesalazine	Ulcerative colitis/Crohn's disease	14 847	0,3	5 423 901	78 244
21	B01AA03	warfarin	Antithrombotic	94 265	1,9	20 591 537	77 074
22	L03AA13	pegfilgrastim	Cancer	2 206	0,0	161 380	77 069
23	N06AB10	escitalopram	Antidepressant	107 960	2,2	34 106 171	72 884
24	R03AC02	salbutamol	Asthma/COPD	180 559	3,6	18 351 550	72 661
25	N03AX16	pregabalin	Neuropathic pain/ epilepsy	8 700	0,2	3 254 079	71 299
26	J05AR03	tenofovir disoproxil and emtricitabine	HIV infections	1 403	0,0	399 090	69 869
27	L04AD01	ciclosporin	Immune suppression	3 260	0,1	716 184	67 293
28	C09DA04	irbesartan and diuretics	Antihypertensive/cardiac disease	28 599	0,6	9 507 125	66 713
29	C10AX09	ezetimibe	Cholesterol-lowering	18 680	0,4	5 352 677	64 682
30	H01CB02	octreotide	Cancer	504	0,0	202 085	62 508

2.3 Beskrivelse av hovedtabellene

Tabellene i del 2 i denne boken gir en oversikt over antall individer som har fått utlevert legemidler etter resept fra apotekene i Norge. Alle som har hentet ut minst ett legemiddel er inkludert og opplysningene er fordelt på enkeltlegemidler og legemiddelgrupper. Selv om et individ har fått utlevert samme legemiddel flere ganger, telles vedkommende som bruker bare én gang. Det er kun utleveringer til individer med fullt fødselsnummer som er inkludert i tabellene i boken. I Reseptregisteret er 0,76 % av utleveringene til individer hvor fullstendig fødselsnummer ikke er angitt i 2012.

Tabellene inneholder tall for perioden 2008–2012. I tillegg er følgende opplysninger for 2012 inkludert:

- Andel kvinner (%) av totalt antall individer som har hentet ut minst én resept
- Antall individer som har hentet ut minst ett legemiddel etter resept fordelt på følgende aldersgrupper: <15, 15–44, 45–69, ≥70
- Salg i kroner fra apotek for utvalget i tabellen, dvs. til individer med fullt fødselsnummer. Kronebeløpet tilsvarer reell utsalgspris fra apotek.

Tabellene er sortert i henhold til ATC-systemet (se nærmere beskrivelse på s. 15). De aller fleste ATC-grupper med legemidler på det norske markedet er inkludert. Legemidler til pasienter i sykehus eller sykehjem er ikke tilgjengelig på individnivå i Reseptregisteret. Det totale antall legemiddelbrukere vil derfor være høyere enn det som fremgår av tabellene for en del legemidler, og spesielt for legemidler som brukes mye i sykehus. Vi har valgt å utelate noen ATC-grupper. Dette er legemidler som hovedsaklig brukes i sykehus eller institusjoner. Følgende ATC-grupper er utelatt:

B05 Blodsubstitutter og infeksjonsløsninger
 B06 Andre hematologiske midler
 J06 Immunsera og immunoglobuliner
 J07 Vaksiner
 L01 Antineoplastiske midler
 M03A Perifert virkende muskelrelaxerende midler
 N01 Anestetika
 S01H Lokalanestetika
 S01J Diagnostika
 S01L Midler ved okulær vaskulær sykdom
 V Varia (kun ATC-gruppe V01 *Allergener* er inkludert i tabellen)

Reseptfrie legemidler skrives i noen tilfeller også ut på resept, men i hovedsak vil salg av reseptfrie legemidler ikke være inkludert i denne boken. Salg av reseptfrie

2.3 Description of the main tables

The tables in section 2 of this book provide an overview of the number of individuals who have had prescriptions dispensed from pharmacies in Norway. Anyone who has had at least one prescription dispensed is included and the data are given for each medicinal substance and for groups of medicines. Even if an individual has been given the same medicine several times, he or she is counted as a user only once. Only dispensing data to individuals with a personal identification number are included in the tables. In NorPD the complete personal identification number is missing for 0.76% of the dispensed medicines to individuals in 2012.

The tables contain figures for the period 2008–2012. In addition, the following information for 2012 includes:

- Share of women (%) of the total number of individuals who have had at least one prescription dispensed
- The number of individuals who have had at least one prescription dispensed in the following age groups: <15, 15–44, 45–69, ≥70
- Sales in million Norwegian kroner (mNOK), i.e. for prescriptions dispensed to individuals with a personal identification number. The amount in NOK corresponds to the actual retail price from the pharmacy.

The tables are arranged according to the ATC system (see further description in p. 15). The majority of ATC groups containing drugs on the Norwegian market are included. Medicine use by individuals in hospitals and nursing homes is not included at the individual level in the Norwegian Prescription Database. The total number of medicine users will therefore be higher than the figures in the tables for a number of drugs, particularly for drugs that are frequently used in hospitals or institutions. We have chosen to exclude some ATC groups in this book that are mainly used in hospitals or institutions. The following ATC groups have been omitted:

B05 Blood substitutes and perfusion solutions
 B06 Other hematological agents
 J06 Immune sera and immunoglobulins
 J07 Vaccines
 L01 Antineoplastic agents
 M03A Muscle relaxants, peripherally acting agents
 N01 Anesthetics
 S01H Local anesthetics
 S01J Diagnostic agents
 S01L Ocular vascular disorder agents
 V Various (ATC group V01 Allergens is included in the table)




Figure 2.2: The report generator at www.reseptregisteret.no (English version at www.norpd.no)

legemidler, både i og utenom apotek, er med i den grossistbaserte legemiddelstatistikken, hvor tallmaterialet blir publisert i publikasjonen Legemiddelforbruket i Norge (se også s. 15). I tabellene i del 2 i denne boken er det tatt med en fotnote tilknyttet de ulike ATC-kodene hvor det i tillegg også selges reseptfrie pakninger. I 2012 utgjorde reseptfrie legemidler en andel på 15 % av totalt antall solgte doser (DDD). Disse andelene har holdt seg relativt konstant over tid.

De fleste legemidler som forskrives på resept, har godkjent markedsføringstillatelse i Norge. Leger har imidlertid anledning til å forskrive legemidler uten markedsføringstillatelse. Det må da søkes om spesielt godkjenningfritak fra Statens legemiddelverk. Det finnes også enkelte legemidler som inngår i en såkalt negativliste, og som bare kan utleveres etter spesiell tillatelse fra Legemiddelverket. Legemidler som er forskrevet på resept etter søknad om godkjenningfritak eller etter spesiell tillatelse fra Legemiddelverket, er inkludert i tabellene i boken. Antall individer som behandles med disse legemidlene vil ofte være lavt. Dersom antall individer er lavere enn fem, angis < 5 i tabellene.

Mange individer bruker flere legemidler. Vær derfor oppmerksom på at man ikke kan summere antall brukere av ulike legemidler, eller legemiddelgrupper i tabellene, for å finne totalt antall brukere av to eller flere legemidler. Statistikk på aggregert nivå i tabellene vil imidlertid inneholde brukere av minst ett av

Non-prescription medicines are sometimes prescribed, but the majority of the OTC medicine sales will not be included in the tables in this book. Sales of OTC medicines are, however, included in the Norwegian Drug Wholesales Statistics database and the figures are published in "Drug Consumption in Norway" (see also p. 15). A footnote is used in the tables in part 2 of this book in the various ATC codes where OTC medicines are available in Norway. In 2012, OTC medicines had a share of 15% of total sales measured in DDDs. These shares have remained almost unchanged over time.

Most prescribed medicines have an approved marketing authorisation in Norway. However, physicians can prescribe drugs without approved marketing authorisation. They must then apply for a licence from the Norwegian Medicines Agency. There are also some medicines that are part of a so-called "negative list" which can only be prescribed by special permission from the Medicines Agency. Drugs that are prescribed on licence or by special permission are included in the tables in the book. The number of individuals who are prescribed these medicines is often low. If the number of individuals is less than five, <5 is used in the tables.

Many individuals use more than one medicine. Please be aware that it is not possible to add together the number of users of various drugs or drug groups in the tables to find the total number of users of two or more drugs. Statistics on the aggregate level in the

legemidlene i undernivåene. For eksempel viser tallene at totalt antall brukere av sovemidler (ATC-gruppe N05C) er lavere enn summen av antall brukere av de enkelte legemidlene som er klassifisert i N05C. Det betyr at noen individer har fått utlevert mer enn en type sovemiddel i løpet av et år, enten ved bruk av flere sovemidler samtidig eller ved bytte fra ett middel til et annet.

Reseptregisterets nettsider: www.reseptregisteret.no
Reseptregisteret har eget nettsted som kan brukes sammen med tabellene i denne rapporten for å få kompletterende informasjon. På søkesidene (figur 2.2) kan man selv lage rapporter over antall brukere av et bestemt legemiddel eller en legemiddelgruppe. Dette kan gjøres ved søk på forhåndsdefinerte legemiddelgrupper, via ATC-systemet eller ved søk på virkestoff eller produktnavn.

Følgende data om legemiddelbruk kan hentes ut fra nettstedet:

- Antall brukere, eventuelt fordelt på kjønn, 5 års aldersgrupper, fylke eller helseregion
- Antall brukere per 1 000 innbyggere (prevalens per 1 000)
- Omsetning i kroner
- Omsetning i doser (DDD – definerte døgndoser)
- Befolkningsgrunnlag i statistikken, eventuelt fordelt på kjønn, alder, fylke eller helseregion

Data er tilgjengelige fra 2004, og nettstedet oppdateres årlig med foregående års tall.

Tallene i denne rapporten kan avvike noe fra tallene som finnes på nettstedet. Årsaken er at uttrekket av data til boken er gjort på et noe senere tidspunkt enn datagrunnlaget for nettsiden. Rapporteringen av data fra apotek til Reseptregisteret er for en liten andel av reseptutleveringene forsinket. Forsinkelsen kan være på noen måneder, og dette innebærer at noen data fra foregående år blir rapportert på etterskudd. I tillegg er individer uten kjent bostedsadresse utelatt fra nettsiden, men inkludert i tabellene i denne rapporten. Nettstedet finnes også i engelsk versjon (www.norpd.no).

Utlevering av data fra Reseptregisteret

Det er mulig å søke om data fra Reseptregisteret til forskning eller til andre formål som er i henhold til formålet for Reseptregisteret. Søknadsskjema er tilgjengelige på nettstedet til FHI (www.fhi.no), og alle søknader om tilgang til data fra FHI skal sendes til datatilgang@fhi.no. Dataene er gratis, men kostnader i forbindelse med administrativ håndtering og filbehandling må påregnes.

tables will, however, include the use of at least one of the drugs in the included drug groups. For example, the figures in the tables show that the total number of users of sleeping pills (ATC group N05C) is lower than the sum of the number of users of the individual medicines that are classified in N05C. This means that some individuals have been given more than one type of sleeping pill during a year, either through the use of more than one simultaneously or by switching from one agent to another.

The NorPD website: www.norpd.no

The Norwegian Prescription Database has its own website which can be used together with the tables in this report for complementary information. On the website (figure 2.2), one can create reports on the number of users of a particular drug or drug group. This can be done by searching for pre-defined drug groups, through the ATC system or by searching the active substance or product name.

The following data on drug use can be extracted from the website:

- Number of users, split by gender, 5-year age groups, county or health region
- Number of users per 1 000 population (prevalence per 1 000)
- Turnover in NOK (pharmacy retail price)
- Turnover in doses (DDD – defined daily doses)
- Population base for the statistics, split by gender, age, county or health region

Data are available from 2004 with an annual update for the preceding year.

The figures in this book may differ slightly from the numbers found on the website. This is because the data extraction for the book was made at another date than the data on the website. Reporting of data from the pharmacy to NorPD is delayed for a minor number of prescriptions. The delay may be a few months, meaning that reports of data from a year can arrive the following year. Besides, individuals without known address are included in the tables in this book but not on the website.

Access to data from NorPD

It is possible to apply for data from the Norwegian Prescription Database for research or for other purposes which are according to the objectives of NorPD. Application forms are available on the website of NIPH (www.fhi.no) and all applications for access to data from NIPH should be sent to datatilgang@fhi.no. The data is free of charge, but fees for administration and file processing will be required.

Beregning av prevalens per 1000 innbyggere

Prevalens er ofte definert som antall individer som har fått utlevert ett legemiddel per 1000 innbyggere. Antall individer oppgitt i tabellene kan benyttes til å beregne prevalens av legemiddelbruken i befolkningen. Hvordan dette kan gjøres er vist i eksemplet nedenfor.

Antall individer som fikk minst ett hjerte-/karmiddel (ATC-gruppe C) i Norge i 2012: 1 017 917

Antall innbyggere i Norge per 1. juli 2012: 5 018 415

Beregning av prevalens (per 1000) for brukere av hjerte-/karmidler i Norge i 2012:

$$\frac{\text{Antall individer} \times 1000}{\text{Antall innbyggere}} = \frac{1\,017\,917 \times 1000}{5\,018\,415} = 202,8 \text{ individer per 1000 innbyggere}$$

På s. 101 finnes tabeller over befolkningstallet i Norge for årene 2008–2012. Befolkningstallet for de fire aldersgruppene i tabellene er også angitt. Det brukes middelfolkemengden for hvert år, dvs folketallet per 1. juli, beregnet ut fra Statistisk Sentralbyrås folketall 1.1 og 31.12. Alder er definert som den alder individet har ved slutten av året (utleveringsår minus fødselsår).

Calculation of prevalence per 1000 inhabitants

Prevalence is often defined as the number of individuals per 1000 inhabitants who have had at least one prescription dispensed in a pharmacy during a specific time period. The number of individuals listed in the tables can be used to calculate the prevalence of drug users in the population. Please read the following example:

The number of individuals who had at least one cardiovascular drug dispensed (ATC group C) in Norway in 2012: 1 017 917

The number of inhabitants in Norway as of 1st July 2012: 5 018 415

Calculation of the prevalence (per 1000) of users of cardiovascular drugs in Norway in 2012:

$$\frac{\text{The number of individuals} \times 1000}{\text{The number of inhabitants}} = \frac{1\,017\,917 \times 1000}{5\,018\,415} = 202,8 \text{ individuals per 1000 inhabitants}$$

The population in Norway for the years 2008–2012 is shown on p. 101. The population of the four age groups in the tables is also provided. The population as of 1st July each year is used, calculated from the population figures by Statistics Norway from 1st January and 31st December. Age is defined as the age of the individual at the end of the year (year of dispensing minus birth year).

2.4 ATC main groups

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
							<15	15–44	45–69	≥70	
A ALIMENTARY TRACT AND METABOLISM	647 826	678 403	702 509	742 204	787 544	57	21 153	183 105	353 754	229 532	1 472 867
B BLOOD AND BLOOD FORMING ORGANS	541 141	562 344	581 349	597 921	616 372	50	2 637	59 063	268 325	286 347	787 836
C CARDIOVASCULAR SYSTEM	917 229	945 886	975 141	998 461	1 018 128	51	6 118	95 480	532 968	383 562	1 691 608
D DERMATOLOGICALS	589 450	587 812	611 440	624 493	628 955	54	76 390	237 819	212 640	102 106	235 358
G GENITO URINARY SYSTEM AND SEX HORMONES	692 715	703 423	721 846	745 367	760 023	81	3 267	420 137	234 951	101 668	862 673
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	357 070	375 465	387 821	402 923	413 526	67	16 074	108 837	178 811	109 804	430 101
J ANTIINFECTIVES FOR SYSTEMIC USE	1 247 202	1 394 508	1 252 392	1 326 405	1 330 660	59	164 678	534 345	435 678	195 959	802 758
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	70 154	72 795	76 656	81 612	86 248	54	1 255	18 728	40 814	25 451	2 400 496
M MUSCULO-SKELETAL SYSTEM	907 360	891 127	901 910	927 355	935 824	57	14 643	332 879	429 400	158 902	303 497
N NERVOUS SYSTEM	1 208 796	1 230 918	1 248 505	1 279 676	1 301 538	59	30 853	414 409	565 804	290 472	2 626 256
P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	89 343	86 714	88 743	92 296	94 797	63	3 329	42 623	37 887	10 958	33 814
R RESPIRATORY SYSTEM	1 151 928	1 183 767	1 183 735	1 223 490	1 234 841	56	169 146	451 770	445 061	168 864	1 448 923
S SENSORY ORGANS	596 101	596 290	609 467	617 742	614 238	57	112 776	177 918	192 459	131 085	302 360

2.5 ATC group A – Alimentary tract and metabolism

ATC group A

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
A ALIMENTARY TRACT AND METABOLISM	647 826	678 403	702 509	742 204	787 544	57	21 153	183 105	353 754	229 532	1 472 867
A01 STOMATOLOGICAL PREPARATIONS	18 176	11 205	6 463	9 155	15 069	57	404	6 273	4 981	3 411	2 596
A01A STOMATOLOGICAL PREPARATIONS	18 176	11 205	6 463	9 155	15 069	57	404	6 273	4 981	3 411	2 596
A01AA Caries prophylactic agents	618	665	776	4 792	10 844	57	111	4 472	3 568	2 693	1 774
A01AA01 sodium fluoride ¹⁾	618	665	776	4 792	10 844	57	111	4 472	3 568	2 693	1 774
A01AB Antiinfectives and antiseptics for local oral treatment	8 943	8 998	4 088	2 553	2 396	54	143	969	790	494	241
A01AB02 hydrogen peroxide ¹⁾	0	0	<5	<5	0	-	0	0	0	0	0
A01AB03 chlorhexidine ¹⁾	2 312	2 293	2 540	2 482	2 341	53	141	951	770	479	206
A01AB04 amphotericin B	6 554	6 690	1 529	52	36	78	0	12	12	12	31
A01AB09 miconazole	<5	5	<5	5	8	50	0	<5	<5	<5	2
A01AB11 various ¹⁾	18	22	26	14	11	36	<5	<5	<5	<5	2
A01AB17 metronidazole	108	45	0	0	0	-	0	0	0	0	0
A01AC Corticosteroids for local oral treatment	8 434	1 026	1 155	1 379	1 408	63	110	495	567	236	361
A01AC01 triamcinolone	8 434	1 026	1 155	1 379	1 397	63	110	493	559	235	349
A01AD Other agents for local oral treatment	550	598	508	516	530	59	40	366	104	20	221
A01AD01 epinephrine	7	6	9	10	10	50	0	<5	6	0	10
A01AD02 benzydamine	515	562	475	494	494	59	30	351	95	18	207
A01AD11 various	28	30	24	12	26	69	10	11	<5	<5	3
A02 DRUGS FOR ACID RELATED DISORDERS	298 397	316 609	338 746	366 465	392 558	54	6 792	86 931	188 818	110 017	339 723
A02A ANTACIDS	4 296	4 537	4 691	4 772	4 415	43	126	837	1 598	1 854	5 572
A02AA Magnesium compounds	0	0	0	0	<5	50	0	0	0	<5	1
A02AA04 magnesium hydroxide	0	0	0	0	<5	50	0	0	0	<5	1
A02AC Calcium compounds	1 398	1 293	1 229	1 085	1 001	36	17	133	368	483	666
A02AC01 calcium carbonate ¹⁾	1 398	1 293	1 229	1 085	1 001	36	17	133	368	483	666
A02AD Combinations and complexes of aluminium, calcium and magnesium compounds	1 240	1 495	1 485	1 526	1 024	61	26	455	332	211	148
A02AD01 ordinary salt combinations ¹⁾	1 240	1 495	1 485	1 526	1 024	61	26	455	332	211	148
A02AH Antacids with sodium bicarbonate	2 166	2 187	2 341	2 471	2 676	36	46	283	1 013	1 334	4 495
A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	296 148	314 287	336 339	364 176	390 415	55	6 700	86 566	188 120	109 029	334 151
A02BA H2-receptor antagonists	59 188	58 630	57 804	57 052	54 899	59	1 179	14 814	25 342	13 564	16 658

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
A02BA01 cimetidine	356	56	46	34	28	64	0	<5	18	8	25
A02BA02 ranitidine ¹⁾	55 440	55 484	54 984	54 650	53 271	59	1 172	14 607	24 573	12 919	15 232
A02BA03 famotidine ¹⁾	3 448	2 878	2 547	2 313	1 614	56	7	193	768	646	1 372
A02BA07 ranitidine bismuth citrate	<5	0	0	0	0	-	0	0	0	0	0
A02BA53 famotidine, combinations ¹⁾	351	378	367	221	127	58	0	34	56	37	29
A02BB Prostaglandins	267	248	259	255	346	81	<5	214	86	44	192
A02BB01 misoprostol	267	248	259	255	346	81	<5	214	86	44	192
A02BC Proton pump inhibitors	250 321	269 754	292 835	321 967	351 006	54	5 686	75 822	170 509	98 989	316 703
A02BC01 omeprazole	44 880	46 873	47 082	48 114	47 239	55	3 141	9 584	21 048	13 466	48 764
A02BC02 pantoprazole ¹⁾	74 965	85 176	102 237	125 091	148 280	54	586	34 201	71 066	42 427	43 846
A02BC03 lansoprazole	50 410	50 018	48 809	47 348	46 270	51	418	8 519	23 599	13 734	31 609
A02BC05 esomeprazole	108 181	111 446	117 963	125 642	134 776	55	1 945	30 160	67 346	35 325	192 485
A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	1 837	1 807	1 909	2 143	2 310	63	182	803	792	533	598
A02BX02 sucralfate	424	403	366	419	440	61	<5	119	188	131	255
A02BX13 alginic acid	1 424	1 414	1 549	1 739	1 880	64	180	685	610	405	343
A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	58 718	60 485	62 554	65 509	69 438	71	1 562	24 008	26 338	17 530	14 911
A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	3 364	3 471	3 623	3 150	3 500	55	152	769	1 248	1 331	1 657
A03AA Synthetic anticholinergics, esters with tertiary amino group	45	28	29	26	26	65	0	9	15	<5	29
A03AA04 mebeverine	42	27	29	26	26	65	0	9	15	<5	29
A03AA07 dicycloverine	<5	<5	0	0	0	-	0	0	0	0	0
A03AB Synthetic anticholinergics, quaternary ammonium compounds	32	112	132	160	209	44	<5	14	78	116	269
A03AB02 glycopyrronium bromide	25	105	128	155	201	45	<5	8	76	116	261
A03AB05 propantheline	7	7	<5	5	8	13	0	6	<5	0	8
A03AD Papaverine and derivatives	48	37	59	47	62	13	0	<5	35	23	117
A03AD01 papaverine	48	37	59	47	62	13	0	<5	35	23	117
A03AX Other drugs for functional gastrointestinal disorders	3 239	3 302	3 405	2 924	3 209	57	151	742	1 124	1 192	1 242
A03AX13 silicones	3 239	3 302	3 405	2 924	3 209	57	151	742	1 124	1 192	1 242
A03B BELLADONNA AND DERIVATIVES, PLAIN	1 101	1 382	1 617	1 910	2 125	59	14	856	897	358	808
A03BA Belladonna alkaloids, tertiary amines	861	1 098	1 297	1 510	1 664	58	7	691	681	285	548

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
A03BA01 atropine	27	26	22	23	28	18	0	<5	18	6	14
A03BA03 hyoscyamine	834	1 072	1 276	1 487	1 636	59	7	687	663	279	535
A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds	242	285	321	406	468	63	7	169	217	75	260
A03BB01 butylscopolamine	223	267	300	386	455	63	6	165	211	73	256
A03BB03 methylscopolamine	19	18	23	21	13	69	<5	<5	6	<5	3
A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS	27	18	19	20	16	44	0	<5	12	<5	29
A03CA Synthetic anticholinergic agents in combination with psycholeptics	27	18	19	20	16	44	0	<5	12	<5	29
A03CA02 clidinium and psycholeptics	27	18	19	20	16	44	0	<5	12	<5	29
A03F PROPULSIVES	54 797	56 321	58 104	61 221	64 702	72	1 412	22 589	24 578	16 123	12 418
A03FA Propulsives	54 797	56 321	58 104	61 221	64 702	72	1 412	22 589	24 578	16 123	12 418
A03FA01 metoclopramide	54 676	56 214	57 999	61 099	64 570	72	1 392	22 558	24 521	16 099	11 830
A03FA02 cisapride	116	93	83	79	83	58	13	24	34	12	451
A03FA03 domperidone	39	44	55	71	62	56	8	11	26	17	110
A03FA05 alizapride	0	0	0	0	11	82	0	8	<5	0	28
A04 ANTIEMETICS AND ANTINAUSEANTS	12 918	13 055	13 797	14 669	15 259	59	304	2 640	8 396	3 919	33 276
A04A ANTIEMETICS AND ANTINAUSEANTS	12 918	13 055	13 797	14 669	15 259	59	304	2 640	8 396	3 919	33 276
A04AA Serotonin (5HT₃) antagonists	10 498	10 867	11 434	11 986	12 399	59	228	1 641	7 011	3 519	25 567
A04AA01 ondansetron	10 010	10 437	11 150	11 784	12 270	59	228	1 634	6 931	3 477	24 900
A04AA02 granisetron	<5	<5	0	<5	<5	0	<5	0	0	0	27
A04AA03 tropisetron	755	613	440	324	210	62	<5	16	131	62	630
A04AA05 palonosetron	6	<5	5	<5	7	29	0	<5	<5	<5	11
A04AD Other antiemetics	3 138	3 194	3 887	4 658	5 178	68	78	1 392	3 009	699	7 709
A04AD01 scopolamine	2 412	2 112	2 135	2 400	2 313	57	75	885	995	358	739
A04AD05 metopimazine	<5	0	0	0	0	-	0	0	0	0	0
A04AD10 dronabinol	7	5	<5	5	5	0	0	<5	<5	0	65
A04AD12 aprepitant	719	1 078	1 761	2 269	2 871	77	<5	505	2 020	343	6 904
A05 BILE AND LIVER THERAPY	1 749	1 909	2 015	2 303	2 592	75	75	938	1 176	403	9 325
A05A BILE THERAPY	1 749	1 909	2 015	2 303	2 592	75	75	938	1 176	403	9 325
A05AA Bile acid preparations	1 749	1 909	2 015	2 303	2 592	75	75	938	1 176	403	9 325
A05AA02 ursodeoxycholic acid	1 749	1 909	2 015	2 303	2 592	75	75	938	1 176	403	9 325
A06 DRUGS FOR CONSTIPATION	28 856	31 408	44 230	50 571	49 659	57	5 865	7 157	16 837	19 800	27 774
A06A DRUGS FOR CONSTIPATION	28 856	31 408	44 230	50 571	49 659	57	5 865	7 157	16 837	19 800	27 774

ATC group A

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
A06AA Softeners, emollients	69	105	112	208	365	47	61	40	107	157	290
A06AA01 liquid paraffin ¹⁾	69	105	112	194	351	47	55	37	105	154	154
A06AB Contact laxatives	12 341	13 383	15 058	21 757	22 471	58	354	2 380	8 828	10 909	6 951
A06AB02 bisacodyl ¹⁾	3 847	3 858	4 056	6 514	6 005	63	80	690	1 977	3 258	1 961
A06AB06 senna glycosides ¹⁾	2 002	2 020	2 120	4 322	2 808	62	19	168	848	1 773	1 342
A06AB08 sodium picosulfate ¹⁾	7 574	8 584	10 082	10 948	11 635	55	258	1 227	4 369	5 781	2 448
A06AB20 contact laxatives in combination ¹⁾	6	<5	6	8	<5	100	0	0	<5	<5	1
A06AB53 dantron, combinations	<5	<5	<5	0	0	-	0	0	0	0	0
A06AB56 senna glycosides, combinations ¹⁾	17	17	10	12	11	82	0	<5	5	5	3
A06AB58 sodium picosulfate, combinations ¹⁾	0	0	31	1 581	3 529	60	<5	421	2 161	944	1 195
A06AC Bulk-forming laxatives	1 508	1 772	1 996	2 054	2 080	60	42	566	791	681	582
A06AC01 ispaghula (psylla seeds) ¹⁾	1 505	1 772	1 996	2 054	2 080	60	42	566	791	681	582
A06AC51 ispaghula, combinations ¹⁾	<5	0	0	0	0	-	0	0	0	0	0
A06AD Osmotically acting laxatives	17 176	18 687	30 442	30 643	29 153	55	5 354	4 112	9 083	10 604	11 951
A06AD11 lactulose ¹⁾	13 475	13 507	14 464	14 513	14 509	51	645	1 805	5 396	6 663	3 964
A06AD12 lactitol	68	78	59	58	51	55	33	9	5	<5	36
A06AD15 macrogol	0	0	45	79	134	54	122	11	<5	0	122
A06AD17 sodium phosphate ¹⁾	923	847	9 665	7 334	2 814	59	<5	589	1 434	787	568
A06AD65 macrogol, combinations ¹⁾	3 327	4 947	7 273	9 943	12 875	57	4 679	1 827	2 709	3 660	7 261
A06AG Enemas	4 522	4 649	4 892	5 458	5 288	50	532	1 190	1 775	1 791	6 975
A06AG02 bisacodyl ¹⁾	1 468	1 475	1 410	1 680	1 671	47	47	459	683	482	724
A06AG04 glycerol ¹⁾	689	772	827	905	852	48	188	220	212	232	3 158
A06AG10 docusate sodium, incl. combinations ¹⁾	1 213	1 217	1 394	1 484	1 365	50	93	281	480	511	1 595
A06AG11 laurilsulfate, incl. combinations ¹⁾	1 511	1 567	1 647	1 826	1 767	52	226	297	541	703	1 498
A06AH Peripheral opioid receptor antagonists	18	164	197	195	180	51	<5	17	108	54	1 001
A06AH01 methylnaltrexone bromide	18	164	197	195	180	51	<5	17	108	54	1 001
A06AX Other drugs for constipation	<5	0	0	0	9	78	0	7	<5	<5	24
A06AX05 prucalopride	0	0	0	0	9	78	0	7	<5	<5	24
A06AX06 tegaserod	<5	0	0	0	0	-	0	0	0	0	0
A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS	60 714	62 586	69 807	72 492	72 187	59	4 873	20 234	30 464	16 616	127 222

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70							
A07A INTESTINAL ANTIINFECTIVES	24 718	25 618	31 199	32 204	30 625	65	4 327	7 901	11 208	7 189	12 190
A07AA Antibiotics	24 718	25 618	31 199	32 204	30 625	65	4 327	7 901	11 208	7 189	12 190
A07AA02 nystatin	24 493	25 376	30 730	31 544	29 999	65	4 312	7 649	10 946	7 092	10 628
A07AA06 paromomycin	90	81	154	316	257	71	13	142	100	<5	190
A07AA09 vancomycin	158	177	182	200	234	60	<5	41	97	94	818
A07AA11 rifaximin	0	<5	184	211	188	73	<5	93	87	7	522
A07AA12 fidaxomicin	0	0	0	0	<5	50	0	0	<5	<5	31
A07B INTESTINAL ADSORBENTS	146	95	80	84	101	44	13	37	33	18	18
A07BA Charcoal preparations	146	95	80	84	95	42	13	36	30	16	12
A07BA01 medicinal charcoal ¹⁾	146	95	80	84	95	42	13	36	30	16	12
A07BB Bismuth preparations	0	0	0	0	6	67	0	<5	<5	<5	7
A07C ELECTROLYTES WITH CARBOHYDRATES	118	182	259	279	356	56	176	92	52	36	186
A07CA Oral rehydration salt formulations¹⁾	118	182	259	279	356	56	176	92	52	36	186
A07D ANTIPROPULSIVES	15 904	16 106	16 710	17 200	18 001	56	141	3 584	8 114	6 162	7 441
A07DA Antipropulsives	15 904	16 106	16 710	17 200	18 001	56	141	3 584	8 114	6 162	7 441
A07DA01 diphenoxylate	<5	<5	<5	<5	<5	33	0	<5	<5	<5	14
A07DA02 opium	99	94	124	112	99	54	0	6	44	49	234
A07DA03 loperamide ¹⁾	15 718	15 829	16 464	16 933	17 689	57	136	3 482	7 986	6 085	7 165
A07DA53 loperamide, combinations ¹⁾	221	326	294	283	356	56	5	108	147	96	121
A07E INTESTINAL ANTI-INFLAMMATORY AGENTS	21 365	21 914	22 753	23 690	24 459	52	218	8 614	11 819	3 808	104 840
A07EA Corticosteroids acting locally	4 806	5 014	5 212	5 155	5 204	60	62	1 795	2 411	936	15 304
A07EA01 prednisolone	1 002	1 011	1 175	1 292	1 220	50	7	503	550	160	1 212
A07EA02 hydrocortisone	1 195	1 233	1 154	408	355	71	6	123	180	46	679
A07EA06 budesonide	2 820	2 972	3 190	3 583	3 764	63	54	1 235	1 727	748	13 412
A07EB Antiallergic agents, excl. corticosteroids	63	54	53	64	50	76	17	12	19	<5	435
A07EB01 cromoglicic acid	63	54	53	64	50	76	17	12	19	<5	435
A07EC Aminosalicilic acid and similar agents	18 950	19 275	19 918	20 669	21 322	50	171	7 730	10 325	3 096	89 101
A07EC01 sulfasalazine	6 461	6 194	6 104	5 966	5 800	55	<5	1 419	3 288	1 089	6 740
A07EC02 mesalazine	11 965	12 549	13 330	14 229	15 066	48	166	6 173	6 796	1 931	78 624
A07EC03 olsalazine	494	488	494	452	406	46	<5	104	224	76	1 444
A07EC04 balsalazide	859	809	750	687	612	43	0	216	313	83	2 294
A07F ANTIDIARRHEAL MICROORGANISMS	302	694	1 252	1 507	1 243	73	35	668	470	70	2 129

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70							
A07FA Antidiarrheal microorganisms	302	694	1 252	1 507	1 243	73	35	668	470	70	2 129
A07FA01 lactic acid producing organisms	204	581	918	912	767	73	13	440	297	17	1 579
A07FA02 saccharomyces boulardii	98	116	283	381	431	69	24	198	157	52	340
A07FA51 lactic acid producing organisms, combinations	0	0	0	0	16	69	0	9	5	<5	25
A07X OTHER ANTIDIARRHEALS	107	139	99	117	64	83	<5	34	24	<5	41
A07XA Other antidiarrheals	107	139	99	117	64	83	<5	34	24	<5	41
A08 ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS	37 873	38 343	19 168	10 373	7 674	77	<5	2 866	4 155	651	11 743
A08A ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS	37 873	38 343	19 168	10 373	7 674	77	<5	2 866	4 155	651	11 743
A08AA Centrally acting antiobesity products	22 024	25 710	5 782	0	0	-	0	0	0	0	0
A08AA10 sibutramine	22 024	25 710	5 782	0	0	-	0	0	0	0	0
A08AB Peripherally acting antiobesity products	14 563	14 540	14 575	10 373	7 674	77	<5	2 866	4 155	651	11 743
A08AB01 orlistat	14 563	14 540	14 575	10 373	7 674	77	<5	2 866	4 155	651	11 743
A08AX Other antiobesity drugs	4 206	<5	<5	0	0	-	0	0	0	0	0
A08AX01 rimonabant	4 206	<5	<5	0	0	-	0	0	0	0	0
A09 DIGESTIVES, INCL. ENZYMES	5 053	5 126	5 479	5 758	5 732	58	131	959	2 722	1 920	15 035
A09A DIGESTIVES, INCL. ENZYMES	5 053	5 126	5 479	5 758	5 732	58	131	959	2 722	1 920	15 035
A09AA Enzyme preparations	4 965	5 070	5 441	5 699	5 684	58	130	947	2 709	1 898	15 009
A09AA02 multienzymes (lipase, protease etc.)	4 965	5 070	5 441	5 699	5 679	58	130	946	2 705	1 898	14 994
A09AB Acid preparations	104	65	50	61	52	63	<5	9	19	23	21
A09AB01 glutamic acid hydrochloride ¹⁾	66	52	44	54	39	72	0	<5	16	19	18
A09AB02 betaine hydrochloride	0	0	0	<5	<5	33	0	<5	0	<5	2
A09AB03 hydrochloric acid ¹⁾	<5	<5	6	6	10	40	<5	<5	<5	<5	1
A09AB04 citric acid	35	10	0	0	0	-	0	0	0	0	0
A09AC Enzyme and acid preparations, combinations	0	0	15	17	9	78	0	8	<5	0	6
A09AC02 multienzymes and acid preparations	0	0	15	17	9	78	0	8	<5	0	6
A10 DRUGS USED IN DIABETES	139 101	145 677	152 065	156 542	160 789	44	1 802	23 046	83 009	52 932	580 953
A10A INSULINS AND ANALOGUES	51 156	52 603	54 014	54 994	56 373	43	1 780	14 038	25 481	15 074	343 169
A10AB Insulins and analogues for injection, fast-acting	32 514	33 562	34 874	35 659	36 860	43	1 775	12 753	16 085	6 247	124 674

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
A10AB01 insulin (human)	2 184	1 823	1 604	1 403	1 293	39	9	217	702	365	2 655
A10AB03 insulin (pork)	<5	0	0	0	0	-	0	0	0	0	0
A10AB04 insulin lispro	8 672	8 615	8 835	9 021	9 091	42	184	3 947	3 973	987	34 660
A10AB05 insulin aspart	22 740	23 900	25 159	25 860	27 003	43	1 639	8 802	11 613	4 949	86 202
A10AB06 insulin glulisine	145	270	375	404	379	47	<5	142	194	41	1 157
A10AC Insulins and analogues for injection, intermediate-acting	33 505	33 129	32 520	31 916	31 962	42	618	5 474	15 288	10 582	103 184
A10AC01 insulin (human)	33 503	33 129	32 520	31 916	31 962	42	618	5 474	15 288	10 582	103 184
A10AC03 insulin (pork)	<5	0	0	0	0	-	0	0	0	0	0
A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting	10 261	9 736	9 112	8 304	7 684	43	6	498	3 589	3 591	35 198
A10AD01 insulin (human)	33	17	<5	<5	<5	0	0	0	0	<5	18
A10AD03 insulin (pork)	0	0	0	<5	0	-	0	0	0	0	0
A10AD04 Insulin lispro	750	672	647	643	607	44	<5	102	317	186	2 721
A10AD05 insulin aspart	9 506	9 075	8 476	7 672	7 091	43	<5	399	3 276	3 412	32 459
A10AE Insulins and analogues for injection, long-acting	9 845	11 310	13 695	15 222	16 394	45	731	6 633	7 129	1 901	80 114
A10AE03 insulin (pork)	<5	<5	<5	<5	<5	0	0	<5	0	0	19
A10AE04 insulin glargine	6 167	6 958	8 433	9 559	10 603	45	241	4 349	4 737	1 276	47 484
A10AE05 insulin detemir	3 802	4 493	5 526	5 927	6 017	46	504	2 385	2 488	640	32 610
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	105 413	111 436	117 293	121 207	124 901	44	25	10 615	69 396	44 865	237 784
A10BA Biguanides	88 638	95 537	101 637	103 523	104 983	45	18	9 564	59 517	35 884	50 711
A10BA02 metformin	88 638	95 537	101 637	103 523	104 983	45	18	9 564	59 517	35 884	50 711
A10BB Sulfonamides, urea derivatives	47 057	47 349	46 112	43 116	40 597	41	7	1 809	20 895	17 886	17 870
A10BB01 glibenclamide	1 912	1 738	1 539	1 343	1 177	43	6	45	515	611	620
A10BB02 chlorpropamide	<5	<5	<5	<5	<5	100	0	0	<5	0	2
A10BB07 glipizide	5 707	5 229	4 807	4 281	3 856	42	0	114	1 596	2 146	2 192
A10BB12 glimepiride	39 867	40 684	40 028	37 733	35 737	41	<5	1 662	18 852	15 222	15 056
A10BD Combinations of oral blood glucose lowering drugs	2 652	3 852	8 219	10 974	13 273	37	0	978	8 941	3 354	59 582
A10BD03 metformin and rosiglitazone	2 641	2 575	2 284	0	0	-	0	0	0	0	0
A10BD04 glimepiride and rosiglitazone	<5	<5	0	0	0	-	0	0	0	0	0
A10BD05 metformin and pioglitazone	<5	27	32	35	26	54	0	<5	19	<5	107
A10BD07 metformin and sitagliptin	0	318	2 187	4 053	5 215	37	0	386	3 533	1 296	23 023
A10BD08 metformin and vildagliptin	10	1 068	4 791	7 030	8 144	37	0	595	5 465	2 084	36 452

ATC group A

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
A10BF Alpha glucosidase inhibitors	988	922	813	701	640	44	0	33	310	297	950
A10BF01 acarbose	988	922	813	701	640	44	0	33	310	297	950
A10BG Thiazolidinediones	5 719	5 401	4 672	1 912	1 637	39	0	97	1 082	458	6 956
A10BG02 rosiglitazone	4 193	3 798	3 104	20	<5	0	0	0	<5	0	1
A10BG03 pioglitazone	1 568	1 641	1 779	1 894	1 636	39	0	97	1 081	458	6 955
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors	798	1 752	6 478	9 436	11 088	42	0	716	6 724	3 648	46 906
A10BH01 sitagliptin	793	1 491	4 799	6 711	7 196	41	0	464	4 466	2 266	32 690
A10BH02 vildagliptin	6	288	935	1 274	1 749	45	0	116	974	659	5 086
A10BH03 saxagliptin	0	0	854	1 616	1 763	40	0	121	1 126	516	7 892
A10BH05 linagliptin	0	0	0	0	608	41	0	25	276	307	1 239
A10BX Other blood glucose lowering drugs, excl. insulins	725	847	1 335	3 523	5 421	46	0	781	3 950	690	54 808
A10BX02 repaglinide	399	330	283	252	234	36	0	5	127	102	445
A10BX03 nateglinide	13	13	11	9	10	30	0	<5	6	<5	25
A10BX04 exenatide	314	491	554	795	873	47	0	124	654	95	6 684
A10BX07 liraglutide	0	19	535	2 605	4 427	46	0	667	3 253	507	47 654
A11 VITAMINS	79 347	91 052	93 046	102 139	118 610	60	805	29 723	45 597	42 485	67 050
A11A MULTIVITAMINS, COMBINATIONS	0	0	0	28	92	49	46	42	<5	0	389
A11AA Multivitamins with minerals	0	0	0	28	92	49	46	42	<5	0	389
A11AA03 multivitamins and other minerals, incl. combinations	0	0	0	28	92	49	46	42	<5	0	389
A11B MULTIVITAMINS, PLAIN	39	78	100	74	59	86	15	44	0	0	51
A11BA Multivitamins, plain	39	78	100	74	59	86	15	44	0	0	51
A11C VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO	7 962	9 836	11 360	17 026	25 067	58	365	9 183	10 279	5 240	15 805
A11CA Vitamin A, plain	38	29	30	42	58	71	<5	26	24	<5	157
A11CA01 retinol (vit A)	22	13	14	20	37	76	0	16	18	<5	38
A11CA02 betacarotene	16	16	16	22	21	62	<5	10	6	<5	119
A11CC Vitamin D and analogues	7 931	9 815	11 337	16 992	25 029	58	361	9 166	10 265	5 237	15 648
A11CC01 ergocalciferol	2 034	3 096	4 250	8 654	13 261	64	140	5 972	5 507	1 642	4 546
A11CC03 alfalcidol	3 526	3 790	3 884	4 123	4 852	47	139	825	1 910	1 978	6 684
A11CC04 calcitriol	2 085	2 297	2 396	2 632	2 930	46	15	527	1 224	1 164	3 413
A11CC05 colecalciferol	367	753	939	1 733	4 359	63	72	1 954	1 815	518	1 005
A11D VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12¹⁾	697	762	790	749	798	37	6	123	475	194	598

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
A11DA Vitamin B1, plain	677	745	782	739	786	37	6	118	472	190	592
A11DA01 thiamine (vit B1) ¹⁾	677	745	782	739	786	37	6	118	472	190	592
A11DB Vitamin B1 in combination with vitamin B6 and/or vitamin B12	20	17	8	10	12	83	0	5	<5	<5	6
A11E VITAMIN B-COMPLEX, INCL. COMBINATIONS	68 574	78 387	78 352	82 349	92 260	60	290	20 237	35 488	36 245	47 388
A11EA Vitamin B-complex, plain¹⁾	67 559	77 313	77 144	80 810	90 830	61	256	19 963	34 927	35 684	45 979
A11EB Vitamin B-complex with vitamin C	58	114	92	155	231	60	<5	82	89	58	58
A11EX Vitamin B-complex, other combinations	986	1 008	1 155	1 443	1 266	39	32	201	501	532	1 351
A11G ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS	3 410	3 507	3 677	3 759	3 639	66	9	339	788	2 503	1 076
A11GA Ascorbic acid (vitamin C), plain	3 410	3 507	3 677	3 759	3 639	66	9	339	788	2 503	1 076
A11GA01 ascorbic acid (vit C) ¹⁾	3 410	3 507	3 677	3 759	3 639	66	9	339	788	2 503	1 076
A11H OTHER PLAIN VITAMIN PREPARATIONS	1 181	1 462	1 604	1 730	1 501	62	124	874	355	148	1 040
A11HA Other plain vitamin preparations	1 181	1 462	1 604	1 730	1 501	62	124	874	355	148	1 040
A11HA01 nicotinamide	14	5	13	11	19	47	<5	<5	12	<5	9
A11HA02 pyridoxine (vit B6) ¹⁾	568	871	1 072	1 134	1 030	61	55	691	212	72	416
A11HA03 tocopherol (vit E) ¹⁾	590	572	442	412	311	55	62	95	86	68	445
A11HA04 riboflavin (vit B2)	13	16	12	11	9	56	<5	<5	<5	<5	3
A11HA06 pyridoxal phosphate	0	0	66	161	131	88	<5	83	43	<5	60
A11HA08 tocopherol	0	0	0	<5	<5	50	<5	0	0	0	106
A11J OTHER VITAMIN PRODUCTS, COMBINATIONS	63	59	61	91	84	74	36	36	12	0	117
A11JA Combinations of vitamins	63	59	48	53	45	58	36	9	0	0	85
A11JB Vitamins with minerals	0	0	13	38	39	92	0	27	12	0	32
A12 MINERAL SUPPLEMENTS	83 190	91 581	100 943	111 514	125 310	78	424	11 747	51 030	62 109	82 885
A12A CALCIUM	62 611	70 986	80 569	91 211	104 272	82	240	10 410	43 860	49 762	66 290
A12AA Calcium	1 515	1 467	1 417	1 137	1 066	67	60	168	447	391	1 215
A12AA02 calcium glubionate	<5	8	7	<5	6	33	5	0	<5	0	21
A12AA04 calcium carbonate ¹⁾	397	371	412	188	<5	100	0	0	<5	<5	1
A12AA06 calcium lactate gluconate ¹⁾	1 123	1 090	984	928	1 029	68	55	163	434	377	1 160
A12AA12 calcium acetate anhydrous	22	12	28	24	32	38	<5	5	13	13	34
A12AX Calcium, combinations with vitamin D and/or other drugs	61 293	69 722	79 351	90 245	103 401	82	181	10 265	43 500	49 455	65 074

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
A12B POTASSIUM	20 403	20 533	20 544	20 029	20 949	65	86	1 062	6 807	12 994	12 954
A12BA Potassium	20 403	20 533	20 544	20 029	20 949	65	86	1 062	6 807	12 994	12 954
A12BA01 potassium chloride	18 834	18 968	18 800	18 295	19 019	65	21	884	6 179	11 935	10 061
A12BA02 potassium citrate	1 860	1 828	2 055	2 034	2 256	63	67	218	747	1 224	2 874
A12BA30 combinations	5	<5	<5	<5	<5	50	0	<5	<5	0	18
A12C OTHER MINERAL SUPPLEMENTS	3 628	3 773	4 004	4 809	5 366	61	101	576	1 998	2 691	3 424
A12CA Sodium	464	622	715	878	979	66	<5	44	304	628	527
A12CA01 sodium chloride ¹⁾	464	622	715	878	979	66	<5	44	304	628	527
A12CB Zinc	909	865	767	697	764	68	43	152	258	311	346
A12CB01 zinc sulfate	909	865	767	697	764	68	43	152	258	311	346
A12CC Magnesium	2 292	2 338	2 591	3 300	3 690	58	56	385	1 472	1 777	2 551
A12CC04 magnesium citrate	19	<5	0	0	0	-	0	0	0	0	0
A12CC10 magnesium oxide	9	13	18	103	173	55	<5	25	67	80	123
A12CC30 magnesium (different salts in combination) ¹⁾	2 272	2 328	2 573	3 212	3 537	59	45	365	1 412	1 715	2 158
A14 ANABOLIC AGENTS FOR SYSTEMIC USE	660	728	847	866	885	82	<5	237	575	71	595
A14A ANABOLIC STEROIDS	660	728	847	866	885	82	<5	237	575	71	595
A14AA Androstan derivatives	561	645	827	841	847	84	<5	226	549	70	468
A14AA07 prasterone	560	644	827	841	847	84	<5	226	549	70	468
A14AA08 oxandrolone	<5	<5	0	0	0	-	0	0	0	0	0
A14AB Estren derivatives	100	84	21	25	24	17	0	5	18	<5	72
A14AB01 nandrolone	100	84	21	25	24	17	0	5	18	<5	72
A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	329	293	548	663	598	66	95	286	199	18	159 653
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	329	293	317	335	373	56	88	159	110	16	159 399
A16AA Amino acids and derivatives	93	107	123	131	152	56	60	63	26	<5	3 035
A16AA01 levocarnitine	63	73	87	79	82	50	51	22	6	<5	1 244
A16AA03 glutamine	13	17	12	19	11	36	0	7	<5	0	17
A16AA04 mercaptamine	8	7	10	8	8	38	5	<5	0	0	826
A16AA06 betaine	10	11	16	20	21	48	5	12	<5	0	937
A16AB Enzymes	44	51	50	56	59	39	5	26	24	<5	122 990
A16AB02 imiglucerase	9	10	7	7	<5	75	0	<5	<5	0	12 047
A16AB03 agalsidase alfa	17	16	32	33	34	35	<5	17	12	<5	56 752
A16AB04 agalsidase beta	19	23	18	7	14	43	0	5	9	0	16 304

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<5	5-14	15-44	45-69	≥70		<15	15-44	45-69	≥70	
A16AB05 laronidase	0	0	<5	<5	0	-	0	0	0	0	0
A16AB07 alglucosidase alfa	<5	<5	<5	<5	<5	0	0	0	<5	0	12 886
A16AB08 galsulfase	0	0	0	0	<5	100	<5	0	0	0	803
A16AB09 idursulfase	0	<5	<5	<5	<5	0	<5	<5	0	0	10 964
A16AB10 velaglucrase alfa	0	0	0	6	5	20	0	<5	<5	0	13 234
A16AX Various alimentary tract and metabolism products	198	139	149	151	165	61	24	71	61	9	33 373
A16AX01 thioctic acid	180	122	121	109	112	64	<5	42	59	9	176
A16AX03 sodium phenylbutyrate	<5	<5	<5	<5	<5	0	<5	0	0	0	252
A16AX04 nitisinone	12	12	13	14	14	21	11	<5	0	0	10 123
A16AX05 zinc acetate	<5	<5	7	8	11	55	<5	9	<5	0	90
A16AX06 miglustat	0	0	<5	<5	<5	75	<5	0	0	0	2 597
A16AX07 sapropterin	0	0	5	15	22	73	<5	17	<5	0	20 135

2.6 ATC group B – Blood and bloodforming organs

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<5	5-14	15-44	45-69	≥70		<15	15-44	45-69	≥70	
B BLOOD AND BLOOD FORMING ORGANS	541 172	562 393	581 403	597 973	616 453	50	2 641	59 109	268 354	286 349	813 935
B01 ANTITHROMBOTIC AGENTS	455 766	472 410	485 783	497 174	508 904	45	402	22 096	222 773	263 633	417 935
B01A ANTITHROMBOTIC AGENTS	455 766	472 410	485 783	497 174	508 904	45	402	22 096	222 773	263 633	417 935
B01AA Vitamin K antagonists	84 246	86 427	88 730	92 222	94 644	40	56	3 395	28 862	62 331	77 944
B01AA01 dicoumarol	88	93	90	93	81	51	0	10	32	39	434
B01AA02 phenindione	33	27	24	15	<5	75	0	0	<5	<5	80
B01AA03 warfarin	84 154	86 322	88 631	92 133	94 563	40	56	3 385	28 830	62 292	77 430
B01AB Heparin group	28 157	32 041	36 949	42 027	46 904	58	170	10 136	21 190	15 408	107 362
B01AB01 heparin	789	826	926	943	1 043	55	99	200	491	253	2 382
B01AB02 antithrombin III	<5	<5	<5	0	0	0	0	0	0	0	0
B01AB04 dalteparin	15 439	15 917	21 249	25 588	28 569	59	47	5 983	13 128	9 411	65 075
B01AB05 enoxaparin	12 275	15 744	15 363	16 078	17 952	57	25	4 060	7 915	5 952	39 866
B01AB10 tinzaparin	0	0	0	6	7	71	0	<5	0	<5	39
B01AC Platelet aggregation inhibitors excl. heparin	368 206	380 882	390 081	394 911	399 381	44	188	10 211	184 478	204 504	208 146
B01AC04 clopidogrel	25 178	26 429	28 372	29 470	28 302	34	<5	836	14 168	13 296	33 149
B01AC05 ticlopidine	429	420	327	273	229	48	0	0	93	136	622
B01AC06 acetylsalicylic acid	359 578	370 132	376 011	377 738	379 659	44	186	9 787	176 106	193 580	100 589
B01AC07 dipyridamole	18 072	18 755	19 310	19 501	19 708	44	0	316	7 530	11 862	21 802
B01AC09 epoprostenol	9	7	<5	<5	<5	50	0	0	<5	0	3 521
B01AC11 iloprost	<5	<5	<5	6	10	70	0	<5	6	<5	2 605
B01AC21 treprostinil	9	9	9	8	9	78	0	7	<5	0	16 977
B01AC22 prasugrel	0	31	214	487	1 126	22	0	73	812	241	4 169
B01AC24 ticagrelor	0	0	0	26	2 335	26	0	104	1 435	796	9 654
B01AC30 combinations	2 230	5 557	8 788	11 324	13 193	44	<5	285	5 563	7 344	15 028
B01AC56 acetylsalicylic acid and esomeprazole	0	0	0	0	80	49	0	<5	35	44	28
B01AD Enzymes	<5	<5	<5	<5	<5	100	<5	0	0	0	603
B01AD02 alteplase	<5	<5	<5	<5	<5	100	<5	0	0	0	603
B01AE Direct thrombin inhibitors	<5	9	187	1 168	4 098	43	0	82	1 509	2 507	20 504
B01AE07 dabigatran etexilate	<5	9	187	1 168	4 098	43	0	82	1 509	2 507	20 504
B01AF Direct factor Xa inhibitors	0	45	191	899	1 663	56	<5	139	769	754	3 288
B01AF01 rivaroxaban	0	45	191	899	1 329	54	<5	133	591	604	2 905
B01AF02 apixaban	0	0	0	0	335	61	0	6	178	151	383
B01AX Other antithrombotic agents	7	16	17	8	5	80	0	<5	0	<5	88
B01AX05 fondaparinux	7	16	17	8	5	80	0	<5	0	<5	88
B02 ANTIHEMORRHAGICS	12 599	12 439	12 210	12 954	13 285	92	277	6 474	5 855	679	204 832

ATC group B

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
B02A ANTIFIBRINOLYTICS	12 205	12 034	11 846	12 577	12 871	94	188	6 322	5 770	591	6 640
B02AA Amino acids	12 204	12 033	11 845	12 575	12 869	94	188	6 320	5 770	591	4 741
B02AA02 tranexamic acid	12 204	12 033	11 845	12 575	12 869	94	188	6 320	5 770	591	4 741
B02AB Proteinase inhibitors	<5	<5	<5	<5	<5	50	0	<5	0	0	1 900
B02AB02 alfa1 antitrypsin	<5	<5	<5	<5	<5	50	0	<5	0	0	1 900
B02B VITAMIN K AND OTHER HEMOSTATICS	451	468	419	427	492	36	104	190	105	93	198 192
B02BA Vitamin K	263	275	212	208	212	65	34	69	36	73	121
B02BA01 phytomenadione	263	275	212	208	212	65	34	69	36	73	121
B02BB Fibrinogen	0	0	0	<5	<5	100	0	0	<5	0	95
B02BB01 fibrinogen, human	0	0	0	<5	<5	100	0	0	<5	0	95
B02BD Blood coagulation factors	188	187	189	190	238	8	70	113	49	6	188 203
B02BD01 coagulation factor IX, II, VII and X in combination	<5	<5	<5	<5	<5	100	0	<5	<5	0	341
B02BD02 coagulation factor VIII	138	129	134	132	166	1	54	77	33	<5	149 706
B02BD03 factor VIII inhibitor bypassing activity	8	6	6	7	6	0	0	<5	<5	<5	9 008
B02BD04 coagulation factor IX	23	30	28	30	37	0	10	21	5	<5	14 272
B02BD06 von Willebrand factor and coagulation factor VIII in combination	14	15	12	9	14	64	<5	7	<5	<5	5 049
B02BD07 coagulation factor XIII	0	0	0	0	<5	100	0	0	<5	0	19
B02BD08 eptacog alfa (activated)	<5	7	7	7	10	30	5	<5	<5	0	4 547
B02BD09 nonacog alfa	0	0	<5	<5	<5	0	0	<5	<5	0	1 419
B02BD10 von Willebrand factor	0	0	<5	<5	<5	67	<5	<5	0	0	3 843
B02BX Other systemic hemostatics	0	6	18	28	41	49	0	8	19	14	9 774
B02BX04 romiplostim	0	6	14	15	17	35	0	<5	6	7	6 566
B02BX05 eltrombopag	0	0	<5	15	25	60	0	5	13	7	3 208
B03 ANTIANEMIC PREPARATIONS	113 448	120 950	129 328	135 640	144 194	65	1 817	32 810	54 056	55 511	118 247
B03A IRON PREPARATIONS	20 058	22 178	24 019	25 072	25 520	68	1 098	7 042	5 518	11 862	7 957
B03AA Iron bivalent, oral preparations	18 754	20 801	22 588	23 597	23 942	67	1 092	6 216	5 026	11 608	6 111
B03AA01 ferrous glycine sulfate ¹⁾	2 024	2 892	3 574	4 189	4 937	70	52	1 666	1 182	2 037	2 495
B03AA02 ferrous fumarate ¹⁾	1 337	1 333	1 320	1 324	1 281	50	852	192	75	162	198
B03AA03 ferrous gluconate	10	112	101	52	0	-	0	0	0	0	0
B03AA07 ferrous sulfate ¹⁾	15 544	16 693	17 767	18 255	18 052	67	192	4 413	3 834	9 613	3 418
B03AC Iron trivalent, parenteral preparations	1 395	1 461	1 524	1 577	1 697	85	7	867	527	296	1 846

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group B

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
B03AC01 ferric oxide polymaltose complexes	0	0	0	<5	18	72	0	11	5	<5	57
B03AC02 saccharated iron oxide	297	288	280	325	303	77	<5	132	99	70	404
B03AC06 ferric oxide dextran complexes	1 113	1 189	1 254	1 267	1 393	86	5	732	428	228	1 385
B03B VITAMIN B12 AND FOLIC ACID	94 767	100 602	107 727	113 339	121 848	65	732	27 036	48 951	45 129	33 291
B03BA Vitamin B12 (cyanocobalamin and analogues)	65 578	69 156	76 095	79 008	85 251	67	127	19 579	31 782	33 763	19 251
B03BA01 cyanocobalamin	5 696	6 558	7 389	7 469	8 479	69	24	2 651	3 183	2 621	1 764
B03BA02 cyanocobalamin tannin complex	34 255	36 404	39 772	40 827	44 083	67	37	10 280	16 334	17 432	9 582
B03BA03 hydroxocobalamin	27 457	28 055	31 131	32 969	35 193	67	65	7 352	13 208	14 568	7 790
B03BA05 mecobalamin	26	16	38	91	125	75	5	66	50	<5	115
B03BB Folic acid and derivatives	34 058	36 595	36 321	39 074	41 579	61	617	8 204	18 841	13 917	14 040
B03BB01 folic acid ¹⁾	34 058	36 595	36 321	39 074	41 579	61	617	8 204	18 841	13 917	14 040
B03X OTHER ANTIANEMIC PREPARATIONS	3 520	3 639	3 485	3 456	3 427	40	36	309	1 228	1 854	76 999
B03XA Other antianemic preparations	3 520	3 639	3 485	3 456	3 427	40	36	309	1 228	1 854	76 999
B03XA01 erythropoietin	681	470	334	279	280	43	<5	25	106	146	6 056
B03XA02 darbepoetin alfa	2 716	2 785	2 714	2 704	2 859	39	33	263	1 022	1 541	62 233
B03XA03 methoxy polyethylene glycol-epoetin beta	230	452	475	516	445	40	0	40	160	245	8 710
B06 OTHER HEMATOLOGICAL AGENTS	31	49	54	52	81	60	<5	46	29	<5	26 099
B06A OTHER HEMATOLOGICAL AGENTS	31	49	54	52	81	60	<5	46	29	<5	26 099
B06AC Drugs used in hereditary angioedema	29	41	47	46	76	58	<5	42	28	<5	25 500
B06AC01 c1-inhibitor, plasma derived	29	39	37	29	44	64	<5	26	13	<5	15 650
B06AC02 icatibant	0	6	14	23	53	57	0	29	23	<5	9 148
B06AC04 conestat alfa	0	0	0	0	<5	75	0	<5	<5	0	702

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.7 ATC group C – Cardiovascular system

ATC group C

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012	
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK	
	<15	15-44	45-69	≥70								
C	CARDIOVASCULAR SYSTEM	917 229	945 886	975 141	998 461	1 018 128	51	6 118	95 480	532 968	383 562	1 691 608
C01	CARDIAC THERAPY	129 660	124 930	122 995	120 544	118 979	48	4 373	8 331	40 218	66 057	82 799
C01A	CARDIAC GLYCOSIDES	27 043	25 820	24 749	23 214	20 073	49	36	133	3 682	16 222	5 024
C01AA	Digitalis glycosides	27 043	25 820	24 749	23 214	20 073	49	36	133	3 682	16 222	5 024
C01AA04	digitoxin	25 926	24 736	23 709	22 197	14 045	49	0	65	2 364	11 616	3 467
C01AA05	digoxin	1 144	1 123	1 068	1 084	10 585	49	36	93	2 176	8 280	1 557
C01B	ANTIARRHYTHMICS, CLASS I AND III	9 879	10 321	11 688	12 400	13 113	35	52	607	7 110	5 344	25 468
C01BA	Antiarrhythmics, class Ia	184	173	159	131	121	54	0	5	46	70	303
C01BA01	quinidine	5	<5	<5	5	<5	100	0	0	<5	<5	28
C01BA03	disopyramide	179	170	156	126	117	52	0	5	45	67	276
C01BB	Antiarrhythmics, class Ib	26	23	17	17	18	39	0	5	9	<5	129
C01BB01	lidocaine	0	0	0	0	<5	100	0	0	<5	0	0
C01BB02	mexiletine	26	23	17	17	17	35	0	5	8	<5	129
C01BC	Antiarrhythmics, class Ic	5 517	5 783	6 393	6 735	7 030	39	48	446	4 434	2 102	13 605
C01BC03	propafenone	<5	<5	<5	5	<5	67	0	<5	<5	0	7
C01BC04	flecainide	5 515	5 780	6 390	6 730	7 027	39	48	445	4 432	2 102	13 598
C01BD	Antiarrhythmics, class III	4 273	4 475	5 432	5 809	6 265	30	<5	166	2 839	3 256	11 431
C01BD01	amiodarone	4 273	4 475	4 853	4 912	5 232	28	<5	136	2 230	2 862	4 033
C01BD07	dronedrone	0	0	767	1 034	1 166	36	0	34	694	438	7 398
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES	12 191	12 217	14 121	15 618	18 359	58	4 286	6 466	6 259	1 348	12 596
C01CA	Adrenergic and dopaminergic agents	12 191	12 217	14 121	15 618	18 359	58	4 286	6 466	6 259	1 348	12 596
C01CA01	etilefrine	115	114	95	112	110	61	0	33	44	33	260
C01CA02	isoprenaline	0	0	0	0	<5	100	0	<5	0	0	1
C01CA03	norepinephrine	<5	0	0	0	0	-	0	0	0	0	0
C01CA17	midodrine	14	14	16	20	20	70	0	13	6	<5	156
C01CA24	epinephrine	12 058	12 082	14 006	15 480	18 221	58	4 286	6 417	6 204	1 314	12 158
C01CA26	ephedrine	6	7	6	8	8	0	0	<5	6	0	22
C01D	VASODILATORS USED IN CARDIAC DISEASES	88 490	83 930	79 479	75 844	73 206	47	<5	1 167	24 434	47 604	39 683
C01DA	Organic nitrates	88 490	83 930	79 479	75 844	73 206	47	<5	1 167	24 434	47 604	39 683
C01DA02	glyceryl trinitrate	68 613	65 061	60 717	58 282	56 554	46	<5	1 097	21 351	34 105	13 835
C01DA08	isosorbide dinitrate	3 257	2 787	2 311	1 950	1 703	53	0	<5	234	1 465	1 278
C01DA14	isosorbide mononitrate	38 046	35 905	34 145	31 873	30 269	51	0	129	6 202	23 938	24 570
C01E	OTHER CARDIAC PREPARATIONS	133	138	138	67	11	64	0	<5	6	<5	27
C01EB	Other cardiac preparations	133	138	138	67	11	64	0	<5	6	<5	27

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012	
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK	
	<15	15-44	45-69	≥70								
C01EB09	ubidecarenone	123	129	126	59	0	-	0	0	0	0	0
C01EB15	trimetazidine	10	9	10	6	7	57	0	<5	5	<5	9
C01EB17	ivabradine	0	0	0	0	<5	75	0	<5	<5	0	18
C02	ANTIHYPERTENSIVES	17 795	17 689	17 442	17 597	17 535	27	21	724	8 268	8 522	60 883
C02A	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	7 114	6 702	6 469	6 521	6 512	41	<5	322	3 622	2 567	6 118
C02AB	Methylidopa	1 084	410	141	107	88	68	0	37	28	23	210
C02AB01	methylidopa (levorotatory)	1 084	410	141	107	88	68	0	37	28	23	210
C02AC	Imidazoline receptor agonists	6 119	6 347	6 340	6 427	6 432	40	<5	285	3 601	2 545	5 909
C02AC01	clonidine	74	78	64	85	77	55	<5	26	41	9	95
C02AC05	moxonidine	6 045	6 269	6 276	6 342	6 356	40	0	259	3 561	2 536	5 814
C02C	ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING	10 920	11 234	11 221	11 285	11 258	18	0	370	4 842	6 046	13 981
C02CA	Alpha-adrenoreceptor antagonists	10 920	11 233	11 221	11 285	11 258	18	0	370	4 842	6 046	13 981
C02CA04	doxazosin	10 920	11 233	11 221	11 285	11 258	18	0	370	4 842	6 046	13 981
C02CC	Guanidine derivatives	0	<5	0	0	0	-	0	0	0	0	0
C02CC02	guanethidine	0	<5	0	0	0	-	0	0	0	0	0
C02D	ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON	331	319	301	317	318	36	5	16	134	163	320
C02DB	Hydrazinophthalazine derivatives	300	285	270	288	294	37	5	11	119	159	200
C02DB02	hydralazine	300	285	270	288	294	37	5	11	119	159	200
C02DC	Pyrimidine derivatives	31	34	32	29	23	26	0	5	15	<5	120
C02DC01	minoxidil	31	34	32	29	23	26	0	5	15	<5	120
C02DD	Nitroferricyanide derivatives	0	0	0	0	<5	100	0	0	0	<5	0
C02DD01	nitroprusside	0	0	0	0	<5	100	0	0	0	<5	0
C02K	OTHER ANTIHYPERTENSIVES	106	119	142	161	177	68	15	52	77	33	40 464
C02KD	Serotonin antagonists	22	18	19	20	14	93	0	<5	9	<5	479
C02KD01	ketanserin	22	18	19	20	14	93	0	<5	9	<5	479
C02KX	Other antihypertensives	85	102	124	142	165	67	15	51	69	30	39 985
C02KX01	bosentan	83	91	103	114	123	65	15	41	46	21	28 341
C02KX02	ambisentan	<5	12	19	33	46	74	0	12	24	10	11 644
C02KX03	sitaxentan	<5	0	<5	0	0	-	0	0	0	0	0
C03	DIURETICS	233 975	235 555	223 842	208 905	201 658	60	185	8 578	77 149	115 746	86 711
C03A	LOW-CEILING DIURETICS, THIAZIDES	71 861	74 216	66 001	53 889	49 010	61	9	2 089	25 098	21 814	22 523
C03AA	Thiazides, plain	44 489	45 271	36 364	16 033	14 920	58	<5	727	7 734	6 455	4 276

ATC group C

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
C03AA01 bendroflumethiazide	30 790	31 710	22 807	<5	0	-	0	0	0	0	0
C03AA03 hydrochlorothiazide	13 766	13 625	16 731	16 032	14 920	58	<5	727	7 734	6 455	4 276
C03AB Thiazides and potassium in combination	28 814	30 363	41 642	38 130	34 245	62	5	1 370	17 433	15 437	18 247
C03AB01 bendroflumethiazide and potassium	28 814	30 363	41 642	38 130	34 245	62	5	1 370	17 433	15 437	18 247
C03B LOW-CEILING DIURETICS, EXCL. THIAZIDES	6	6	5	6	8	38	0	0	<5	5	23
C03BA Sulfonamides, plain	6	6	5	6	8	38	0	0	<5	5	23
C03BA04 chlortalidone	6	6	5	6	6	50	0	0	<5	<5	20
C03BA08 metolazone	0	0	0	0	<5	0	0	0	0	<5	3
C03C HIGH-CEILING DIURETICS	128 686	127 997	127 391	125 517	125 149	60	162	5 266	38 460	81 261	46 848
C03CA Sulfonamides, plain	128 686	127 997	127 391	125 517	125 149	60	162	5 266	38 460	81 261	46 848
C03CA01 furosemide	104 728	101 621	99 010	95 661	93 391	62	161	4 466	30 306	58 458	19 852
C03CA02 bumetanide	28 833	31 193	33 444	34 790	36 730	53	<5	909	9 281	26 538	26 984
C03CA04 torasemide	<5	<5	<5	<5	<5	100	0	0	0	<5	12
C03D POTASSIUM-SPARING AGENTS	17 302	17 602	17 636	17 868	18 190	48	23	921	7 110	10 136	11 983
C03DA Aldosterone antagonists	17 287	17 589	17 623	17 851	18 175	48	22	919	7 104	10 130	11 842
C03DA01 spironolactone	16 795	17 028	17 038	17 160	17 397	50	22	861	6 650	9 864	6 865
C03DA02 potassium canrenoate	0	0	<5	<5	0	-	0	0	0	0	0
C03DA04 eplerenone	579	658	678	798	912	13	0	65	532	315	4 978
C03DB Other potassium-sparing agents	15	18	18	22	16	31	<5	<5	7	6	141
C03DB01 amiloride	15	18	18	22	16	31	<5	<5	7	6	141
C03E DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION	35 388	34 026	31 692	28 452	25 722	66	14	704	11 796	13 208	4 600
C03EA Low-ceiling diuretics and potassium-sparing agents	35 388	34 026	31 692	28 452	25 722	66	14	704	11 796	13 208	4 600
C03EA01 hydrochlorothiazide and potassium-sparing agents	35 388	34 026	31 692	28 452	25 722	66	14	704	11 796	13 208	4 600
C03X OTHER DIURETICS	0	0	<5	<5	17	59	0	<5	8	8	734
C03XA Vasopressin antagonists	0	0	<5	<5	17	59	0	<5	8	8	734
C03XA01 tolvaptan	0	0	<5	<5	17	59	0	<5	8	8	734
C04 PERIPHERAL VASODILATORS	1 524	1 340	1 165	1 019	926	45	0	22	265	639	965
C04A PERIPHERAL VASODILATORS	1 524	1 340	1 165	1 019	926	45	0	22	265	639	965
C04AD Purine derivatives	1 520	1 334	1 160	1 018	925	45	0	22	264	639	961
C04AD03 pentoxifylline	1 520	1 334	1 160	1 018	925	45	0	22	264	639	961
C04AX Other peripheral vasodilators	<5	6	5	<5	<5	100	0	0	<5	0	4

ATC group C

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
C04AX02 phenoxybenzamine	<5	6	5	<5	<5	100	0	0	<5	0	4
C05 VASOPROTECTIVES	55 015	56 622	59 372	62 337	61 591	57	732	25 015	24 911	10 933	11 731
C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	49 681	51 350	54 315	56 902	56 107	56	686	24 078	22 582	8 761	9 887
C05AA Corticosteroids	48 507	49 667	52 387	54 740	53 649	56	648	22 920	21 590	8 491	7 242
C05AA01 hydrocortisone ¹⁾	9 924	9 649	9 749	9 666	11 127	54	219	4 491	4 495	1 922	2 194
C05AA04 prednisolone ¹⁾	40 337	41 682	44 303	46 731	45 152	56	441	19 553	18 131	7 027	5 048
C05AE Muscle relaxants	1 360	2 137	2 732	2 893	3 160	52	28	1 547	1 334	251	2 428
C05AE01 glyceryl trinitrate	1 360	2 137	2 732	2 893	3 160	52	28	1 547	1 334	251	2 428
C05AX Other agents for treatment of hemorrhoids and anal fissures for topical use	993	901	826	852	1 132	55	23	476	397	236	218
C05AX03 other preparations, combinations	963	885	807	832	1 110	55	23	459	392	236	180
C05B ANTIVARICOSE THERAPY	5 555	5 490	5 250	5 664	5 651	67	46	993	2 386	2 226	1 819
C05BA Heparins or heparinoids for topical use	5 551	5 486	5 245	5 654	5 646	67	46	992	2 382	2 226	1 816
C05BA01 organo-heparinoid ¹⁾	5 525	5 462	5 211	5 627	5 615	67	46	989	2 366	2 214	715
C05BA04 pentosan polysulfate sodium	26	25	34	27	31	90	0	<5	16	12	1 101
C05BB Sclerosing agents for local injection	<5	<5	5	10	5	60	0	<5	<5	0	3
C05BB02 polidocanol	<5	<5	5	10	5	60	0	<5	<5	0	3
C05C CAPILLARY STABILIZING AGENTS	0	0	0	0	48	83	0	<5	22	24	25
C05CA Bioflavonoids	0	0	0	0	<5	100	0	0	<5	<5	3
C05CA01 rutoside	0	0	0	0	<5	100	0	0	<5	<5	3
C05CX Other capillary stabilizing agents	0	0	0	0	45	82	0	<5	21	22	22
C05CX03 Hippocastani semen	0	0	0	0	45	82	0	<5	21	22	22
C07 BETA BLOCKING AGENTS	351 983	356 313	361 077	364 247	368 143	49	403	20 475	165 793	181 472	177 261
C07A BETA BLOCKING AGENTS	346 545	350 748	355 652	359 141	363 574	49	403	20 242	162 961	179 968	174 105
C07AA Beta blocking agents, non-selective	27 359	25 833	24 967	24 720	24 299	59	150	4 748	10 520	8 881	11 579
C07AA03 pindolol	31	28	28	26	20	70	0	<5	9	9	31
C07AA05 propranolol	16 403	16 540	16 856	17 413	17 616	64	140	4 549	8 127	4 800	7 350
C07AA06 timolol	1 337	636	13	9	10	90	<5	<5	<5	<5	18
C07AA07 sotalol	9 646	8 818	8 082	7 269	6 703	47	<5	185	2 415	4 099	4 061
C07AA12 nadolol	12	13	17	29	39	59	8	25	5	<5	119
C07AB Beta blocking agents, selective	299 225	305 475	311 151	315 104	320 560	49	240	13 546	143 471	163 303	145 695

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group C

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
C07AB02 metoprolol	244 333	250 953	256 754	261 252	266 647	48	221	11 348	120 115	134 963	124 642
C07AB03 atenolol	42 914	39 561	36 754	33 974	31 783	59	17	1 381	13 484	16 901	8 014
C07AB07 bisoprolol	15 502	18 388	21 004	23 115	25 371	46	<5	973	11 271	13 125	13 039
C07AG Alpha and beta blocking agents	24 683	24 389	23 887	23 378	22 876	45	24	2 305	10 823	9 724	16 831
C07AG01 labetalol	2 173	2 324	2 392	2 447	2 468	81	5	1 548	580	335	2 277
C07AG02 carvedilol	22 530	22 092	21 525	20 958	20 426	41	19	768	10 249	9 390	14 553
C07B BETA BLOCKING AGENTS AND THIAZIDES	5 991	6 057	5 815	5 485	5 212	55	0	270	3 163	1 779	3 156
C07BB Beta blocking agents, selective, and thiazides	5 991	6 057	5 815	5 485	5 212	55	0	270	3 163	1 779	3 156
C07BB07 bisoprolol and thiazides	5 991	6 057	5 815	5 485	5 212	55	0	270	3 163	1 779	3 156
C08 CALCIUM CHANNEL BLOCKERS	208 610	214 671	221 256	224 233	229 861	48	73	9 156	110 219	110 413	147 484
C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	185 199	192 742	200 625	205 165	211 928	48	65	8 392	103 503	99 968	129 687
C08CA Dihydropyridine derivatives	185 199	192 742	200 625	205 165	211 928	48	65	8 392	103 503	99 968	129 687
C08CA01 amlodipine	113 649	115 250	119 283	121 607	125 737	46	42	4 246	61 169	60 280	53 934
C08CA02 felodipine	17 106	16 692	16 309	16 008	15 415	51	0	382	6 738	8 295	11 371
C08CA03 isradipine	683	664	620	568	518	55	<5	9	212	296	955
C08CA05 nifedipine	28 302	29 940	31 649	32 708	34 526	49	22	2 577	16 871	15 056	40 428
C08CA06 nimodipine	36	32	44	51	56	54	0	13	39	<5	46
C08CA13 lercanidipine	28 958	33 491	36 038	37 460	39 034	51	<5	1 337	20 132	17 564	22 953
C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS	24 757	23 260	21 851	20 196	19 100	56	8	792	7 141	11 159	17 797
C08DA Phenylalkylamine derivatives	18 204	17 237	16 444	15 365	14 673	56	8	715	5 469	8 481	9 501
C08DA01 verapamil	18 204	17 237	16 444	15 365	14 673	56	8	715	5 469	8 481	9 501
C08DB Benzothiazepine derivatives	6 633	6 091	5 473	4 875	4 462	55	0	79	1 684	2 699	8 296
C08DB01 diltiazem	6 633	6 091	5 473	4 875	4 462	55	0	79	1 684	2 699	8 296
C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	452 974	473 388	498 501	517 053	534 991	48	437	28 634	291 236	214 684	697 864
C09A ACE INHIBITORS, PLAIN	123 584	125 439	130 265	132 249	134 580	41	375	7 268	63 202	63 735	58 498
C09AA ACE inhibitors, plain	123 584	125 439	130 265	132 249	134 580	41	375	7 268	63 202	63 735	58 498
C09AA01 captopril	3 500	3 233	2 858	2 509	2 178	45	160	90	713	1 215	3 975
C09AA02 enalapril	42 623	43 095	45 453	45 871	46 428	46	211	3 043	22 424	20 750	18 352
C09AA03 lisinopril	27 936	27 084	26 749	26 060	25 476	47	<5	1 448	12 445	11 581	11 081
C09AA05 ramipril	50 153	52 684	55 804	58 431	61 100	35	6	2 721	27 854	30 519	24 895

ATC group C

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
C09AA10 trandolapril	119	111	92	85	83	23	0	6	44	33	194
C09B ACE INHIBITORS, COMBINATIONS	35 757	35 260	35 985	35 727	35 191	49	<5	1 197	18 012	15 981	26 059
C09BA ACE inhibitors and diuretics	35 757	35 023	35 193	34 459	33 691	49	<5	1 106	17 141	15 443	24 254
C09BA02 enalapril and diuretics	20 161	20 154	20 520	20 244	20 030	48	<5	719	10 335	8 975	15 189
C09BA03 lisinopril and diuretics	15 625	14 889	14 697	14 237	13 702	49	0	388	6 828	6 486	9 066
C09BB ACE inhibitors and calcium channel blockers	0	259	820	1 307	1 533	45	0	93	890	550	1 804
C09BB02 enalapril and lercanidipine	0	259	820	1 307	1 533	45	0	93	890	550	1 804
C09C ANGIOTENSIN II ANTAGONISTS, PLAIN	162 375	168 742	180 140	187 470	197 152	51	86	14 228	111 285	71 553	256 856
C09CA Angiotensin II antagonists, plain	162 375	168 742	180 140	187 470	197 152	51	86	14 228	111 285	71 553	256 856
C09CA01 losartan	44 127	42 955	51 872	57 364	61 555	51	35	3 836	34 114	23 570	38 193
C09CA02 eprosartan	2 386	2 322	2 063	1 785	1 601	52	0	54	726	821	3 129
C09CA03 valsartan	20 016	20 380	20 748	22 462	25 144	47	0	1 656	14 555	8 933	29 423
C09CA04 irbesartan	23 422	22 328	21 419	20 347	19 729	50	<5	907	11 227	7 594	39 468
C09CA06 candesartan	67 536	74 704	78 234	79 742	83 507	53	47	7 451	47 274	28 735	130 946
C09CA07 telmisartan	5 222	5 866	5 988	5 977	5 825	44	0	338	3 423	2 064	12 375
C09CA08 olmesartan medoxomil	1 539	1 751	1 680	1 642	1 640	50	<5	145	1 013	479	3 322
C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS	172 489	184 232	195 551	202 970	210 260	49	<5	8 297	122 298	79 664	356 224
C09DA Angiotensin II antagonists and diuretics	168 660	174 848	179 893	180 857	181 843	51	<5	6 478	104 187	71 177	277 942
C09DA01 losartan and diuretics	64 598	63 952	66 088	66 981	67 478	53	<5	2 219	37 118	28 140	49 994
C09DA02 eprosartan and diuretics	1 840	2 042	1 924	1 774	1 661	48	0	54	889	718	3 569
C09DA03 valsartan and diuretics	24 767	25 424	25 643	25 522	25 924	49	0	992	15 106	9 826	43 312
C09DA04 irbesartan and diuretics	31 288	31 418	30 818	29 807	28 619	50	0	794	16 166	11 659	66 770
C09DA06 candesartan and diuretics	43 908	48 685	51 649	52 876	54 252	50	0	2 272	32 537	19 443	102 210
C09DA07 telmisartan and diuretics	3 320	3 724	3 991	3 940	3 818	41	0	146	2 337	1 335	9 779
C09DA08 olmesartan medoxomil and diuretics	813	1 144	1 124	1 146	1 116	49	0	42	700	374	2 308
C09DB Angiotensin II antagonists and calcium channel blockers	5 351	11 764	16 484	18 665	21 164	41	0	1 350	13 400	6 414	46 202
C09DB01 valsartan and amlodipine	5 351	11 764	16 483	18 494	20 892	41	0	1 323	13 226	6 343	45 572
C09DB02 olmesartan medoxomil and amlodipine	0	0	<5	185	277	40	0	28	177	72	630
C09DX Angiotensin II antagonists, other combinations	0	0	4 017	8 368	12 224	38	0	775	7 855	3 594	32 080
C09DX01 valsartan, amlodipine and hydrochlorothiazide	0	0	4 017	8 368	12 224	38	0	775	7 855	3 594	32 080

ATC group C

ATC level		2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
		Number of individuals						Number of individuals per age group				
		<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
C09X	OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	47	93	93	84	78	40	0	<5	50	24	226
C09XA	Renin-inhibitors	47	93	93	84	78	40	0	<5	50	24	226
C09XA02	aliskiren	47	93	92	84	78	40	0	<5	50	24	226
C09XA52	aliskiren and hydrochlorothiazide	0	0	<5	0	0	-	0	0	0	0	0
C10	LIPID MODIFYING AGENTS	426 023	452 790	478 362	495 451	503 792	46	140	21 097	277 221	205 334	425 910
C10A	LIPID MODIFYING AGENTS, PLAIN	425 411	452 090	477 639	494 337	501 407	46	140	21 008	275 643	204 616	414 305
C10AA	HMG CoA reductase inhibitors	421 813	447 810	472 860	488 704	494 804	46	124	20 233	271 846	202 601	312 627
C10AA01	simvastatin	348 045	356 768	349 782	336 480	314 174	47	21	10 729	161 726	141 698	129 817
C10AA02	lovastatin	1 715	1 424	1 260	1 134	1 048	57	0	16	408	624	1 633
C10AA03	pravastatin	23 056	22 329	21 340	20 827	20 320	49	6	468	9 745	10 101	22 197
C10AA04	fluvastatin	7 268	7 465	7 510	7 474	7 443	47	<5	544	4 303	2 595	12 232
C10AA05	atorvastatin	59 209	79 686	112 783	140 852	166 510	44	74	8 714	104 759	52 963	126 152
C10AA07	rosuvastatin	355	571	2 115	4 420	6 708	45	23	738	4 584	1 363	20 595
C10AB	Fibrates	328	317	331	317	314	30	<5	61	223	29	1 749
C10AB02	bezafibrate	70	64	58	49	50	36	0	<5	39	7	174
C10AB04	gemfibrozil	105	101	104	103	93	28	0	14	66	13	920
C10AB05	fenofibrate	156	154	170	167	173	29	<5	43	120	9	656
C10AC	Bile acid sequestrants	2 134	2 090	2 238	2 413	2 438	54	13	491	1 323	611	7 818
C10AC01	colestyramine	1 563	1 566	1 686	1 817	1 795	58	12	426	904	453	2 274
C10AC02	colestipol	384	308	292	273	280	44	<5	15	156	108	743
C10AC04	colesevelam	204	237	280	351	406	43	0	57	291	58	4 801
C10AD	Nicotinic acid and derivatives	234	285	396	391	350	26	0	46	264	40	1 451
C10AD02	nicotinic acid	216	218	153	107	30	30	0	5	22	<5	473
C10AD06	acipimox	20	11	12	9	9	22	0	0	8	<5	50
C10AD52	nicotinic acid, combinations	0	69	249	301	314	25	0	42	236	36	929
C10AX	Other lipid modifying agents	12 591	14 589	16 505	19 315	22 152	43	<5	1 758	14 895	5 495	90 659
C10AX06	omega-3-triglycerides incl. other esters and acids	2 417	2 754	3 038	3 591	3 988	30	<5	585	2 851	550	25 873
C10AX09	ezetimibe	10 425	12 126	13 819	16 166	18 703	45	<5	1 215	12 471	5 015	64 786
C10B	LIPID MODIFYING AGENTS, COMBINATIONS	<5	0	81	1 370	2 661	40	0	138	1 791	732	9 017
C10BA	HMG CoA reductase inhibitors in combination with other lipid modifying agents	<5	0	81	1 370	2 661	40	0	138	1 791	732	9 017
C10BA02	simvastatin and ezetimibe	<5	0	81	1 370	2 661	40	0	138	1 791	732	9 017

2.8 ATC group D – Dermatologicals

ATC level		2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
		Number of individuals						Number of individuals per age group				
		<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
D	DERMATOLOGICALS	589 450	587 812	611 440	624 493	628 955	54	76 390	237 819	212 640	102 106	235 358
D01	ANTIFUNGALS FOR DERMATOLOGICAL USE	113 854	111 682	116 703	120 515	120 328	47	11 029	44 592	44 169	20 538	30 895
D01A	ANTIFUNGALS FOR TOPICAL USE	98 958	96 750	101 082	105 109	104 211	48	10 771	38 328	36 418	18 694	16 014
D01AA	Antibiotics	3 467	219	54	52	36	81	<5	20	7	5	7
D01AA01	nystatin	3 467	219	54	52	36	81	<5	20	7	5	7
D01AC	Imidazole and triazole derivatives	73 508	74 998	79 238	83 294	82 436	48	8 769	29 659	28 475	15 533	10 378
D01AC01	clotrimazole ¹⁾	8 369	8 811	9 516	8 746	7 893	52	1 076	2 754	2 109	1 954	1 185
D01AC02	miconazole ¹⁾	1 927	1 880	2 121	2 193	1 909	46	256	664	645	344	309
D01AC03	econazole ¹⁾	2 197	2 177	1 119	588	691	61	34	127	230	300	88
D01AC08	keetoconazole ¹⁾	15 005	14 992	15 121	16 258	16 162	41	1 023	7 241	5 739	2 159	2 691
D01AC20	combinations ¹⁾	49 639	50 909	55 208	59 481	59 415	49	6 671	20 211	20 957	11 576	6 105
D01AC60	bifonazole, combinations	<5	0	0	0	0	-	0	0	0	0	0
D01AE	Other antifungals for topical use	24 966	24 330	24 671	24 755	24 760	46	2 250	9 785	9 000	3 725	5 628
D01AE02	methylrosaniline ¹⁾	716	696	694	751	687	54	172	168	188	159	75
D01AE14	ciclopirox ¹⁾	14	<5	<5	13	47	55	6	23	12	6	9
D01AE15	terbinafine ¹⁾	17 148	16 909	17 514	17 812	18 128	43	1 804	7 785	5 984	2 555	3 074
D01AE16	amorolfine	7 481	7 081	6 829	6 520	6 226	55	286	1 929	2 959	1 052	2 470
D01B	ANTIFUNGALS FOR SYSTEMIC USE	18 326	18 300	19 232	19 020	19 723	40	375	7 809	9 301	2 238	14 881
D01BA	Antifungals for systemic use	18 326	18 300	19 232	19 020	19 723	40	375	7 809	9 301	2 238	14 881
D01BA01	griseofulvin	16	19	15	19	21	48	19	<5	0	0	10
D01BA02	terbinafine	18 314	18 285	19 222	19 009	19 705	40	359	7 807	9 301	2 238	14 871
D02	EMOLLIENTS AND PROTECTIVES	1 750	1 841	2 223	2 338	2 503	51	381	848	803	471	921
D02A	EMOLLIENTS AND PROTECTIVES	1 750	1 841	2 223	2 338	2 503	51	381	848	803	471	921
D02AB	Zinc products¹⁾	10	6	10	15	6	50	0	<5	<5	<5	1
D02AE	Carbamide products	459	670	859	971	1 173	53	146	438	338	251	610
D02AE01	carbamide ¹⁾	459	670	859	971	1 173	53	146	438	338	251	610
D02AF	Salicylic acid preparations	1 197	1 048	1 229	1 206	1 154	50	128	373	449	204	176
D02AX	Other emollients and protectives	93	125	148	168	221	49	122	51	29	19	134
D03	PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS	143	91	60	68	80	49	5	10	33	32	20
D03A	CICATRIZANTS	143	91	60	68	80	49	5	10	33	32	20

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group D

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
D03AA Cod-liver oil ointments	54	7	0	0	0	-	0	0	0	0	0
D03AX Other cicatrizants	89	84	60	68	80	49	5	10	33	32	20
D03AX03 dexpanthenol	89	84	60	68	80	49	5	10	33	32	20
D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.	3 195	3 676	3 871	4 259	4 297	66	497	1 723	1 181	896	829
D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.	3 195	3 676	3 871	4 259	4 297	66	497	1 723	1 181	896	829
D04AA Antihistamines for topical use	<5	<5	0	<5	8	75	<5	<5	<5	<5	6
D04AA02 mepyramine	<5	0	0	0	0	-	0	0	0	0	0
D04AA13 dimetindene	<5	<5	0	<5	8	75	<5	<5	<5	<5	6
D04AB Anesthetics for topical use	2 094	2 637	2 798	3 097	3 650	68	373	1 586	1 034	657	751
D04AB01 lidocaine ¹⁾	2 094	2 637	2 798	3 097	3 650	68	373	1 586	1 034	657	751
D04AX Other antipruritics	1 119	1 052	1 093	1 169	662	57	125	141	154	242	73
D05 ANTIPSORIATICS	26 570	27 497	29 930	31 269	31 690	45	487	9 644	16 319	5 240	46 972
D05A ANTIPSORIATICS FOR TOPICAL USE	25 328	26 165	28 654	29 921	30 239	45	481	9 337	15 400	5 021	39 093
D05AA Tars¹⁾	1 007	980	1 044	1 017	900	60	75	279	325	221	230
D05AC Antracen derivatives	15	11	9	7	<5	33	<5	0	<5	<5	1
D05AC01 dithranol	15	11	9	7	<5	33	<5	0	<5	<5	1
D05AD Psoralens for topical use	10	6	<5	0	0	-	0	0	0	0	0
D05AD01 trioxysalen	10	6	<5	0	0	-	0	0	0	0	0
D05AX Other antipsoriatics for topical use	24 515	25 359	27 804	29 076	29 508	45	406	9 125	15 155	4 822	38 862
D05AX02 calcipotriol	9 932	8 744	8 029	5 640	2 223	40	24	514	1 225	460	1 103
D05AX03 calcitriol	1 125	1 084	1 127	1 092	1 170	49	30	322	629	189	827
D05AX52 calcipotriol, combinations	17 660	19 312	22 343	25 237	27 735	45	376	8 729	14 178	4 452	36 933
D05B ANTIPSORIATICS FOR SYSTEMIC USE	1 765	1 886	1 880	1 943	2 106	43	6	487	1 302	311	7 880
D05BA Psoralens for systemic use	35	34	40	32	26	46	0	9	13	<5	23
D05BA02 methoxsalen	29	33	35	29	26	46	0	9	13	<5	23
D05BA03 bergapten	7	<5	5	<5	0	-	0	0	0	0	0
D05BB Retinoids for treatment of psoriasis	1 709	1 819	1 808	1 866	2 019	43	6	454	1 257	302	5 447
D05BB02 acitretin	1 709	1 819	1 808	1 866	2 019	43	6	454	1 257	302	5 447
D05BX Other antipsoriatics for systemic use	25	41	42	50	71	39	0	28	38	5	2 410
D05BX51 fumaric acid derivatives, combinations	25	41	42	50	71	39	0	28	38	5	2 410

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group D

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE	108 179	105 182	111 213	113 829	110 220	58	13 393	44 931	34 713	17 183	22 713
D06A ANTIBIOTICS FOR TOPICAL USE	57 269	54 026	58 829	61 008	58 208	56	11 228	18 497	18 127	10 356	5 123
D06AA Tetracycline and derivatives	2 844	2 682	2 729	2 878	2 916	56	374	868	1 077	597	368
D06AA02 chlortetracycline	16	23	19	28	27	44	<5	12	10	<5	9
D06AA03 oxytetracycline	2 828	2 659	2 710	2 850	2 891	56	373	856	1 069	593	359
D06AX Other antibiotics for topical use	54 594	51 499	56 239	58 299	55 451	56	10 874	17 683	17 102	9 792	4 755
D06AX01 fusidic acid	52 409	49 106	53 684	55 137	52 776	56	9 914	16 874	16 584	9 404	4 367
D06AX05 bacitracin	1 972	1 802	1 739	2 378	1 961	50	614	611	396	340	241
D06AX09 mupirocin	19	17	14	31	40	60	9	20	8	<5	8
D06AX13 retapamulin	374	746	1 008	1 005	867	56	407	227	155	78	138
D06B CHEMOTHERAPEUTICS FOR TOPICAL USE	52 801	53 024	54 414	54 942	53 937	61	2 300	27 197	17 220	7 220	17 590
D06BA Sulfonamides	3 491	3 202	3 373	3 410	3 549	53	605	1 199	1 083	662	526
D06BA01 silver sulfadiazine	3 491	3 202	3 373	3 410	3 549	53	605	1 199	1 083	662	526
D06BB Antivirals	41 381	41 307	41 885	40 813	38 973	59	1 515	21 842	10 765	4 851	15 188
D06BB03 aciclovir ¹⁾	20 673	20 098	19 696	18 274	16 749	72	1 051	7 824	6 245	1 629	2 803
D06BB04 podophyllotoxin	13 170	13 402	13 567	13 738	12 921	46	135	11 559	1 170	57	2 761
D06BB06 penciclovir ¹⁾	5 031	4 000	3 349	2 738	1 885	70	82	761	792	250	378
D06BB10 imiquimod	3 407	4 705	6 196	7 040	8 404	53	257	2 515	2 682	2 950	9 246
D06BB11 docosanol	6	<5	0	0	0	-	0	0	0	0	0
D06BX Other chemotherapeutics	8 151	8 721	9 426	11 017	11 719	68	185	4 275	5 500	1 759	1 875
D06BX01 metronidazole	8 151	8 721	9 426	11 017	11 719	68	185	4 275	5 500	1 759	1 875
D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	349 460	347 215	359 113	361 203	363 604	54	50 502	112 261	131 827	69 014	80 509
D07A CORTICOSTEROIDS, PLAIN	285 574	286 433	299 004	300 645	309 061	55	45 086	94 992	110 582	58 401	62 344
D07AA Corticosteroids, weak (group I)	27 439	26 763	28 352	28 849	29 943	55	12 978	8 072	5 282	3 611	3 513
D07AA02 hydrocortisone ¹⁾	27 439	26 763	28 352	28 849	29 943	55	12 978	8 072	5 282	3 611	3 513
D07AB Corticosteroids, moderately potent (group II)	95 779	96 512	102 087	102 552	101 418	55	23 183	30 541	30 188	17 506	13 653
D07AB02 hydrocortisone butyrate	64 610	64 889	67 907	70 580	96 967	55	22 518	29 405	28 446	16 598	13 016
D07AB08 desonide	32 620	33 079	35 702	33 950	5 819	52	908	1 444	2 269	1 198	636
D07AC Corticosteroids, potent (group III)	154 910	153 609	158 099	157 096	164 253	54	16 662	52 893	61 606	33 092	33 425
D07AC01 betamethasone	52 701	50 086	52 441	54 076	58 061	54	3 624	18 633	23 359	12 445	7 710

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group D

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
D07AC03 desoximetasone	13 814	13 853	13 701	12 998	12 647	53	533	3 490	5 549	3 075	4 816
D07AC04 fluocinolone acetonide	7 162	6 572	6 500	6 008	5 844	53	194	1 237	2 652	1 761	1 065
D07AC08 fluocinonide	872	792	724	670	601	50	9	113	307	172	113
D07AC13 mometasone	71 674	74 342	78 920	78 528	82 615	54	10 993	27 724	28 672	15 226	16 551
D07AC17 fluticasone	16 949	15 468	13 078	11 896	12 032	54	1 965	4 076	3 843	2 148	3 169
D07AD Corticosteroids, very potent (group IV)	48 233	49 945	52 825	54 584	57 304	56	1 779	17 359	26 948	11 218	11 753
D07AD01 clobetasol	48 233	49 945	52 825	54 584	57 304	56	1 779	17 359	26 948	11 218	11 753
D07B CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS	41 193	37 064	36 056	37 823	29 301	49	3 019	9 020	11 115	6 147	3 019
D07BB Corticosteroids, moderately potent, combinations with antiseptics	29 399	17 785	15 445	15 218	194	51	37	49	62	46	24
D07BB02 desonide and antiseptics	13 954	17 619	15 445	15 217	194	51	37	49	62	46	24
D07BB03 triamcinolone and antiseptics	<5	0	0	<5	0	-	0	0	0	0	0
D07BB04 hydrocortisone butyrate and antiseptics	15 968	193	0	0	0	-	0	0	0	0	0
D07BC Corticosteroids, potent, combinations with antiseptics	13 184	20 114	21 373	23 508	29 135	49	2 988	8 975	11 063	6 109	2 996
D07BC01 betamethasone and antiseptics	9 686	17 301	18 864	21 243	26 780	49	2 789	8 334	10 054	5 603	2 770
D07BC02 fluocinolone acetonide and antiseptics	3 872	2 918	2 601	2 358	2 463	48	206	670	1 054	533	226
D07C CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS	26 606	26 357	26 769	26 158	26 106	54	5 096	7 674	8 539	4 797	3 243
D07CA Corticosteroids, weak, combinations with antibiotics	25 877	26 351	26 768	26 158	26 102	54	5 096	7 672	8 538	4 796	3 242
D07CA01 hydrocortisone and antibiotics	25 877	26 351	26 768	26 158	26 102	54	5 096	7 672	8 538	4 796	3 242
D07CC Corticosteroids, potent, combinations with antibiotics	768	6	<5	0	5	60	0	<5	<5	<5	2
D07CC01 betamethasone and antibiotics	768	6	<5	0	<5	50	0	<5	<5	<5	1
D07CC05 fluocinonide and antibiotics	0	0	0	0	<5	100	0	<5	0	0	1
D07X CORTICOSTEROIDS, OTHER COMBINATIONS	27 135	26 626	26 439	25 912	26 232	49	784	8 835	11 591	5 022	11 902
D07XB Corticosteroids, moderately potent, other combinations	556	0	0	0	0	-	0	0	0	0	0
D07XB02 triamcinolone	556	0	0	0	0	-	0	0	0	0	0

ATC group D

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
D07XC Corticosteroids, potent, other combinations	26 672	26 626	26 439	25 912	26 232	49	784	8 835	11 591	5 022	11 902
D07XC01 betamethasone	26 672	26 626	26 439	25 912	26 232	49	784	8 835	11 591	5 022	11 902
D08 ANTISEPTICS AND DISINFECTANTS	18 291	18 621	19 280	19 088	19 058	59	3 079	7 658	6 135	2 186	2 560
D08A ANTISEPTICS AND DISINFECTANTS¹⁾	18 291	18 621	19 280	19 088	19 058	59	3 079	7 658	6 135	2 186	2 560
D08AB Aluminium agents	265	285	278	338	411	47	142	110	114	45	64
D08AC Biguanides and amidines	14 689	15 171	15 910	15 689	15 682	61	2 121	6 676	5 235	1 650	2 012
D08AC01 dibrompropamide ¹⁾	5 342	5 115	5 282	3 802	4 662	52	1 562	1 420	918	762	518
D08AC02 chlorhexidine ¹⁾	9 595	10 315	10 883	12 095	11 235	65	651	5 333	4 341	910	1 494
D08AG Iodine products	53	54	74	62	85	54	11	11	28	35	18
D08AG01 iodine/octylphenoxyglycoether ¹⁾	15	5	<5	0	0	-	0	0	0	0	0
D08AG02 povidone-iodine	0	20	31	26	56	48	<5	8	17	27	15
D08AG03 iodine ¹⁾	38	29	42	36	29	66	7	<5	11	8	3
D08AJ Quaternary ammonium compounds	147	135	151	173	131	49	17	31	40	43	52
D08AJ03 cetylpyridinium ¹⁾	147	135	151	173	131	49	17	31	40	43	52
D08AL Silver compounds	0	0	<5	<5	<5	50	<5	<5	<5	0	3
D08AL01 silver nitrate	0	0	<5	<5	<5	50	<5	<5	<5	0	3
D08AX Other antiseptics and disinfectants	3 292	3 131	3 022	2 970	2 884	52	847	865	740	432	411
D08AX01 hydrogen peroxide ¹⁾	2 223	2 059	1 829	1 740	1 657	54	517	523	385	232	182
D08AX06 potassium permanganate ¹⁾	1 090	1 095	1 207	1 240	1 238	50	335	346	357	200	230
D09 MEDICATED DRESSINGS	2 077	1 937	1 913	1 848	1 761	57	120	390	582	669	503
D09A Medicated dressings with anti-infectives	2 077	1 937	1 913	1 848	1 678	58	118	385	555	620	235
D09AA02 fusidic acid	2 077	1 937	1 913	1 848	1 678	58	118	385	555	620	235
D09AB Zinc bandages	0	0	0	0	84	51	<5	5	27	50	269
D09AB01 zinc bandage without supplements	0	0	0	0	84	51	<5	5	27	50	269
D10 ANTI-ACNE PREPARATIONS	48 261	51 472	54 317	60 886	66 617	65	4 033	49 171	10 623	2 790	33 690
D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE	45 378	47 904	50 390	56 374	61 511	66	3 923	44 426	10 383	2 779	18 100
D10AD Retinoids for topical use in acne	21 578	24 388	27 056	32 174	35 937	66	2 581	27 519	4 340	1 497	11 184
D10AD01 tretinoin	9 451	9 888	10 547	10 221	10 953	78	382	5 859	3 403	1 309	1 092
D10AD02 retinol	97	117	170	176	185	59	27	49	90	19	68
D10AD03 adapalene	10 560	8 449	7 113	6 598	5 944	65	488	4 883	427	146	1 291

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group D

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
D10AD53 adapalene, combinations	2 247	7 081	10 280	16 392	20 070	61	1 799	17 773	472	26	8 732
D10AE Peroxides	2 001	2 245	2 267	2 354	2 614	56	278	2 197	120	19	485
D10AE01 benzoyl peroxide ¹⁾	2 001	2 245	2 267	2 354	2 614	56	278	2 197	120	19	485
D10AF Antiinfectives for treatment of acne	16 763	16 046	16 076	16 714	17 015	65	1 211	12 810	2 561	433	3 390
D10AF01 clindamycin	16 729	16 009	16 054	16 677	16 976	65	1 208	12 779	2 556	433	3 369
D10AF02 erythromycin	39	41	24	38	41	63	<5	32	6	0	21
D10AX Other anti-acne preparations for topical use	13 521	13 292	13 285	13 815	14 915	69	669	9 559	3 820	867	3 041
D10AX03 azelaic acid	13 516	13 286	13 276	13 810	14 908	69	669	9 556	3 818	865	3 039
D10AX30 various combinations	7	7	11	5	7	71	0	<5	<5	<5	2
D10B ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE	4 227	5 153	5 748	6 609	7 829	47	219	7 275	317	18	15 590
D10BA Retinoids for treatment of acne	4 227	5 153	5 748	6 609	7 829	47	219	7 275	317	18	15 590
D10BA01 isotretinoin	4 227	5 153	5 748	6 609	7 829	47	219	7 275	317	18	15 590
D11 OTHER DERMATOLOGICAL PREPARATIONS	14 730	15 690	16 780	18 059	18 362	56	2 733	8 554	5 400	1 675	15 494
D11A OTHER DERMATOLOGICAL PREPARATIONS	14 730	15 690	16 780	18 059	18 362	56	2 733	8 554	5 400	1 675	15 494
D11AC Medicated shampoos	1 027	974	1 059	1 205	1 210	53	96	767	261	86	155
D11AC03 selenium compounds ¹⁾	1 027	974	1 059	1 205	1 210	53	96	767	261	86	155
D11AF Wart and anti-corn preparations¹⁾	1 375	1 498	1 926	2 068	1 956	52	829	735	293	99	301
D11AH Agents for dermatitis, excluding corticosteroids	9 500	10 323	10 818	12 174	12 626	57	1 796	5 814	4 024	992	10 534
D11AH01 tacrolimus	6 175	6 804	7 498	8 318	8 675	56	1 216	4 019	2 744	696	4 167
D11AH02 pimecrolimus	3 511	3 712	3 534	3 996	3 937	59	610	1 827	1 208	292	1 887
D11AH04 alitretinoin	0	0	0	80	221	55	0	77	137	7	4 480
D11AX Other dermatologicals	2 868	2 940	3 036	2 677	2 626	58	12	1 270	844	500	4 504
D11AX01 minoxidil	192	175	202	161	194	67	<5	108	68	16	119
D11AX10 finasteride	815	797	742	673	625	0	<5	481	139	<5	3 136
D11AX16 eflornithine	0	0	<5	126	296	99	5	189	81	21	208
D11AX18 diclofenac	1 697	1 702	1 604	1 132	709	51	0	16	286	407	772

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.9 ATC group G – Genito urinary system and sex hormones

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
G GENITO URINARY SYSTEM AND SEX HORMONES	692 715	703 423	721 846	745 367	760 023	81	3 267	420 137	234 951	101 668	862 673
G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS	30 558	30 699	32 068	33 034	33 485	99	113	24 192	7 673	1 507	7 200
G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS	30 558	30 699	32 068	33 034	33 485	99	113	24 192	7 673	1 507	7 200
G01AA Antibiotics	14 416	15 244	20 707	20 475	20 853	100	57	15 185	4 936	675	4 858
G01AA10 clindamycin	14 416	15 244	20 707	20 475	20 853	100	57	15 185	4 936	675	4 858
G01AD Organic acids	0	0	0	0	<5	50	0	0	<5	<5	4
G01AD02 acetic acid	0	0	0	0	<5	50	0	0	<5	<5	4
G01AF Imidazole derivatives	17 328	16 777	12 788	13 896	13 937	99	59	10 011	2 993	874	2 327
G01AF01 metronidazole	10 346	9 685	5 467	6 546	7 306	99	5	5 389	1 661	251	1 016
G01AF02 clotrimazole ¹⁾	5 028	5 326	5 614	5 949	5 591	99	33	3 916	1 090	552	1 068
G01AF04 miconazole ¹⁾	960	768	634	64	0	-	0	0	0	0	0
G01AF05 econazole ¹⁾	1 407	1 324	1 335	1 621	1 321	96	21	910	299	91	244
G01AX Other antiinfectives and antiseptics	18	6	<5	5	8	75	0	<5	<5	<5	10
G01AX03 pollicresulen	18	6	<5	5	8	75	0	<5	<5	<5	10
G02 OTHER GYNECOLOGICALS	42 936	44 047	45 250	46 752	47 182	99	11	41 429	5 569	173	49 314
G02A OXYTOCICS	26	12	15	11	7	100	0	6	<5	0	1
G02AB Ergot alkaloids	26	12	15	11	7	100	0	6	<5	0	1
G02AB01 methylergometrine	26	12	15	11	7	100	0	6	<5	0	1
G02B CONTRACEPTIVES FOR TOPICAL USE	40 634	41 674	42 960	44 425	45 010	100	9	40 127	4 868	6	46 372
G02BA Intrauterine contraceptives	24 795	24 803	24 858	25 084	25 460	100	<5	21 050	4 404	5	29 378
G02BA03 plastic IUD with progestogen	24 795	24 803	24 858	25 084	25 460	100	<5	21 050	4 404	5	29 378
G02BB Intravaginal contraceptives	16 010	17 064	18 263	19 552	19 776	100	8	19 298	469	<5	16 994
G02BB01 vaginal ring with progestogen and estrogen	16 010	17 064	18 263	19 552	19 776	100	8	19 298	469	<5	16 994
G02C OTHER GYNECOLOGICALS	2 381	2 458	2 367	2 414	2 261	77	<5	1 389	703	167	2 941
G02CB Prolactin inhibitors	2 381	2 458	2 367	2 414	2 261	77	<5	1 389	703	167	2 941
G02CB01 bromocriptine	1 247	1 312	1 226	1 248	1 052	90	<5	776	219	55	676
G02CB03 cabergoline	987	943	921	948	1 004	64	<5	513	393	97	1 395
G02CB04 quinagolide	189	302	284	260	244	75	0	127	100	17	869
G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	512 608	515 229	525 683	538 164	544 066	99	2 481	361 117	141 669	38 799	404 442

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group G

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
G03A HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE	304 423	307 262	315 379	321 843	326 053	100	1 102	312 156	12 783	12	174 580
G03AA Progestogens and estrogens, fixed combinations	212 576	214 962	221 431	225 448	227 640	100	931	222 120	4 580	9	127 009
G03AA07 levonorgestrel and ethinylestradiol	88 668	87 148	90 257	97 290	113 028	100	617	110 459	1 948	<5	51 249
G03AA09 desogestrel and ethinylestradiol	48 476	55 278	61 035	63 104	56 331	100	208	55 036	1 084	<5	20 112
G03AA12 drospirenone and ethinylestradiol	79 229	74 740	72 600	68 101	59 567	100	139	58 093	1 333	<5	48 648
G03AA13 norelgestromin and ethinylestradiol	9 016	8 924	8 982	9 054	8 927	100	7	8 688	232	0	6 392
G03AA14 nomegestrol and estradiol	0	0	0	0	965	100	<5	938	23	0	609
G03AB Progestogens and estrogens, sequential preparations	22 034	18 862	17 640	16 199	14 775	100	37	13 988	749	<5	5 765
G03AB03 levonorgestrel and ethinylestradiol	<5	<5	0	<5	0	-	0	0	0	0	0
G03AB04 norethisterone and ethinylestradiol	22 031	18 546	16 059	14 345	12 772	100	27	12 107	637	<5	3 933
G03AB08 dienogest and estradiol	0	326	1 624	1 895	2 042	100	11	1 916	115	0	1 833
G03AC Progestogens	87 693	89 490	92 562	96 460	100 145	100	185	92 305	7 653	<5	41 776
G03AC01 norethisterone	9 195	8 182	7 402	6 657	6 110	100	<5	5 244	862	0	1 400
G03AC03 levonorgestrel	193	141	115	<5	0	-	0	0	0	0	0
G03AC06 medroxyprogesterone	21 186	19 971	19 607	19 338	18 818	100	42	15 421	3 353	<5	4 482
G03AC08 etonogestrel	2 683	2 807	3 298	4 147	5 354	100	11	5 193	150	0	6 198
G03AC09 desogestrel	56 589	60 277	64 136	68 331	72 036	100	130	68 565	3 341	0	29 696
G03AD Emergency contraceptives	119	100	159	165	133	99	<5	125	6	0	31
G03AD01 levonorgestrel ¹⁾	119	99	79	87	81	99	<5	75	5	0	16
G03AD02 ulipristal	0	<5	80	78	53	100	<5	51	<5	0	15
G03B ANDROGENS	4 801	5 234	5 552	6 300	7 254	8	39	2 024	4 253	938	23 296
G03BA 3-oxoandrostens (4) derivatives	4 801	5 231	5 550	6 282	7 246	8	39	2 018	4 251	938	23 284
G03BA03 testosterone	4 801	5 231	5 550	6 282	7 246	8	39	2 018	4 251	938	23 284
G03BB 5-androstanon (3) derivatives	0	<5	<5	22	8	0	0	6	<5	0	12
G03BB01 mesterolone	0	<5	<5	22	8	0	0	6	<5	0	12
G03C ESTROGENS	109 009	112 831	116 574	121 775	123 225	100	164	5 092	83 765	34 204	76 662
G03CA Natural and semisynthetic estrogens, plain	99 840	104 463	108 549	114 351	116 281	100	164	4 896	77 713	33 508	66 685
G03CA01 ethinylestradiol	146	140	127	112	71	92	29	31	10	<5	444

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group G

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
G03CA03 estradiol	83 236	89 792	95 212	102 308	105 452	100	35	4 611	74 741	26 065	60 934
G03CA04 estriol ¹⁾	18 208	16 213	14 807	13 574	12 294	100	100	273	3 679	8 242	5 306
G03CA53 estradiol, combinations	0	<5	0	0	0	-	0	0	0	0	0
G03CA57 conjugated estrogens	5	<5	<5	<5	<5	100	0	0	<5	0	1
G03CX Other estrogens	10 007	9 183	8 841	8 224	7 702	100	0	241	6 704	757	9 977
G03CX01 tibolone	10 007	9 183	8 841	8 224	7 702	100	0	241	6 704	757	9 977
G03D PROGESTOGENS	40 529	37 790	38 788	39 101	40 006	100	1 163	29 256	9 424	163	18 257
G03DA Pregnen (4) derivatives	13 004	13 106	12 990	13 134	13 765	100	46	10 045	3 524	150	15 721
G03DA02 medroxyprogesterone	7 504	7 215	6 869	6 816	6 623	100	46	3 597	2 871	109	1 236
G03DA04 progesterone	5 588	5 987	6 240	6 465	7 279	100	0	6 564	674	41	14 485
G03DB Pregnadien derivatives	0	0	0	12	125	100	0	106	19	0	260
G03DB08 dienogest	0	0	0	12	125	100	0	106	19	0	260
G03DC Estren derivatives	28 284	25 413	26 536	26 716	26 878	100	1 117	19 696	6 051	14	2 276
G03DC02 norethisterone	28 284	25 413	26 536	26 716	26 878	100	1 117	19 696	6 051	14	2 276
G03F PROGESTOGENS AND ESTROGENS IN COMBINATION	47 395	45 758	44 082	43 373	41 772	100	0	2 559	35 895	3 318	31 630
G03FA Progestogens and estrogens, fixed combinations	37 409	36 195	35 051	34 460	33 173	100	0	784	29 233	3 156	25 837
G03FA01 norethisterone and estrogen	36 729	35 628	34 521	33 827	32 500	100	0	744	28 632	3 124	25 037
G03FA12 medroxyprogesterone and estrogen	474	527	715	764	795	100	0	44	712	39	799
G03FA15 dienogest and estrogen	280	233	<5	<5	0	-	0	0	0	0	0
G03FB Progestogens and estrogens, sequential preparations	11 369	10 851	10 322	10 082	9 636	100	0	1 855	7 608	173	5 793
G03FB05 norethisterone and estrogen	11 369	10 851	10 322	10 082	9 636	100	0	1 855	7 608	173	5 793
G03G GONADOTROPINS AND OTHER OVULATION STIMULANTS	10 938	11 093	10 343	10 634	10 433	95	0	10 162	270	<5	70 050
G03GA Gonadotropins	5 884	6 013	6 137	6 273	6 238	97	0	6 121	117	0	68 456
G03GA01 chorionic gonadotrophin	1 667	1 277	1 476	1 660	1 314	91	0	1 261	53	0	633
G03GA02 human menopausal gonadotrophin	1 405	1 601	1 540	1 842	2 059	100	0	2 031	28	0	19 441
G03GA04 urofollitropin	0	0	85	154	198	100	0	195	<5	0	1 870
G03GA05 follitropin alfa	1 631	1 770	1 743	1 799	1 936	99	0	1 917	19	0	19 886
G03GA06 follitropin beta	3 052	2 916	3 016	2 824	2 406	100	0	2 385	21	0	21 199
G03GA07 lutropin alfa	62	65	26	21	16	100	0	16	0	0	58
G03GA08 choriogonadotropin alfa	4 179	4 556	4 538	4 600	4 813	99	0	4 756	57	0	2 975

ATC group G

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
G03GA09 corifollitropin alfa	0	0	132	316	283	100	0	281	<5	0	1 983
G03GA30 combinations	<5	8	<5	<5	16	100	0	16	0	0	412
G03GB Ovulation stimulants, synthetic	6 453	6 483	5 387	5 646	5 284	92	0	5 110	173	<5	1 595
G03GB02 clomifene	6 453	6 483	5 387	5 646	5 284	92	0	5 110	173	<5	1 595
G03H ANTIANDROGENS	16 971	16 171	16 764	17 326	18 020	99	114	17 430	384	92	7 421
G03HA Antiandrogens, plain	189	181	205	199	177	6	0	34	52	91	471
G03HA01 cyproterone	189	181	205	199	177	6	0	34	52	91	471
G03HB Antiandrogens and estrogens	16 792	15 999	16 565	17 130	17 849	100	114	17 402	332	<5	6 950
G03HB01 cyproterone and estrogen	16 792	15 999	16 565	17 130	17 849	100	114	17 402	332	<5	6 950
G03X OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	1 507	1 298	1 142	979	867	95	<5	24	303	539	2 545
G03XA Antigonadotropins and similar agents	51	50	49	50	51	31	<5	17	27	6	186
G03XA01 danazol	51	50	49	50	51	31	<5	17	27	6	186
G03XB Antiprogestogens	<5	0	<5	<5	6	100	0	5	<5	0	5
G03XB01 mifepristone	<5	0	<5	<5	6	100	0	5	<5	0	5
G03XC Selective estrogen receptor modulators	1 452	1 248	1 092	927	810	99	0	<5	275	533	2 354
G03XC01 raloxifene	1 452	1 248	1 092	927	810	99	0	<5	275	533	2 354
G04 UROLOGICALS	141 633	148 765	156 067	166 514	174 852	20	676	16 647	90 573	66 956	401 718
G04B UROLOGICALS	106 579	109 819	113 502	119 124	122 872	28	674	14 504	70 096	37 598	329 667
G04BA Acidifiers	<5	<5	0	0	0	-	0	0	0	0	0
G04BA01 ammonium chloride	<5	<5	0	0	0	-	0	0	0	0	0
G04BD Drugs for urinary frequency and incontinence	42 828	44 578	46 177	49 166	50 146	68	658	3 910	21 623	23 955	155 132
G04BD04 oxybutynin	1 690	1 480	1 504	1 516	1 523	66	181	341	552	449	8 932
G04BD07 tolterodine	21 577	18 355	15 679	14 238	12 760	72	392	729	4 831	6 808	39 966
G04BD08 solifenacin	15 757	17 349	19 877	21 934	22 310	68	89	1 822	9 998	10 401	63 355
G04BD10 darifenacin	5 430	5 630	5 126	4 566	4 054	71	<5	230	1 723	2 099	11 469
G04BD11 fesoterodine	1 818	5 380	7 639	10 610	12 938	66	22	1 082	6 028	5 806	31 410
G04BE Drugs used in erectile dysfunction	65 120	66 640	68 779	71 519	74 409	0	14	10 698	49 492	14 205	174 511
G04BE01 alprostadil	2 335	2 180	2 543	2 525	2 808	0	0	122	1 910	776	4 782
G04BE03 sildenafil	34 776	34 734	34 385	34 578	34 330	1	13	4 842	22 106	7 369	76 214
G04BE04 yohimbine	13	19	15	10	6	0	0	<5	<5	<5	3
G04BE08 tadalafil	23 981	26 821	29 887	32 997	36 616	0	<5	5 734	25 114	5 767	78 012

ATC group G

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
G04BE09 vardenafil	11 561	10 376	9 934	9 427	9 060	0	0	1 148	6 225	1 687	14 682
G04BE30 combinations	537	616	495	539	347	0	0	23	233	91	818
G04BX Other urologicals	10	10	11	11	13	46	<5	6	5	0	24
G04BX01 magnesium hydroxide	10	10	11	11	13	46	<5	6	5	0	24
G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	41 018	45 440	49 918	55 531	60 946	1	<5	2 335	24 889	33 720	72 051
G04CA Alpha-adrenoreceptor antagonists	31 502	34 945	38 363	43 210	48 567	1	<5	1 305	21 435	25 825	51 089
G04CA01 alfuzosin	777	536	498	451	398	2	0	12	164	222	575
G04CA02 tamsulosin	30 169	33 877	37 383	41 362	43 535	1	<5	1 201	19 205	23 127	40 357
G04CA03 terazosin	898	744	649	598	599	1	0	90	247	262	499
G04CA52 tamsulosin and dutasteride	0	0	<5	1 628	6 160	0	0	9	2 784	3 367	9 659
G04CB Testosterone-5-alpha reductase inhibitors	13 253	14 939	16 984	18 676	18 623	0	0	1 039	5 695	11 889	20 961
G04CB01 finasteride	10 194	12 852	15 194	17 122	17 266	0	0	1 008	5 340	10 918	17 033
G04CB02 dutasteride	4 054	2 331	1 939	1 661	1 421	0	0	37	368	1 016	3 928

2.10 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins

ATC group H

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70							
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	357 070	375 465	387 821	402 923	413 526	67	16 074	108 837	178 811	109 804	430 101
H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES	24 310	24 490	24 833	24 910	24 913	66	9 134	12 836	1 838	1 105	289 370
H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES	1 485	1 577	1 658	1 767	1 863	43	1 000	536	297	30	155 967
H01AA ACTH	<5	<5	<5	<5	0	-	0	0	0	0	0
H01AA02 tetracosactide	<5	<5	<5	<5	0	-	0	0	0	0	0
H01AB Thyrotropin	0	0	<5	7	10	100	0	7	<5	<5	96
H01AB01 thyrotropin	0	0	<5	7	10	100	0	7	<5	<5	96
H01AC Somatropin and somatropin agonists	1 470	1 555	1 631	1 735	1 822	43	1 000	517	277	28	146 901
H01AC01 somatropin	1 470	1 555	1 631	1 735	1 822	43	1 000	517	277	28	146 901
H01AX Other anterior pituitary lobe hormones and analogues	13	21	24	24	31	39	0	12	18	<5	8 970
H01AX01 pegvisomant	13	21	24	24	31	39	0	12	18	<5	8 970
H01B POSTERIOR PITUITARY LOBE HORMONES	18 859	18 807	18 982	19 167	18 668	62	8 167	8 519	1 160	822	36 432
H01BA Vasopressin and analogues	11 623	11 288	11 248	11 388	11 182	37	8 134	1 100	1 128	820	34 975
H01BA02 desmopressin	11 623	11 288	11 248	11 387	11 182	37	8 134	1 100	1 128	820	34 975
H01BA04 terlipressin	0	0	0	<5	0	-	0	0	0	0	0
H01BB Oxytocin and analogues	7 237	7 522	7 736	7 781	7 489	99	33	7 421	33	<5	1 457
H01BB02 oxytocin	7 237	7 522	7 736	7 781	7 489	99	33	7 421	33	<5	1 457
H01C HYPOTHALAMIC HORMONES	4 147	4 315	4 430	4 218	4 634	92	6	3 920	451	257	96 971
H01CA Gonadotropin-releasing hormones	3 101	2 829	2 314	2 076	2 357	100	0	2 333	24	0	6 100
H01CA02 nafarelin	3 101	2 829	2 314	2 076	2 357	100	0	2 333	24	0	6 100
H01CB Somatostatin and analogues	494	498	593	630	724	48	6	64	397	257	85 567
H01CB02 octreotide	406	398	472	497	567	49	6	50	319	192	63 186
H01CB03 lanreotide	118	118	137	148	184	47	<5	18	89	73	22 381
H01CC Anti-gonadotropin-releasing hormones	675	1 246	1 887	1 774	1 810	100	0	1 778	32	0	5 304
H01CC01 ganirelix	555	975	1 513	1 397	1 425	100	0	1 398	27	0	3 946
H01CC02 cetrorelix	149	298	481	413	406	100	0	401	5	0	1 358
H02 CORTICOSTEROIDS FOR SYSTEMIC USE	177 573	190 388	197 259	208 089	214 161	56	4 808	61 514	89 532	58 307	52 034

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70							
H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	177 454	190 244	197 075	207 853	213 941	56	4 808	61 470	89 404	58 259	51 959
H02AA Mineralocorticoids	1 160	1 178	1 223	1 267	1 322	57	86	400	601	235	352
H02AA02 fludrocortisone	1 160	1 178	1 223	1 267	1 322	57	86	400	601	235	352
H02AB Glucocorticoids	177 308	190 110	196 940	207 710	213 785	56	4 801	61 439	89 346	58 199	51 607
H02AB01 betamethasone	1 736	1 700	1 637	1 528	1 476	44	850	216	325	85	477
H02AB02 dexamethasone	1 931	2 118	2 552	2 786	3 188	48	81	317	1 730	1 060	3 400
H02AB04 methylprednisolone	10 159	10 745	10 812	11 020	11 087	53	49	2 697	5 753	2 588	4 016
H02AB06 prednisolone	136 459	143 524	152 240	159 525	167 532	58	3 184	38 719	71 992	53 637	30 851
H02AB07 prednisone	<5	<5	82	246	266	73	0	42	130	94	665
H02AB08 triamcinolone	29 048	34 538	32 179	35 711	33 504	49	534	20 119	10 990	1 861	4 686
H02AB09 hydrocortisone	422	437	481	549	596	68	57	237	262	40	1 298
H02AB10 cortisone	2 510	2 593	2 662	2 750	2 813	52	133	733	1 376	571	6 096
H02AB13 deflazacort	17	18	17	25	24	46	12	<5	7	<5	118
H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS	340	332	372	415	409	63	0	73	217	119	75
H02BX Corticosteroids for systemic use, combinations	340	332	372	415	409	63	0	73	217	119	75
H02BX01 methylprednisolone, combinations	340	332	372	415	409	63	0	73	217	119	75
H03 THYROID THERAPY	167 746	174 354	180 847	185 868	191 754	82	1 345	35 960	96 166	58 283	60 990
H03A THYROID PREPARATIONS	164 071	170 772	177 261	182 151	187 631	82	1 321	34 814	94 338	57 158	57 934
H03AA Thyroid hormones	164 071	170 772	177 261	182 151	187 631	82	1 321	34 814	94 338	57 158	57 934
H03AA01 levothyroxine sodium	163 750	170 484	176 910	181 641	186 965	82	1 312	34 580	93 978	57 095	53 255
H03AA02 liothyronine sodium	3 986	4 095	4 142	4 538	4 697	89	24	1 467	2 804	402	3 368
H03AA03 combinations of levothyroxine and liothyronine	404	429	328	549	698	90	<5	268	402	26	847
H03AA05 thyroid gland preparations	0	0	182	187	265	91	0	111	141	13	464
H03B ANTITHYROID PREPARATIONS	5 131	5 019	5 125	5 432	5 905	80	42	1 856	2 703	1 304	3 056
H03BA Thiouracils	552	552	521	651	578	88	<5	322	199	55	515
H03BA02 propylthiouracil	552	552	521	651	578	88	<5	322	199	55	515
H03BB Sulfur-containing imidazole derivatives	4 741	4 590	4 727	5 042	5 491	80	40	1 634	2 561	1 256	2 541
H03BB01 carbimazole	4 741	4 590	4 727	5 042	5 491	80	40	1 634	2 561	1 256	2 541
H04 PANCREATIC HORMONES	5 265	5 336	5 490	5 591	5 578	46	1 117	2 763	1 404	294	2 378
H04A GLYCOGENOLYTIC HORMONES	5 265	5 336	5 490	5 591	5 578	46	1 117	2 763	1 404	294	2 378
H04AA Glycogenolytic hormones	5 265	5 336	5 490	5 591	5 578	46	1 117	2 763	1 404	294	2 378

ATC group H

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
H04AA01 glucagon	5 265	5 336	5 490	5 591	5 578	46	1 117	2 763	1 404	294	2 378
H05 CALCIUM HOMEOSTASIS	644	748	803	916	1 084	58	<5	122	530	431	25 329
H05A PARATHYROID HORMONES AND ANALOGUES	225	237	263	294	377	78	0	42	212	123	10 629
H05AA Parathyroid hormones and analogues	225	237	263	294	377	78	0	42	212	123	10 629
H05AA02 teriparatide	201	213	253	281	367	78	0	41	206	120	10 125
H05AA03 parathyroid hormone	25	25	12	13	11	91	0	<5	7	<5	504
H05B ANTI-PARATHYROID AGENTS	421	511	541	623	707	48	<5	80	318	308	14 700
H05BA Calcitonin preparations	110	86	80	83	69	86	0	6	16	47	257
H05BA01 calcitonin (salmon synthetic)	110	86	80	83	69	86	0	6	16	47	257
H05BX Other anti-parathyroid agents	313	425	461	540	638	44	<5	74	302	261	14 443
H05BX01 cinacalcet	304	391	418	474	499	48	<5	52	225	221	11 888
H05BX02 paricalcitol	11	44	59	87	184	32	<5	28	95	60	2 555

2.11 ATC group J – Antiinfectives for systemic use

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
J ANTIINFECTIVES FOR SYSTEMIC USE	1 247 202	1 394 508	1 252 392	1 326 405	1 330 660	59	164 678	534 345	435 678	195 959	802 758
J01 ANTIBACTERIALS FOR SYSTEMIC USE	1 181 387	1 138 247	1 180 410	1 250 480	1 255 603	59	160 267	495 562	410 706	189 068	302 241
J01A TETRACYCLINES	172 668	161 073	167 058	188 189	206 035	57	2 310	89 333	81 214	33 178	38 006
J01AA Tetracyclines	172 668	161 073	167 058	188 189	206 035	57	2 310	89 333	81 214	33 178	38 006
J01AA02 doxycycline	135 973	124 472	129 848	148 596	164 478	57	1 208	59 937	71 981	31 352	21 044
J01AA04 lymecycline	12 748	13 528	14 771	19 412	22 455	56	598	15 971	4 918	968	11 417
J01AA06 oxytetracycline	5 605	5 244	5 164	2 625	<5	100	0	0	<5	0	0
J01AA07 tetracycline	20 731	20 086	19 710	21 378	22 112	56	561	15 333	5 148	1 070	5 364
J01AA08 minocycline	8	16	58	85	145	60	<5	80	55	7	165
J01AA12 tigecycline	6	<5	<5	<5	<5	0	0	0	<5	0	15
J01B AMPHENICOLS	<5	0	<5	0	0	-	0	0	0	0	0
J01BA Amphenicols	<5	0	<5	0	0	-	0	0	0	0	0
J01BA01 chloramphenicol	<5	0	<5	0	0	-	0	0	0	0	0
J01C BETA-LACTAM ANTIBACTERIALS, PENICILLINS	764 657	744 434	776 398	797 519	797 966	60	115 812	307 792	249 508	124 854	126 464
J01CA Penicillins with extended spectrum	281 587	283 578	301 349	309 246	316 692	74	37 215	101 129	103 654	74 694	51 536
J01CA01 ampicillin	35	19	39	24	56	48	<5	<5	17	35	49
J01CA02 pivampicillin	<5	0	0	<5	0	-	0	0	0	0	0
J01CA04 amoxicillin	123 464	118 112	127 541	131 915	136 857	55	32 583	32 194	45 007	27 073	18 664
J01CA08 pivmecillinam	169 588	176 709	186 059	189 598	193 245	87	4 956	72 303	63 251	52 735	32 802
J01CA11 mecillinam	8	<5	<5	<5	10	60	0	<5	6	<5	20
J01CE Beta-lactamase sensitive penicillins	475 189	444 689	458 149	466 195	455 868	54	82 487	190 020	134 499	48 862	43 429
J01CE01 benzylpenicillin	54	58	52	64	85	48	<5	7	21	56	50
J01CE02 phenoxymethylpenicillin	475 113	444 622	458 036	466 096	455 753	54	82 486	189 979	134 462	48 826	43 177
J01CE08 benzathine benzylpenicillin	46	40	99	83	74	20	<5	42	24	7	202
J01CF Beta-lactamase resistant penicillins	79 411	85 870	92 702	100 307	104 650	48	5 821	44 820	36 582	17 427	31 082
J01CF01 dicloxacillin	77 178	84 083	91 099	98 912	103 429	48	5 740	44 383	36 149	17 157	30 039
J01CF02 cloxacillin	2 683	2 153	1 929	1 714	1 515	49	73	549	533	360	1 005
J01CF05 flucloxacillin	19	32	22	17	18	56	13	<5	0	<5	38
J01CR Combinations of penicillins, incl. beta-lactamase inhibitors	52	120	135	114	178	58	101	16	24	37	418
J01CR02 amoxicillin and enzyme inhibitor	38	101	118	94	141	63	100	8	11	22	208
J01CR05 piperacillin and enzyme inhibitor	14	19	17	20	37	38	<5	8	13	15	210

ATC group J

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
J01D OTHER BETA-LACTAM ANTI-BACTERIALS	27 291	24 378	23 566	23 142	21 414	59	2 613	7 726	7 409	3 666	7 108
J01DB First-generation cephalosporins	26 924	23 974	23 116	22 707	20 600	60	2 567	7 454	7 112	3 467	3 012
J01DB01 cefalexin	26 914	23 952	23 099	22 698	20 581	60	2 565	7 452	7 107	3 457	2 987
J01DB03 cefalotin	10	23	17	9	20	35	<5	<5	6	10	25
J01DC Second-generation cephalosporins	67	63	71	72	102	65	0	9	30	63	85
J01DC02 cefuroxime	67	63	71	72	102	65	0	9	30	63	85
J01DD Third-generation cephalosporins	316	346	388	362	704	39	51	254	259	140	2 450
J01DD01 cefotaxime	30	39	42	47	104	33	<5	9	41	51	97
J01DD02 ceftazidime	57	71	80	57	68	44	9	32	16	11	993
J01DD04 ceftriaxone	148	155	190	177	194	39	33	68	60	33	532
J01DF Monobactams	12	11	13	8	9	33	0	9	0	0	330
J01DF01 aztreonam	12	11	13	8	9	33	0	9	0	0	330
J01DH Carbapenems	31	56	43	53	69	49	5	24	24	16	1 231
J01DH02 meropenem	30	46	39	40	58	43	5	21	21	11	929
J01DH03 ertapenem	<5	8	<5	13	10	70	0	<5	<5	<5	271
J01DH04 doripenem	0	0	0	0	<5	0	0	<5	0	0	16
J01DH51 imipenem and enzyme inhibitor	<5	<5	<5	<5	<5	100	0	0	0	<5	16
J01E SULFONAMIDES AND TRIMETHOPRIM	123 869	118 489	117 088	116 661	114 441	76	13 823	29 885	37 737	32 996	10 987
J01EA Trimethoprim and derivatives	93 084	88 503	86 108	84 347	80 448	85	7 941	22 070	25 930	24 507	6 502
J01EA01 trimethoprim	93 084	88 503	86 108	84 347	80 448	85	7 941	22 070	25 930	24 507	6 502
J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives	34 915	34 027	34 976	36 389	38 324	57	6 419	8 610	13 174	10 121	4 485
J01EE01 sulfamethoxazole and trimethoprim	34 915	34 027	34 976	36 389	38 324	57	6 419	8 610	13 174	10 121	4 485
J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS	310 374	283 337	301 083	349 643	342 304	57	49 242	150 578	111 227	31 257	57 070
J01FA Macrolides	272 328	244 678	257 943	304 755	294 690	57	44 865	131 285	93 726	24 814	45 411
J01FA01 erythromycin	142 942	123 140	129 188	170 347	152 191	58	31 380	59 993	47 071	13 747	18 895
J01FA02 spiramycin	3 575	3 033	2 794	2 744	2 645	61	50	1 000	1 247	348	435
J01FA09 clarithromycin	44 208	36 958	37 830	43 161	48 422	57	7 008	17 709	17 984	5 721	7 924
J01FA10 azithromycin	92 794	90 850	98 413	101 180	104 940	58	8 476	58 526	31 969	5 969	18 131
J01FA15 telithromycin	0	0	0	0	<5	50	0	<5	0	0	26
J01FF Lincosamides	46 064	45 847	51 154	53 678	56 442	54	5 396	23 391	20 346	7 309	11 659

ATC group J

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
J01FF01 clindamycin	46 064	45 847	51 154	53 678	56 442	54	5 396	23 391	20 346	7 309	11 659
J01G AMINOGLYCOSIDE ANTIBACTERIALS	278	289	273	252	253	53	69	106	63	15	10 214
J01GA Streptomycins	<5	0	0	0	0	-	0	0	0	0	0
J01GA01 streptomycin	<5	0	0	0	0	-	0	0	0	0	0
J01GB Other aminoglycosides	277	289	273	252	253	53	69	106	63	15	10 214
J01GB01 tobramycin	245	258	250	219	228	53	66	101	53	8	9 414
J01GB03 gentamicin	28	26	16	19	13	31	<5	<5	5	5	91
J01GB06 amikacin	6	5	10	14	12	67	<5	<5	5	<5	710
J01M QUINOLONE ANTIBACTERIALS	59 957	60 651	64 703	67 271	69 544	49	619	17 063	30 033	21 829	16 139
J01MA Fluoroquinolones	59 957	60 651	64 703	67 271	69 544	49	619	17 063	30 033	21 829	16 139
J01MA01 ofloxacin	3 012	2 717	2 516	2 242	2 055	42	<5	586	879	589	720
J01MA02 ciprofloxacin	57 335	58 298	62 445	65 193	67 597	50	618	16 320	29 301	21 358	14 504
J01MA12 levofloxacin	5	15	21	31	20	55	0	5	14	<5	194
J01MA14 moxifloxacin	65	71	142	205	260	52	0	238	20	<5	722
J01X OTHER ANTIBACTERIALS	47 875	51 069	54 632	58 484	59 424	84	1 431	11 722	20 462	25 809	36 253
J01XA Glycopeptide antibacterials	29	27	23	27	35	40	5	<5	12	15	333
J01XA01 vancomycin	23	26	21	24	35	40	5	<5	12	15	333
J01XA02 teicoplanin	6	<5	<5	<5	0	-	0	0	0	0	0
J01XB Polymyxins	60	64	55	63	72	53	14	31	20	7	2 136
J01XB01 colistin	60	64	55	63	72	53	14	31	20	7	2 136
J01XC Steroid antibacterials	865	711	757	663	591	54	22	222	208	139	411
J01XC01 fusidic acid	865	711	757	663	591	54	22	222	208	139	411
J01XD Imidazole derivatives	17	23	24	26	25	52	0	<5	14	8	59
J01XD01 metronidazole	17	23	24	26	25	52	0	<5	14	8	59
J01XE Nitrofurantoin derivatives	29 536	31 296	33 594	36 784	36 138	85	1 302	8 959	12 504	13 373	3 944
J01XE01 nitrofurantoin	29 536	31 296	33 594	36 784	36 138	85	1 302	8 959	12 504	13 373	3 944
J01XX Other antibacterials	21 193	23 185	24 887	25 921	28 054	84	125	3 273	9 631	15 025	29 370
J01XX01 fosfomycin	0	0	0	0	<5	100	0	0	<5	0	2
J01XX05 methenamine	21 023	22 969	24 644	25 647	27 808	84	123	3 226	9 520	14 939	20 441
J01XX08 linezolid	177	223	252	279	252	42	<5	50	110	90	8 862
J01XX09 daptomycin	0	0	0	0	<5	50	0	0	<5	<5	64
J02 ANTIMYCOTICS FOR SYSTEMIC USE	40 785	42 646	45 330	46 501	47 629	86	430	30 047	13 733	3 419	32 847
J02A ANTIMYCOTICS FOR SYSTEMIC USE	40 785	42 646	45 330	46 501	47 629	86	430	30 047	13 733	3 419	32 847
J02AA Antibiotics	<5	<5	0	<5	<5	0	<5	0	0	0	770

ATC group J

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
J02AA01 amphotericin B	<5	<5	0	<5	<5	0	<5	0	0	0	770
J02AB Imidazole derivatives	2 294	2 262	2 163	2 227	2 255	45	19	1 532	633	71	702
J02AB02 ketoconazole	2 294	2 262	2 163	2 227	2 255	45	19	1 532	633	71	702
J02AC Triazole derivatives	38 599	40 488	43 283	44 379	45 482	88	412	28 577	13 137	3 356	25 132
J02AC01 fluconazole	38 354	40 227	42 967	43 936	45 173	88	400	28 452	13 004	3 317	14 155
J02AC02 itraconazole	307	526	471	635	607	79	11	338	218	40	827
J02AC03 voriconazole	66	65	80	80	88	43	<5	20	46	18	6 705
J02AC04 posaconazole	7	9	22	40	55	45	<5	20	30	<5	3 445
J02AX Other antimycotics for systemic use	<5	<5	<5	5	6	33	<5	<5	<5	0	6 243
J02AX04 caspofungin	<5	<5	<5	<5	<5	50	0	<5	<5	0	1 487
J02AX05 micafungin	0	0	0	<5	<5	33	<5	<5	<5	0	4 113
J02AX06 anidulafungin	0	<5	0	<5	<5	0	0	0	<5	0	642
J04 ANTIMYCOBACTERIALS	917	1 336	1 573	1 645	1 775	49	98	780	552	345	5 181
J04A DRUGS FOR TREATMENT OF TUBERCULOSIS	486	931	1 126	1 194	1 353	52	90	692	360	211	4 821
J04AB Antibiotics	318	401	444	474	610	51	65	153	220	172	1 656
J04AB02 rifampicin	303	377	422	458	598	52	65	151	213	169	1 090
J04AB04 rifabutin	16	25	24	17	13	54	0	<5	8	<5	199
J04AB30 capreomycin	<5	0	0	0	<5	0	0	<5	0	0	367
J04AC Hydrazides	38	64	75	88	72	56	13	23	25	11	72
J04AC01 isoniazid	38	64	75	88	72	56	13	23	25	11	72
J04AD Thiocaramide derivatives	<5	<5	0	0	0	-	0	0	0	0	0
J04AD01 protionamide	<5	<5	0	0	0	-	0	0	0	0	0
J04AK Other drugs for treatment of tuberculosis	99	126	203	207	260	53	<5	138	81	37	876
J04AK01 pyrazinamide	13	20	28	37	44	61	<5	30	8	<5	100
J04AK02 ethambutol	97	115	198	200	247	53	<5	131	78	35	776
J04AM Combinations of drugs for treatment of tuberculosis	112	493	645	684	717	52	23	532	124	38	2 217
J04AM02 rifampicin and isoniazid	82	433	578	619	665	52	23	498	112	32	1 813
J04AM05 rifampicin, pyrazinamide and isoniazid	36	76	138	111	164	48	0	107	37	20	404
J04AM06 rifampicin, pyrazinamide, ethambutol and isoniazid	13	58	47	47	0	-	0	0	0	0	0
J04B DRUGS FOR TREATMENT OF LEPRO	433	405	449	454	422	40	8	88	192	134	360
J04BA Drugs for treatment of lepro	433	405	449	454	422	40	8	88	192	134	360
J04BA01 clofazimine	<5	0	0	0	0	-	0	0	0	0	0

ATC group J

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
J04BA02 dapson	432	405	449	454	422	40	8	88	192	134	360
J05 ANTIVIRALS FOR SYSTEMIC USE	24 595	304 693	31 034	32 722	34 699	61	722	17 154	12 730	4 093	393 420
J05A DIRECT ACTING ANTIVIRALS	24 595	304 693	31 034	32 722	34 699	61	722	17 154	12 730	4 093	393 420
J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors	21 809	23 038	24 889	27 463	29 957	64	591	14 753	10 784	3 829	54 696
J05AB01 aciclovir	9 892	10 264	11 316	12 172	12 627	67	415	6 485	4 105	1 622	4 958
J05AB04 ribavirin	803	770	705	760	898	35	<5	448	441	5	20 203
J05AB06 ganciclovir	<5	0	<5	<5	0	-	0	0	0	0	0
J05AB09 famciclovir	0	0	0	0	<5	0	0	<5	0	0	5
J05AB11 valaciclovir	11 348	12 244	13 096	14 811	16 758	64	180	8 128	6 235	2 215	14 842
J05AB12 cidofovir	<5	0	0	0	0	-	0	0	0	0	0
J05AB14 valganciclovir	223	246	283	319	348	36	<5	90	210	46	14 687
J05AD Phosphonic acid derivatives	0	0	0	0	<5	100	0	0	<5	0	21
J05AD01 foscarnet	0	0	0	0	<5	100	0	0	<5	0	21
J05AE Protease inhibitors	588	728	860	1 105	1 531	36	<5	766	742	19	113 609
J05AE01 saquinavir	17	11	9	7	6	17	0	<5	<5	<5	295
J05AE02 indinavir	11	6	<5	<5	<5	100	0	<5	0	0	13
J05AE03 ritonavir	379	499	604	720	843	38	<5	471	359	9	3 261
J05AE07 fosamprenavir	<5	<5	<5	<5	<5	0	0	<5	<5	0	88
J05AE08 atazanavir	517	660	780	920	1 060	36	<5	580	461	16	40 375
J05AE09 tipranavir	<5	<5	0	0	0	-	0	0	0	0	0
J05AE10 darunavir	48	55	70	91	129	28	<5	40	87	<5	8 352
J05AE11 telaprevir	0	0	0	16	94	37	0	32	61	<5	21 007
J05AE12 boceprevir	0	0	0	76	255	37	0	117	138	0	40 219
J05AF Nucleoside and nucleotide reverse transcriptase inhibitors	394	388	399	420	478	37	17	217	236	8	18 368
J05AF01 zidovudine	55	41	34	35	29	38	<5	18	9	<5	588
J05AF02 didanosine	77	53	37	22	17	41	0	7	8	<5	301
J05AF04 stavudine	28	13	13	<5	0	-	0	0	0	0	0
J05AF05 lamivudine	145	117	100	93	89	44	15	28	45	<5	960
J05AF06 abacavir	46	48	51	54	58	50	13	25	20	0	1 418
J05AF07 tenofovir disoproxil	148	158	163	191	222	36	<5	113	106	<5	7 881
J05AF08 adefovir dipivoxil	38	33	22	15	11	36	0	<5	9	0	591
J05AF09 emtricitabine	13	11	11	9	6	33	0	<5	<5	0	136

ATC group J

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
J05AF10 entecavir	56	87	106	126	157	37	0	77	76	<5	6 491
J05AF11 telbivudine	6	8	5	<5	0	-	0	0	0	0	0
J05AG Non-nucleoside reverse transcriptase inhibitors	633	573	529	467	413	39	13	176	211	13	10 421
J05AG01 nevirapine	183	186	191	184	172	40	5	71	89	7	4 119
J05AG03 efavirenz	455	382	321	258	213	39	7	98	102	6	5 168
J05AG04 etravirine	0	12	23	28	28	25	<5	7	20	0	1 125
J05AG05 rilpivirine	0	0	0	0	<5	0	0	<5	0	0	9
J05AH Neuraminidase inhibitors	1 088	282 095	3 860	2 646	1 803	53	107	876	606	214	466
J05AH01 zanamivir	109	2 542	35	36	34	62	<5	13	15	<5	8
J05AH02 oseltamivir	981	279 946	3 829	2 612	1 771	53	104	865	591	211	458
J05AR Antivirals for treatment of HIV infections, combinations	1 620	1 927	2 184	2 445	2 715	35	11	1 400	1 257	47	174 841
J05AR01 zidovudine and lamivudine	648	606	514	421	344	49	0	189	142	13	9 019
J05AR02 lamivudine and abacavir	230	258	279	290	328	30	<5	139	175	12	12 818
J05AR03 tenofovir disoproxil and emtricitabine	738	890	1 065	1 230	1 404	38	<5	762	621	18	70 051
J05AR04 zidovudine, lamivudine and abacavir	37	36	35	31	22	50	0	7	15	0	1 038
J05AR06 emtricitabine, tenofovir disoproxil and efavirenz	130	362	514	650	753	27	0	383	360	10	61 581
J05AR08 emtricitabine, tenofovir disoproxil and rilpivirine	0	0	0	0	142	18	0	90	52	0	6 645
J05AR10 lopinavir and ritonavir	582	583	551	510	466	50	7	292	160	7	13 691
J05AX Other antivirals	50	97	179	271	325	44	<5	142	178	<5	20 998
J05AX05 inosine pranobex	<5	<5	31	81	61	82	<5	41	18	0	219
J05AX07 enfuvirtide	6	<5	0	0	0	-	0	0	0	0	0
J05AX08 raltegravir	48	96	148	190	264	35	0	101	160	<5	20 366
J05AX09 maraviroc	5	5	7	7	7	14	0	<5	6	0	413

2.12 ATC group L – Antineoplastic and immunomodulating agents

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	70 154	72 795	76 656	81 612	86 248	54	1 255	18 728	40 814	25 451	2 400 496
L02 ENDOCRINE THERAPY	24 557	24 457	24 886	25 999	26 119	51	158	2 825	9 093	14 043	280 239
L02A HORMONES AND RELATED AGENTS	10 787	10 788	11 009	11 761	11 166	21	156	1 861	2 042	7 107	94 245
L02AA Estrogens	48	25	17	7	<5	50	0	0	<5	<5	1
L02AA02 polyestradiol phosphate	48	25	17	7	<5	50	0	0	<5	<5	1
L02AB Progestogens	223	188	178	202	166	83	0	9	70	87	368
L02AB01 megestrol	186	178	178	202	166	83	0	9	70	87	368
L02AB02 medroxyprogesterone	44	12	0	0	0	-	0	0	0	0	0
L02AE Gonadotropin releasing hormone analogues	10 547	10 590	10 827	11 558	11 002	20	156	1 852	1 971	7 023	93 876
L02AE01 buserelin	1 337	1 282	1 474	1 898	1 309	99	0	1 290	12	7	2 136
L02AE02 leuprorelin	3 804	3 887	3 891	4 012	3 955	14	155	365	561	2 874	35 996
L02AE03 goserelin	5 557	5 601	5 619	5 783	5 858	7	<5	227	1 426	4 204	55 448
L02AE04 triptorelin	<5	8	<5	12	13	100	0	11	<5	0	55
L02AE05 histrelin	0	0	0	12	20	0	0	0	<5	16	242
L02B HORMONE ANTAGONISTS AND RELATED AGENTS	16 898	16 800	17 127	17 878	18 845	58	<5	1 011	8 173	9 659	185 994
L02BA Anti-estrogens	5 502	4 959	4 109	3 861	3 990	97	<5	625	2 410	953	13 131
L02BA01 tamoxifen	5 251	4 716	3 893	3 597	3 758	97	<5	618	2 278	860	3 380
L02BA03 fulvestrant	270	267	242	296	266	99	0	8	146	112	9 751
L02BB Anti-androgens	6 370	6 380	6 641	7 008	6 978	0	0	<5	1 567	5 408	41 945
L02BB01 flutamide	389	352	305	253	248	1	0	<5	24	222	1 075
L02BB03 bicalutamide	6 003	6 058	6 362	6 775	6 760	0	0	<5	1 548	5 211	40 870
L02BG Aromatase inhibitors	5 968	6 601	7 219	7 378	7 770	99	0	400	4 315	3 055	38 748
L02BG03 anastrozole	3 444	3 276	2 901	2 331	1 855	98	0	25	1 049	781	8 670
L02BG04 letrozole	1 396	2 360	3 478	4 365	5 295	99	0	363	2 927	2 005	26 512
L02BG06 exemestane	1 363	1 200	1 108	929	809	99	0	18	464	327	3 565
L02BX Other hormone antagonists and related agents	0	0	89	377	836	0	0	0	267	569	92 169
L02BX02 degarelix	0	0	89	271	380	0	0	0	134	246	4 020
L02BX03 abiraterone	0	0	0	107	484	0	0	0	147	337	88 149
L03 IMMUNOSTIMULANTS	5 353	5 663	5 883	6 294	6 762	61	60	2 480	3 656	566	346 730
L03A IMMUNOSTIMULANTS	5 353	5 663	5 883	6 294	6 762	61	60	2 480	3 656	566	346 730
L03AA Colony stimulating factors	1 928	2 085	2 222	2 426	2 693	61	41	456	1 666	530	87 962
L03AA02 filgrastim	364	362	415	587	599	48	35	113	342	109	9 907
L03AA13 pegfilgrastim	1 649	1 815	1 919	1 958	2 220	64	8	374	1 399	439	78 055
L03AB Interferons	2 667	2 666	2 649	2 756	2 886	57	20	1 423	1 414	29	172 182

ATC group L

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<5	5-14	15-44	45-69	≥70		<15	15-44	45-69	≥70	
L03AB01 interferon alfa natural	<5	5	11	20	20	50	0	10	10	0	2 765
L03AB03 interferon gamma	11	9	9	9	10	60	<5	6	0	0	1 013
L03AB04 interferon alfa-2a	5	14	19	19	23	35	0	5	13	5	755
L03AB05 interferon alfa-2b	80	62	74	63	49	35	0	9	34	6	1 524
L03AB07 interferon beta-1a	1 335	1 348	1 217	1 183	1 175	71	12	575	587	<5	96 346
L03AB08 interferon beta-1b	363	372	533	637	652	67	<5	360	289	<5	30 913
L03AB10 peginterferon alfa-2b	465	416	310	273	337	36	<5	158	166	9	14 121
L03AB11 peginterferon alfa-2a	424	468	503	594	685	36	0	340	338	7	24 745
L03AC Interleukins	<5	0	0	<5	0	-	0	0	0	0	0
L03AC01 aldesleukin	<5	0	0	<5	0	-	0	0	0	0	0
L03AX Other immunostimulants	862	1 023	1 148	1 266	1 358	72	0	697	654	7	86 586
L03AX03 BCG vaccine	<5	7	13	12	10	10	0	<5	5	<5	76
L03AX13 glatiramer acetate	858	1 016	1 135	1 254	1 348	73	0	696	649	<5	86 510
L04 IMMUNOSUPPRESSANTS	35 076	37 221	39 932	42 913	46 329	55	899	12 749	24 391	8 290	1 432 345
L04A IMMUNOSUPPRESSANTS	35 076	37 221	39 932	42 913	46 329	55	899	12 749	24 391	8 290	1 432 345
L04AA Selective immunosuppressants	4 317	4 619	4 910	5 466	6 246	48	86	1 481	3 672	1 007	168 067
L04AA06 mycophenolic acid	2 647	2 965	3 266	3 591	3 919	37	78	949	2 329	563	41 785
L04AA10 sirolimus	68	70	101	130	149	32	<5	22	106	17	5 179
L04AA13 leflunomide	1 318	1 362	1 458	1 539	1 661	69	<5	194	1 050	415	9 329
L04AA18 everolimus	253	263	294	336	402	30	<5	55	264	80	24 413
L04AA21 efalizumab	196	118	0	0	0	-	0	0	0	0	0
L04AA23 natalizumab	42	58	49	0	0	-	0	0	0	0	0
L04AA24 abatacept	16	<5	<5	0	0	-	0	0	0	0	0
L04AA25 eculizumab	0	<5	<5	5	8	75	<5	<5	<5	<5	21 180
L04AA27 fingolimod	0	0	0	186	487	72	<5	309	177	0	66 182
L04AB Tumor necrosis factor alpha (TNF-) inhibitors	7 626	8 409	9 649	11 057	12 623	53	186	4 680	6 679	1 078	1 026 277
L04AB01 etanercept	5 280	5 162	5 078	6 122	6 944	55	118	2 259	3 880	687	479 052
L04AB02 infliximab	278	83	<5	0	0	-	0	0	0	0	0
L04AB04 adalimumab	2 329	3 519	3 993	4 121	4 588	51	77	2 066	2 173	272	414 454
L04AB05 certolizumab pegol	0	0	135	314	606	75	0	158	351	97	32 159
L04AB06 golimumab	0	0	1 038	1 208	1 218	50	0	498	655	65	100 612
L04AC Interleukin inhibitors	58	69	127	180	293	44	11	126	143	13	32 836
L04AC03 anakinra	58	68	75	85	121	46	8	50	56	7	7 308
L04AC05 ustekinumab	0	<5	50	92	166	43	0	73	87	6	15 904
L04AC08 canakinumab	0	0	<5	6	7	29	<5	<5	0	0	9 624

ATC group L

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<5	5-14	15-44	45-69	≥70		<15	15-44	45-69	≥70	
L04AD Calcineurin inhibitors	4 388	4 578	4 799	5 027	5 279	38	151	1 394	3 006	728	122 162
L04AD01 ciclosporin	3 306	3 289	3 307	3 332	3 272	37	58	701	1 913	600	67 542
L04AD02 tacrolimus	1 161	1 349	1 570	1 770	2 085	39	93	720	1 143	129	54 620
L04AX Other immunosuppressants	25 770	26 860	28 382	29 767	31 195	59	617	7 607	16 359	6 612	83 003
L04AX01 azathioprine	6 028	6 197	6 390	6 714	7 078	52	197	3 252	2 930	699	6 309
L04AX02 thalidomide	340	330	348	320	330	50	6	7	119	198	11 043
L04AX03 methotrexate	19 466	20 347	21 622	22 692	23 678	61	415	4 376	13 255	5 632	10 425
L04AX04 lenalidomide	60	106	157	171	236	49	0	<5	127	106	51 722
L04AX05 pirfenidone	0	0	0	0	21	29	0	0	14	7	3 504

2.13 ATC group M – Musculo-skeletal system

ATC group M

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
M MUSCULO-SKELETAL SYSTEM	907 360	891 127	901 910	927 355	935 824	57	14 643	332 879	429 400	158 902	303 497
M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	829 545	815 420	824 208	833 848	836 532	57	12 780	323 870	393 317	106 565	193 810
M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STERIODS	829 405	815 299	824 121	833 776	836 481	57	12 780	323 863	393 290	106 548	192 860
M01AA Butylpyrazolidines	<5	0	0	0	0	-	0	0	0	0	0
M01AA01 phenylbutazone	<5	0	0	0	0	-	0	0	0	0	0
M01AB Acetic acid derivatives and related substances	498 631	491 574	505 424	508 808	484 532	55	7 381	200 608	226 123	50 420	58 537
M01AB01 indometacin	12 154	11 675	2 710	1 116	1 151	61	15	403	596	137	917
M01AB02 sulindac	600	386	16	0	0	-	0	0	0	0	0
M01AB05 diclofenac ¹⁾	471 691	464 462	481 108	483 169	460 406	54	7 345	195 692	213 181	44 188	46 001
M01AB15 ketorolac	7	11	27	23	9	56	0	<5	7	0	5
M01AB55 diclofenac, combinations	22 250	23 266	29 244	31 576	28 949	63	26	6 232	15 657	7 034	11 614
M01AC Oxicams	88 227	81 319	76 309	69 293	59 377	55	210	18 842	31 871	8 454	15 603
M01AC01 piroxicam	60 698	55 461	51 627	47 991	43 556	52	181	15 679	23 252	4 444	11 193
M01AC06 meloxicam	28 570	26 731	25 438	21 952	16 188	62	29	3 258	8 836	4 065	4 410
M01AE Propionic acid derivatives	278 524	273 810	276 001	294 401	332 008	61	5 424	127 410	155 557	43 617	79 509
M01AE01 ibuprofen ¹⁾	208 791	211 641	215 745	226 838	224 736	62	4 544	94 281	101 681	24 230	32 321
M01AE02 naproxen ¹⁾	66 541	59 487	58 354	62 549	65 047	58	866	22 460	30 758	10 963	21 836
M01AE03 ketoprofen	8 541	7 912	7 478	7 396	6 725	60	16	1 486	3 802	1 421	2 890
M01AE14 dexibuprofen	2 124	1 417	1 025	881	707	62	<5	283	335	88	165
M01AE52 naproxen and esomeprazole	0	0	0	5 217	50 757	63	59	14 335	27 372	8 991	22 298
M01AG Fenamates	827	669	106	304	310	82	<5	197	108	<5	248
M01AG02 tolfenamic acid	827	669	106	304	310	82	<5	197	108	<5	248
M01AH Coxibs	36 485	35 851	35 999	36 515	43 565	56	77	13 922	22 610	6 956	20 378
M01AH01 celecoxib	8 315	8 030	7 851	7 720	9 974	63	27	2 875	5 147	1 925	6 650
M01AH04 parecoxib	<5	<5	0	0	<5	100	0	0	<5	0	9
M01AH05 etoricoxib	28 365	28 047	28 365	29 013	33 988	54	50	11 129	17 706	5 103	13 719
M01AX Other antiinflammatory and antirheumatic agents, non-steroids	55 088	51 313	48 137	41 749	37 352	66	14	2 783	21 163	13 392	18 585
M01AX01 nabumetone	11 261	9 107	7 343	6 378	4 792	66	7	890	2 722	1 173	2 276
M01AX05 glucosamine ¹⁾	43 576	41 918	40 410	34 884	31 944	66	7	1 810	18 112	12 015	14 823
M01C SPECIFIC ANTIRHEUMATIC AGENTS	325	285	242	208	133	71	0	20	72	41	950
M01CB Gold preparations	267	241	199	171	100	79	0	14	51	35	325

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
M01CB01 sodium aurothiomalate	97	74	36	30	26	77	0	<5	10	14	97
M01CB03 auranofin	171	167	163	141	74	80	0	12	41	21	228
M01CC Penicillamine and similar agents	15	12	14	13	12	33	0	<5	8	<5	90
M01CC01 penicillamine	15	12	14	13	12	33	0	<5	8	<5	90
M01CX Other specific antirheumatic agents	43	32	30	24	21	52	0	<5	13	5	535
M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	31 768	27 101	24 394	53 477	59 086	61	2 263	17 779	23 903	15 141	5 553
M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	31 768	27 101	24 394	53 477	59 086	61	2 263	17 779	23 903	15 141	5 553
M02AA Antiinflammatory preparations, non-steroids for topical use	31 675	27 032	24 200	53 269	58 967	61	2 255	17 743	23 864	15 105	5 540
M02AA10 ketoprofen ¹⁾	27 552	23 095	20 122	47 409	51 200	61	1 890	15 355	21 044	12 911	4 157
M02AA13 ibuprofen ¹⁾	4 040	3 853	3 998	4 923	5 812	60	302	1 718	2 008	1 784	987
M02AA15 diclofenac	173	160	167	1 322	2 398	58	68	740	957	633	396
M02AB Capsaicin and similar agents	8	5	6	6	8	63	0	0	<5	5	1
M02AB01 capsaicin	8	5	6	6	8	63	0	0	<5	5	1
M02AC Preparations with salicylic acid derivatives	89	69	189	207	124	55	8	41	37	38	11
M02AX Other topical products for joint and muscular pain	7	11	13	9	5	80	0	0	<5	<5	1
M02AX10 various	7	11	13	9	5	80	0	0	<5	<5	1
M03 MUSCLE RELAXANTS	12 875	5 592	5 918	6 009	5 928	56	104	1 545	3 539	740	12 752
M03B MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS	12 660	5 388	5 657	5 654	5 575	55	103	1 333	3 407	732	9 914
M03BA Carbamic acid esters	8 594	1 087	1 097	1 030	910	68	0	218	616	76	2 764
M03BA02 carisoprodol	8 583	1 087	1 097	1 030	910	68	0	218	616	76	2 764
M03BA52 carisoprodol, combinations excl. psycholeptics	30	<5	0	0	0	-	0	0	0	0	0
M03BB Oxazol, thiazine, and triazine derivatives	<5	0	0	<5	0	-	0	0	0	0	0
M03BB03 chlorzoxazone	<5	0	0	<5	0	-	0	0	0	0	0
M03BC Ethers, chemically close to antihistamines	<5	<5	<5	0	0	-	0	0	0	0	0
M03BC51 orphenadrine, combinations	<5	<5	<5	0	0	-	0	0	0	0	0
M03BX Other centrally acting agents	4 236	4 318	4 583	4 652	4 686	52	103	1 124	2 803	656	7 150
M03BX01 baclofen	4 195	4 277	4 544	4 608	4 640	52	103	1 109	2 777	651	6 748

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group M

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
M03BX02 tizanidine	72	59	59	71	75	41	0	21	48	6	402
M03C MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS	<5	0	0	<5	0	-	0	0	0	0	0
M03CA Dantrolene and derivatives	<5	0	0	<5	0	-	0	0	0	0	0
M03CA01 dantrolene	<5	0	0	<5	0	-	0	0	0	0	0
M04 ANTIGOUT PREPARATIONS	37 888	39 433	40 882	43 057	45 433	29	15	2 731	19 676	23 011	19 516
M04A ANTIGOUT PREPARATIONS	37 888	39 433	40 882	43 057	45 433	29	15	2 731	19 676	23 011	19 516
M04AA Preparations inhibiting uric acid production	34 952	36 397	37 670	39 470	41 647	29	<5	2 361	18 003	21 280	15 461
M04AA01 allopurinol	34 952	36 397	37 661	39 441	41 584	29	<5	2 351	17 974	21 256	13 894
M04AA03 febuxostat	0	0	9	33	75	29	0	12	34	29	1 567
M04AB Preparations increasing uric acid excretion	2 100	2 123	2 062	2 072	2 037	29	<5	127	922	987	2 313
M04AB01 probenecid	2 100	2 123	2 062	2 072	2 037	29	<5	127	922	987	2 313
M04AC Preparations with no effect on uric acid metabolism	2 373	2 597	3 070	3 688	4 202	23	11	457	1 924	1 810	1 742
M04AC01 colchicine	2 373	2 597	3 070	3 688	4 202	23	11	457	1 924	1 810	1 742
M05 DRUGS FOR TREATMENT OF BONE DISEASES	56 634	56 744	57 597	58 371	59 927	88	<5	675	21 602	37 646	71 565
M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	56 634	56 744	57 597	58 371	59 927	88	<5	675	21 602	37 646	71 565
M05BA Bisphosphonates	54 146	54 669	55 785	56 550	57 162	89	<5	630	20 768	35 760	53 316
M05BA01 etidronic acid	372	297	240	205	151	92	0	<5	21	129	111
M05BA02 clodronic acid	48	44	48	48	41	51	0	0	22	19	720
M05BA03 pamidronic acid	10	13	21	19	16	44	0	<5	7	8	76
M05BA04 alendronic acid	51 829	52 053	52 702	52 893	53 104	88	<5	548	18 984	33 568	38 175
M05BA06 ibandronic acid	704	704	696	668	653	93	0	<5	262	388	2 204
M05BA07 risedronic acid	1 405	1 214	1 097	948	832	93	0	6	302	524	2 112
M05BA08 zoledronic acid	221	835	1 584	2 329	2 903	88	0	78	1 426	1 399	9 919
M05BB Bisphosphonates, combinations	2 745	2 267	1 950	1 659	1 433	94	0	<5	298	1 131	2 748
M05BB01 etidronic acid and calcium, sequential	2 745	2 267	1 950	1 659	1 433	94	0	<5	298	1 131	2 748
M05BX Other drugs affecting bone structure and mineralization	0	0	27	398	1 847	78	0	41	653	1 153	15 501
M05BX04 denosumab	0	0	27	398	1 847	78	0	41	653	1 153	15 501
M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	<5	<5	0	0	31	6	0	<5	17	13	301

ATC group M

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	<5	<5	0	0	31	6	0	<5	17	13	301
M09AB Enzymes	0	0	0	0	31	6	0	<5	17	13	301
M09AB02 collagenase clostridium histolyticum	0	0	0	0	31	6	0	<5	17	13	301
M09AX Other drugs for disorders of the musculo-skeletal system	<5	<5	0	0	0	-	0	0	0	0	0
M09AX01 hyaluronic acid	<5	<5	0	0	0	-	0	0	0	0	0

2.14 ATC group N – Nervous system

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15–44	45–69	≥70	<15		15–44	45–69	≥70		
N NERVOUS SYSTEM	1 208 796	1 230 918	1 248 505	1 279 676	1 301 538	59	30 853	414 409	565 804	290 472	2 626 256
N02 ANALGESICS	676 887	693 686	710 536	739 147	765 126	61	9 362	247 387	339 980	168 397	680 919
N02A OPIOIDS	484 768	487 517	491 941	500 644	513 389	56	5 207	169 147	228 467	110 568	398 383
N02AA Natural opium alkaloids	409 141	405 617	401 941	403 516	403 774	56	4 998	138 800	179 620	80 356	254 799
N02AA01 morphine	6 995	7 048	7 000	6 790	6 800	50	25	878	3 242	2 655	13 652
N02AA03 hydromorphone	53	41	40	48	68	47	0	13	40	15	5 584
N02AA05 oxycodone	14 983	16 910	19 067	20 444	22 927	53	16	3 543	10 647	8 721	78 829
N02AA08 dihydrocodeine	40	49	47	52	47	79	0	10	33	<5	277
N02AA55 oxycodone, combinations	5	228	1 001	1 831	2 869	55	0	276	1 221	1 372	9 124
N02AA59 codeine, combinations excl. psycholeptics	397 626	392 734	387 507	387 930	386 295	56	4 970	136 529	171 773	73 023	147 334
N02AB Phenylpiperidine derivatives	10 253	10 453	11 167	11 306	11 480	59	9	1 890	4 987	4 594	46 692
N02AB01 ketobemidone	3 738	3 731	3 994	3 972	3 988	54	<5	1 123	2 026	838	5 432
N02AB02 pethidine	1 377	1 340	1 343	1 243	1 198	61	0	351	662	185	1 923
N02AB03 fentanyl	5 657	5 857	6 331	6 583	6 764	62	8	512	2 556	3 688	39 336
N02AC Diphenylpropylamine derivatives	8 523	7 442	4 700	30	16	63	0	<5	<5	9	31
N02AC04 dextropropoxyphene	0	0	0	9	16	63	0	<5	<5	9	31
N02AC54 dextropropoxyphene, combinations excl. psycholeptics	8 523	7 442	4 700	22	0	-	0	0	0	0	0
N02AD Benzomorphan derivatives	49	45	41	35	30	50	0	<5	19	8	448
N02AD01 pentazocine	49	45	41	35	30	50	0	<5	19	8	448
N02AE Oripavine derivatives	10 244	12 080	13 189	14 009	15 226	71	<5	1 284	3 992	9 948	44 747
N02AE01 buprenorphine	10 244	12 080	13 189	14 009	15 226	71	<5	1 284	3 992	9 948	44 747
N02AG Opioids in combination with antispasmodics	1 819	1 729	1 840	1 776	1 957	58	<5	519	908	526	1 662
N02AG01 morphine and antispasmodics	218	218	263	310	383	52	<5	9	98	274	85
N02AG02 ketobemidone and antispasmodics	1 608	1 515	1 584	1 470	1 576	59	<5	510	811	253	1 577
N02AX Other opioids	106 796	114 947	127 986	138 495	155 275	58	249	44 768	71 570	38 688	50 006
N02AX02 tramadol	106 796	114 947	127 986	138 478	154 986	58	249	44 705	71 402	38 630	48 598
N02AX06 tapentadol	0	0	0	31	490	56	0	119	265	106	1 407
N02B OTHER ANALGESICS AND ANTIPYRETICS	255 894	281 468	305 897	337 952	362 751	64	3 081	86 224	162 270	111 176	69 053
N02BA Salicylic acid and derivatives	769	806	840	883	785	59	241	228	186	130	275
N02BA01 acetylsalicylic acid	768	802	836	879	779	58	241	227	181	130	253
N02BA11 diflunisal	0	<5	<5	<5	<5	100	0	0	<5	0	13

ATC group N

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15–44	45–69	≥70	<15		15–44	45–69	≥70		
N02BA51 acetylsalicylic acid, combinations excl. psycholeptics	<5	<5	<5	<5	<5	67	0	<5	<5	0	9
N02BB Pyrazolones	909	885	887	891	960	69	10	425	348	177	339
N02BB02 metamizole sodium	15	22	12	5	13	62	0	<5	7	5	23
N02BB51 phenazone, combinations excl. psycholeptics	894	863	875	886	947	69	10	424	341	172	315
N02BE Anilides	254 655	280 253	304 673	336 641	361 454	64	2 833	85 730	161 883	111 008	67 716
N02BE01 paracetamol ¹⁾	254 655	280 253	304 673	336 641	361 454	64	2 833	85 730	161 883	111 008	67 716
N02BG Other analgesics and antipyretics	<5	<5	0	<5	68	47	0	19	44	5	723
N02BG07 flupirtine	<5	<5	0	0	<5	100	0	0	<5	0	1
N02BG08 ziconotide	0	0	0	<5	0	-	0	0	0	0	0
N02BG10 nabiximols	0	0	0	<5	67	46	0	19	43	5	722
N02C ANTIMIGRAINE PREPARATIONS	88 060	87 608	88 921	91 693	94 258	79	1 795	44 902	43 843	3 718	213 483
N02CA Ergot alkaloids	3 827	3 477	3 072	2 918	2 492	83	7	385	1 520	580	1 171
N02CA04 methysergide	8	6	6	9	7	43	0	0	<5	<5	17
N02CA52 ergotamine, combinations excl. psycholeptics	14	13	15	15	12	67	0	<5	6	<5	17
N02CA72 ergotamine, combinations with psycholeptics	3 808	3 458	3 053	2 895	2 473	83	7	383	1 510	573	1 137
N02CC Selective serotonin (5HT1) agonists	82 235	81 971	83 476	85 970	88 996	80	1 733	43 765	40 528	2 970	210 112
N02CC01 sumatriptan	35 885	40 472	41 843	43 349	45 173	77	1 538	24 215	18 004	1 416	85 697
N02CC02 naratriptan	1 515	1 497	1 501	1 581	1 651	87	8	697	871	75	4 843
N02CC03 zolmitriptan	14 983	14 223	14 230	14 481	14 776	82	124	6 645	7 444	563	32 761
N02CC04 rizatriptan	24 519	22 306	22 398	23 373	24 226	81	191	12 433	10 861	741	45 452
N02CC05 almotriptan	3 915	3 286	3 053	2 936	2 938	84	10	1 465	1 378	85	5 977
N02CC06 eletriptan	11 871	11 192	11 289	11 403	11 463	83	47	5 196	5 951	269	35 342
N02CC07 frovatriptan	12	19	6	5	7	86	0	<5	<5	0	40
N02CX Other antimigraine preparations	3 129	3 163	3 418	3 920	3 942	76	62	1 118	2 503	259	2 200
N02CX01 pizotifen	63	53	61	60	78	81	0	31	41	6	223
N02CX02 clonidine	3 067	3 111	3 357	3 861	3 867	76	62	1 088	2 464	253	1 978
N03 ANTIEPILEPTICS	97 238	100 382	103 954	108 555	113 208	56	3 499	35 703	52 641	21 365	391 699
N03A ANTIEPILEPTICS	97 238	100 382	103 954	108 555	113 208	56	3 499	35 703	52 641	21 365	391 699
N03AA Barbiturates and derivatives	2 959	2 844	2 700	2 544	2 419	52	14	239	1 317	849	1 817
N03AA02 phenobarbital	2 718	2 574	2 426	2 270	2 140	52	13	210	1 178	739	1 313
N03AA03 primidone	255	284	288	287	291	49	<5	29	144	117	505

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group N

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
N03AB Hydantoin derivatives	2 332	2 218	2 051	1 938	1 796	42	19	206	1 018	553	857
N03AB02 phenytoin	2 332	2 217	2 051	1 937	1 796	42	19	206	1 018	553	857
N03AB05 fosphenytoin	0	<5	0	<5	0	-	0	0	0	0	0
N03AD Succinimide derivatives	116	139	149	173	182	65	91	70	18	<5	1 620
N03AD01 ethosuximide	116	139	149	173	182	65	91	70	18	<5	1 620
N03AE Benzodiazepine derivatives	13 927	13 713	13 528	13 006	12 531	54	169	3 445	6 472	2 445	6 154
N03AE01 clonazepam	13 927	13 713	13 528	13 006	12 531	54	169	3 445	6 472	2 445	6 154
N03AF Carboxamide derivatives	20 748	20 004	19 238	18 449	17 607	46	704	4 830	8 730	3 343	30 508
N03AF01 carbamazepine	18 586	17 750	16 830	15 931	14 986	47	339	3 788	7 834	3 025	13 979
N03AF02 oxcarbazepine	2 173	2 236	2 298	2 375	2 419	44	364	901	836	318	9 698
N03AF03 rufinamide	80	96	96	97	99	41	19	73	6	<5	2 247
N03AF04 eslicarbazepine	0	<5	205	213	232	55	<5	120	98	13	4 584
N03AG Fatty acid derivatives	13 320	13 867	14 184	14 347	14 644	45	1 617	5 825	5 951	1 251	31 858
N03AG01 valproic acid	13 227	13 786	14 111	14 279	14 576	45	1 597	5 805	5 924	1 250	31 000
N03AG03 aminobutyric acid	0	0	0	0	7	43	0	<5	<5	<5	3
N03AG04 vigabatrin	127	114	100	88	88	49	39	25	23	<5	620
N03AG06 tiagabine	15	12	11	13	10	50	0	<5	7	0	236
N03AX Other antiepileptics	57 604	61 469	66 054	71 880	77 686	59	1 869	26 029	35 321	14 467	318 884
N03AX03 sultiame	54	64	98	130	161	44	126	32	<5	0	1 016
N03AX09 lamotrigine	20 820	22 368	23 711	24 878	26 165	60	1 012	13 095	9 846	2 212	83 646
N03AX10 felbamate	24	25	23	21	21	29	0	18	<5	0	463
N03AX11 topiramate	3 051	3 039	3 060	3 047	3 121	70	228	1 713	1 063	117	11 050
N03AX12 gabapentin	14 682	20 412	24 447	26 611	28 872	60	53	6 263	14 991	7 565	42 940
N03AX14 levetiracetam	4 320	4 977	5 539	6 101	6 763	48	628	2 602	2 439	1 094	62 532
N03AX15 zonisamide	349	444	457	473	517	56	82	271	144	20	6 728
N03AX16 pregabalin	20 274	17 120	15 264	16 892	18 299	59	9	4 334	9 590	4 366	102 495
N03AX17 stiripentol	0	19	33	30	24	42	14	10	0	0	1 373
N03AX18 lacosamide	0	122	262	341	410	52	9	240	143	18	5 626
N03AX21 retigabine	0	0	0	18	138	57	<5	103	32	<5	1 017
N04 ANTI-PARKINSON DRUGS	17 191	17 238	17 787	18 178	18 634	50	14	1 556	8 106	8 958	127 394
N04A ANTICHOLINERGIC AGENTS	3 162	3 034	2 915	2 808	2 662	49	<5	593	1 660	405	1 525
N04AA Tertiary amines	3 104	2 991	2 880	2 773	2 631	49	<5	591	1 638	398	1 432
N04AA01 trihexyphenidyl	15	15	22	23	20	55	<5	7	8	<5	156
N04AA02 biperiden	3 085	2 971	2 854	2 747	2 607	49	<5	584	1 628	394	1 269
N04AA04 procyclidine	<5	5	<5	<5	<5	50	0	0	<5	<5	7
N04AB Ethers chemically close to antihistamines	65	48	40	38	36	64	0	<5	27	7	92

ATC group N

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
N04AB02 orphenadrine (chloride)	65	48	40	38	36	64	0	<5	27	7	92
N04B DOPAMINERGIC AGENTS	14 096	14 267	14 940	15 436	16 033	51	10	971	6 476	8 576	125 869
N04BA Dopa and dopa derivatives	7 606	7 716	7 906	8 015	8 274	43	10	121	2 475	5 668	63 300
N04BA02 levodopa and decarboxylase inhibitor	6 995	7 051	7 180	7 277	7 557	44	10	113	2 173	5 261	46 818
N04BA03 levodopa, decarboxylase inhibitor and COMT inhibitor	1 255	1 358	1 448	1 395	1 413	36	0	17	619	777	16 482
N04BB Adamantane derivatives	111	114	114	123	139	57	0	41	86	12	511
N04BB01 amantadine	111	114	114	123	139	57	0	41	86	12	511
N04BC Dopamine agonists	8 542	8 784	9 442	9 976	10 374	53	0	837	5 229	4 308	42 492
N04BC01 bromocriptine	<5	<5	<5	<5	<5	0	0	0	<5	0	12
N04BC04 ropinirole	1 842	2 316	2 665	2 667	2 675	45	0	164	1 456	1 055	16 045
N04BC05 pramipexole	6 236	6 258	6 501	6 946	7 343	57	0	684	3 620	3 039	16 758
N04BC06 cabergoline	514	322	209	177	142	49	0	7	46	89	541
N04BC07 apomorphine	18	19	18	21	19	37	0	0	6	13	2 724
N04BC09 rotigotine	393	427	517	541	528	43	0	12	282	234	6 413
N04BD Monoamine oxidase B inhibitors	2 571	2 862	3 184	3 339	3 518	37	0	45	1 741	1 732	18 329
N04BD01 selegiline	2 081	2 116	2 126	2 087	2 137	38	0	26	1 081	1 030	3 055
N04BD02 rasagiline	575	864	1 183	1 329	1 460	38	0	19	715	726	15 274
N04BX Other dopaminergic agents	287	230	192	152	160	47	0	<5	59	100	1 237
N04BX01 tolcapone	13	13	11	11	9	11	0	0	<5	7	80
N04BX02 entacapone	274	218	181	141	151	49	0	<5	57	93	1 158
N05 PSYCHOLEPTICS	611 554	616 964	614 376	618 313	615 272	63	9 316	139 901	278 452	187 603	582 512
N05A ANTIPSYCHOTICS	104 087	104 082	104 077	104 361	105 768	56	877	36 184	47 492	21 215	291 676
N05AA Phenothiazines with aliphatic side-chain	26 862	25 877	24 617	23 180	21 732	57	15	5 748	11 481	4 488	8 518
N05AA01 chlorpromazine	702	492	439	389	276	55	0	109	127	40	893
N05AA02 levomepromazine	26 247	25 435	24 212	22 826	21 481	57	15	5 649	11 368	4 449	7 624
N05AB Phenothiazines with piperazine structure	20 902	19 829	18 276	17 128	15 731	67	14	3 342	6 742	5 633	8 017
N05AB01 dixyrazine	76	54	32	<5	0	-	0	0	0	0	0
N05AB02 fluphenazine	59	27	22	20	15	53	0	0	7	8	29
N05AB03 perphenazine	5 993	5 736	5 423	5 084	4 717	58	<5	1 061	2 756	899	5 862
N05AB04 prochlorperazine	14 841	14 075	12 860	12 078	11 036	71	13	2 284	3 997	4 742	2 124
N05AB06 trifluoperazine	<5	<5	<5	<5	<5	-	0	0	0	<5	1
N05AC Phenothiazines with piperidine structure	79	70	62	61	50	60	0	<5	28	19	171
N05AC01 periciazine	<5	<5	<5	<5	<5	100	0	0	<5	0	2

ATC group N

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
N05AC02 thioridazine	73	66	58	57	47	57	0	<5	26	18	145
N05AC04 pipotiazine	5	<5	<5	<5	<5	100	0	0	<5	<5	24
N05AD Butyrophenone derivatives	4 735	4 473	4 277	4 089	4 003	54	7	384	1 432	2 180	1 333
N05AD01 haloperidol	4 725	4 466	4 270	4 082	3 994	54	7	382	1 428	2 177	1 322
N05AD03 melperone	10	7	6	6	6	50	0	<5	<5	<5	8
N05AD08 droperidol	0	0	<5	<5	<5	75	0	0	<5	<5	3
N05AE Indole derivatives	1 383	1 302	1 164	1 033	956	60	<5	470	446	38	12 786
N05AE03 sertindole	165	186	161	138	127	57	0	85	40	<5	1 281
N05AE04 ziprasidone	1 231	1 118	1 006	897	830	60	<5	386	406	36	11 505
N05AF Thioxanthene derivatives	24 515	24 245	23 752	22 935	22 479	55	29	7 594	11 271	3 585	10 732
N05AF01 flupentixol	5 381	5 006	4 918	4 621	4 468	66	0	1 144	2 290	1 034	2 423
N05AF03 chlorprothixene	16 666	17 012	16 658	16 269	16 030	53	27	6 060	7 818	2 125	5 984
N05AF05 zuclopenthixol	3 156	2 908	2 822	2 661	2 574	51	<5	624	1 468	480	2 325
N05AG Diphenylbutylpiperidine derivatives	165	142	135	139	127	35	<5	68	40	15	297
N05AG02 pimozide	133	116	118	117	110	39	<5	58	34	14	265
N05AG03 penfluridol	33	27	17	22	17	12	0	10	6	<5	32
N05AH Diazepines, oxazepines, thiazepines and oxepines	26 510	28 510	31 688	35 237	39 762	52	111	18 561	16 945	4 145	127 594
N05AH02 clozapine	2 185	2 299	2 362	2 398	2 455	37	0	1 190	1 186	79	9 374
N05AH03 olanzapine	15 960	16 068	15 799	15 754	15 987	48	29	6 406	7 383	2 169	57 110
N05AH04 quetiapine	9 547	11 509	15 094	18 864	23 280	56	86	12 064	9 122	2 008	60 227
N05AH05 asenapine	0	0	0	0	117	58	0	60	56	<5	883
N05AL Benzamides	589	580	548	527	566	44	<5	294	244	27	3 573
N05AL03 tiapride	7	5	7	7	7	43	<5	<5	<5	<5	41
N05AL05 amisulpride	582	575	541	520	559	44	0	291	242	26	3 532
N05AN Lithium	7 927	7 995	7 877	7 727	7 781	56	6	2 253	4 382	1 140	13 043
N05AN01 lithium	7 927	7 995	7 877	7 727	7 781	56	6	2 253	4 382	1 140	13 043
N05AX Other antipsychotics	10 930	11 446	12 299	12 804	13 142	48	737	5 958	4 411	2 036	105 611
N05AX07 prothipendyl	0	0	0	<5	<5	75	0	<5	<5	0	4
N05AX08 risperidone	8 158	8 150	8 255	8 366	8 269	46	640	2 979	2 780	1 870	39 452
N05AX12 aripiprazole	3 055	3 625	4 379	4 744	4 898	52	131	2 975	1 620	172	54 838
N05AX13 paliperidone	0	0	0	37	511	40	<5	336	165	9	11 318
N05B ANXIOLYTICS	285 503	282 070	277 880	273 985	273 463	64	3 654	62 174	128 190	79 445	104 552
N05BA Benzodiazepine derivatives	265 344	261 074	255 446	250 055	249 237	65	3 230	53 097	118 673	74 237	90 685
N05BA01 diazepam	143 631	138 282	132 588	128 283	125 645	63	3 032	26 159	60 377	36 077	44 547
N05BA02 chlordiazepoxide	<5	<5	<5	<5	<5	0	0	0	<5	0	3
N05BA04 oxazepam	134 012	134 703	133 963	131 939	134 167	67	74	29 544	63 252	41 297	38 919

ATC group N

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
N05BA06 lorazepam	18	20	21	30	31	55	<5	12	13	<5	55
N05BA08 bromazepam	5	7	5	6	7	71	0	0	<5	<5	26
N05BA09 clobazam	547	558	615	645	701	54	218	343	132	8	1 920
N05BA12 alprazolam	4 631	4 521	4 340	4 024	4 112	47	0	1 754	1 926	432	5 216
N05BB Diphenylmethane derivatives	27 294	28 280	30 163	31 960	32 244	62	425	11 264	13 383	7 172	9 153
N05BB01 hydroxyzine	27 294	28 280	30 163	31 960	32 244	62	425	11 264	13 383	7 172	9 153
N05BC Carbamates	9	10	6	7	6	83	0	0	0	6	12
N05BC01 meprobamate	9	10	6	7	6	83	0	0	0	6	12
N05BE Azaspirodecanedione derivatives	2 808	2 394	2 345	2 371	2 573	59	6	933	1 268	366	4 701
N05BE01 buspirone	2 808	2 394	2 345	2 371	2 573	59	6	933	1 268	366	4 701
N05C HYPNOTICS AND SEDATIVES	397 070	405 810	406 162	411 062	406 576	65	5 696	78 638	182 927	139 315	186 284
N05CA Barbiturates, plain	<5	<5	<5	<5	0	-	0	0	0	0	0
N05CA04 barbital	<5	<5	<5	<5	0	-	0	0	0	0	0
N05CD Benzodiazepine derivatives	46 685	44 520	41 807	39 255	34 045	60	856	6 087	13 464	13 638	17 507
N05CD01 flurazepam	22	20	17	16	16	50	0	0	8	8	48
N05CD02 nitrazepam	37 541	35 856	33 406	31 315	27 847	61	319	4 726	11 288	11 514	8 341
N05CD03 flunitrazepam	9 223	8 479	7 690	6 971	5 777	55	<5	888	2 499	2 386	3 680
N05CD04 estazolam	<5	<5	0	0	0	-	0	0	0	0	0
N05CD05 triazolam	103	105	115	98	107	56	<5	35	38	33	99
N05CD08 midazolam	831	1 071	1 493	1 759	2 227	49	630	850	427	320	5 339
N05CF Benzodiazepine related drugs	346 261	351 044	349 542	352 287	354 874	66	71	59 640	166 040	129 123	133 824
N05CF01 zopiclone	306 246	308 363	305 048	306 107	306 040	66	55	47 411	142 379	116 195	116 108
N05CF02 zolpidem	51 245	53 835	55 244	56 956	61 025	66	17	15 263	29 156	16 589	17 716
N05CF03 zaleplon	5	7	<5	0	0	-	0	0	0	0	0
N05CH Melatonin receptor agonists	29 906	38 868	42 795	48 436	53 460	60	4 988	21 250	20 065	7 157	32 688
N05CH01 melatonin	29 906	38 868	42 795	48 436	53 460	60	4 988	21 250	20 065	7 157	32 688
N05CM Other hypnotics and sedatives	1 899	1 944	2 109	2 131	2 157	47	0	194	612	1 351	2 265
N05CM02 clomethiazole	1 843	1 870	2 048	2 057	1 991	46	0	168	556	1 267	2 091
N05CM05 scopolamine	57	77	65	75	89	42	0	<5	28	58	139
N05CM06 propiomazine	0	0	0	0	15	67	0	<5	10	<5	12
N05CM09 valeriana radix	0	0	0	0	65	75	0	19	20	26	23
N05CM11 bromides	0	0	0	<5	<5	100	0	<5	0	0	1
N06 PSYCHOANALEPTICS	319 757	325 942	333 134	341 017	348 615	63	11 056	117 387	145 022	75 150	551 430
N06A ANTIDEPRESSANTS	288 418	292 396	297 124	303 747	309 491	66	673	101 237	142 130	65 451	285 035

ATC group N

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
N06AA Non-selective monoamine reuptake inhibitors	59 391	60 237	61 908	63 098	64 671	72	98	16 079	34 469	14 025	25 378
N06AA02 imipramine	47	34	26	22	19	58	<5	0	8	8	74
N06AA04 clomipramine	3 455	3 276	3 080	2 907	2 709	70	13	457	1 558	681	2 187
N06AA05 opipramol	5	5	6	6	9	44	0	<5	<5	6	14
N06AA06 trimipramine	12 628	11 930	11 431	10 943	10 549	70	5	2 110	5 403	3 031	6 589
N06AA07 lofepramine	18	15	13	12	11	55	0	<5	7	<5	52
N06AA09 amitriptyline	38 809	40 585	43 086	45 318	47 756	72	73	13 066	25 969	8 648	14 018
N06AA10 nortriptyline	1 651	1 837	2 104	1 983	1 978	69	6	550	926	496	710
N06AA12 doxepin	3 580	3 348	3 017	2 749	2 495	70	0	162	1 026	1 307	1 732
N06AA21 maprotiline	<5	<5	<5	<5	<5	100	0	0	<5	0	1
N06AB Selective serotonin reuptake inhibitors	176 994	178 930	180 612	184 013	185 977	66	544	66 377	81 196	37 860	151 065
N06AB03 fluoxetine	8 827	9 010	9 289	9 634	10 545	75	196	6 053	3 608	688	15 334
N06AB04 citalopram	35 572	32 885	30 680	29 143	27 102	68	11	6 296	13 303	7 492	17 943
N06AB05 paroxetine	18 698	17 508	16 895	16 172	15 503	69	<5	3 257	8 480	3 764	14 810
N06AB06 sertraline	26 040	26 427	26 384	27 181	28 723	66	327	11 366	11 827	5 203	28 358
N06AB08 fluvoxamine	653	620	603	586	552	55	0	208	271	73	1 053
N06AB10 escitalopram	93 703	98 493	102 626	107 172	109 202	65	25	41 687	45 876	21 614	73 566
N06AF Monoamine oxidase inhibitors, non-selective	110	111	111	102	95	62	0	22	54	19	1 231
N06AF03 phenelzine	100	102	102	94	88	60	0	19	51	18	584
N06AF04 tranylcypromine	10	9	9	9	7	86	0	<5	<5	<5	647
N06AG Monoamine oxidase A inhibitors	1 081	965	880	853	757	63	0	161	435	161	1 734
N06AG02 moclobemide	1 081	965	880	853	757	63	0	161	435	161	1 734
N06AX Other antidepressants	88 987	90 568	92 850	95 460	98 561	60	48	31 021	45 064	22 428	105 628
N06AX01 oxitriptan	187	244	261	308	292	82	10	149	124	9	356
N06AX02 tryptophan	11	5	<5	<5	6	83	<5	<5	<5	0	7
N06AX03 mianserin	32 133	31 289	30 307	29 477	28 065	62	12	6 604	13 325	8 124	10 736
N06AX05 trazodone	<5	<5	<5	<5	<5	100	0	0	<5	0	6
N06AX06 nefazodone	48	43	42	36	36	47	0	<5	31	<5	278
N06AX11 mirtazapine	28 798	30 394	31 458	33 331	35 629	57	17	9 958	15 070	10 584	30 660
N06AX12 bupropion	3 892	5 978	7 641	8 808	10 186	59	<5	5 010	4 470	704	18 108
N06AX14 tianeptine	<5	<5	<5	<5	<5	33	0	<5	0	0	78
N06AX16 venlafaxine	28 349	28 734	28 791	29 240	30 220	62	6	11 229	14 631	4 354	33 878
N06AX18 reboxetine	569	530	512	424	410	64	0	200	173	37	862
N06AX21 duloxetine	3 945	2 419	2 804	3 021	3 190	68	0	994	1 722	474	10 460
N06AX22 agomelatine	0	0	28	22	15	80	0	<5	11	<5	196

ATC group N

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
N06AX25 Hyperici herba	0	0	0	0	6	67	0	<5	<5	<5	5
N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS	25 207	27 837	30 080	31 221	32 973	38	10 527	19 403	2 897	146	193 589
N06BA Centrally acting sympathomimetics	24 862	27 490	29 711	30 821	32 575	37	10 519	19 186	2 761	109	192 970
N06BA01 amfetamine	221	269	303	336	382	48	23	255	90	14	4 591
N06BA02 dexamfetamine	857	1 024	1 167	1 285	1 473	43	80	1 008	364	21	18 472
N06BA04 methylphenidate	21 769	24 240	26 471	27 302	28 962	37	9 880	16 859	2 160	63	137 038
N06BA07 modafinil	288	291	329	349	366	62	15	218	119	14	4 061
N06BA09 atomoxetine	3 246	3 213	3 055	3 108	3 032	34	1 089	1 776	167	0	28 800
N06BA12 lisdexamfetamine	0	0	0	0	<5	100	0	<5	0	0	8
N06BC Xanthine derivatives	294	281	285	326	321	47	<5	187	105	27	167
N06BC01 caffeine	294	281	285	326	321	47	<5	187	105	27	167
N06BX Other psychostimulants and nootropics	57	75	102	86	87	41	6	37	34	10	452
N06BX03 piracetam	49	65	77	70	76	38	<5	30	34	10	249
N06BX13 idebenone	8	10	8	10	11	64	<5	7	0	0	203
N06BX17 adrafinil	0	0	18	6	0	-	0	0	0	0	0
N06C PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION	0	0	0	0	<5	0	0	<5	0	0	0
N06CA Antidepressants in combination with psycholeptics	0	0	0	0	<5	0	0	<5	0	0	0
N06CA02 melitracen and psycholeptics	0	0	0	0	<5	0	0	<5	0	0	0
N06D ANTI-DEMENTIA DRUGS	13 367	13 344	14 174	14 759	15 484	63	<5	89	1 440	13 953	72 806
N06DA Anticholinesterases	12 377	12 372	12 920	12 850	13 023	63	0	<5	1 217	11 804	52 083
N06DA02 donepezil	9 837	9 243	8 920	8 530	8 303	64	0	<5	731	7 571	24 535
N06DA03 rivastigmine	2 161	2 975	3 935	4 303	4 767	60	0	<5	486	4 280	24 876
N06DA04 galantamine	694	558	502	395	347	57	0	0	52	295	2 672
N06DX Other anti-dementia drugs	1 501	1 538	1 969	3 030	3 578	61	<5	87	382	3 107	20 723
N06DX01 memantine	1 501	1 538	1 816	2 837	3 445	61	0	<5	341	3 101	20 640
N06DX02 Ginkgo folium	0	0	153	193	133	77	<5	84	41	6	83
N07 OTHER NERVOUS SYSTEM DRUGS	42 733	46 042	47 182	48 455	45 068	49	9	16 489	26 054	2 516	280 914
N07A PARASYMPATHOMIMETICS	743	721	660	684	732	66	<5	113	371	246	2 381
N07AA Anticholinesterases	476	493	509	523	567	60	<5	104	248	213	1 166
N07AA02 pyridostigmine	476	492	505	519	565	60	<5	103	247	213	1 160
N07AA30 ambenonium	0	<5	<5	<5	<5	100	0	<5	<5	0	6
N07AA51 neostigmine, combinations	0	0	<5	<5	0	-	0	0	0	0	0
N07AB Choline esters	149	112	22	33	30	60	0	<5	23	6	55

ATC group N

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
N07AB01 carbachol	149	112	22	33	30	60	0	<5	23	6	55
N07AX Other parasymphomimetics	129	123	130	131	138	93	0	8	103	27	1 160
N07AX01 pilocarpine	129	123	130	131	138	93	0	8	103	27	1 160
N07B DRUGS USED IN ADDICTIVE DISORDERS	41 279	44 554	45 745	46 701	41 810	48	0	15 989	23 898	1 923	209 415
N07BA Drugs used in nicotine dependence	31 433	34 174	34 822	35 032	29 849	55	0	10 299	17 925	1 625	42 253
N07BA01 nicotine ¹⁾	770	769	906	1 000	915	53	0	131	528	256	623
N07BA03 varenicline	30 731	33 475	34 002	34 123	29 010	55	0	10 179	17 451	1 380	41 629
N07BB Drugs used in alcohol dependence	4 990	4 984	4 866	4 953	4 934	31	0	1 539	3 135	260	3 966
N07BB01 disulfiram	4 464	4 533	4 450	4 541	4 510	30	0	1 418	2 853	239	3 060
N07BB03 acamprosate	584	550	526	543	587	33	0	179	383	25	804
N07BB04 naltrexone	119	26	19	17	13	69	0	6	6	<5	102
N07BC Drugs used in opioid dependence	5 160	5 704	6 368	7 048	7 346	30	0	4 266	3 038	42	163 196
N07BC01 buprenorphine ²⁾	1 719	1 981	2 133	2 270	2 624	30	0	1 688	933	<5	50 102
N07BC02 methadone ²⁾	2 952	3 140	3 337	3 636	3 629	32	0	1 794	1 797	38	88 613
N07BC51 buprenorphine, combinations ²⁾	1 156	1 194	1 562	1 759	1 851	26	0	1 359	491	<5	24 482
N07C ANTIVERTIGO PREPARATIONS	413	421	424	454	527	65	<5	97	312	115	1 279
N07CA Antivertigo preparations	413	421	424	454	527	65	<5	97	312	115	1 279
N07CA01 betahistine	401	410	413	438	508	64	0	88	305	115	1 247
N07CA03 flunarizine	12	11	11	16	19	68	<5	9	7	0	32
N07X OTHER NERVOUS SYSTEM DRUGS	311	361	366	644	2 060	58	<5	305	1 514	237	67 839
N07XX Other nervous system drugs	311	361	366	644	2 060	58	<5	305	1 514	237	67 839
N07XX02 riluzole	253	286	278	294	297	34	0	18	160	119	7 627
N07XX04 sodium oxybate	28	33	49	58	63	54	<5	45	12	<5	4 896
N07XX05 amifampridine	0	0	0	0	<5	0	0	<5	0	0	927
N07XX06 tetrabenazine	30	42	37	35	40	50	0	8	24	8	647
N07XX07 fampridine	0	0	<5	257	1 659	63	<5	233	1 318	107	53 742

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

²⁾The figures only include methadone dispensed according to prescription from the pharmacies. Patients may also receive this drug dispensed according to special arrangements in the health regions.

2.15 ATC group P – Antiparasitic products, insecticides and repellents

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	89 343	86 714	88 743	92 296	94 797	63	3 329	42 623	37 887	10 958	33 814
P01 ANTIPROTOZOALS	86 259	83 638	85 626	88 926	91 338	63	2 150	41 076	37 327	10 785	31 870
P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES	53 345	54 583	55 588	57 290	57 887	66	576	24 745	24 117	8 449	6 502
P01AB Nitroimidazole derivatives	53 340	54 576	55 587	57 289	57 884	66	576	24 743	24 116	8 449	6 475
P01AB01 metronidazole	53 340	54 571	55 540	57 236	57 820	66	573	24 700	24 098	8 449	6 218
P01AB02 tinidazole	0	7	6	9	124	73	6	81	36	<5	251
P01AB03 ornidazole	0	0	46	73	9	78	0	5	<5	0	4
P01AB06 nimorazole	0	0	0	0	<5	0	0	0	<5	0	2
P01AC Dichloroacetamide derivatives	6	13	<5	11	12	33	<5	5	5	<5	27
P01AC01 diloxanide	6	13	<5	11	12	33	<5	5	5	<5	27
P01AX Other agents against amoebiasis and other protozoal diseases	<5	<5	<5	0	0	-	0	0	0	0	0
P01AX05 mepacrine	<5	0	0	0	0	-	0	0	0	0	0
P01AX11 nitazoxanide	<5	<5	<5	0	0	-	0	0	0	0	0
P01B ANTIMALARIALS	33 502	29 645	30 716	32 446	34 243	59	1 583	16 708	13 570	2 382	25 358
P01BA Aminoquinolines	7 804	5 421	5 684	5 912	6 122	82	43	1 669	3 415	995	3 497
P01BA01 chloroquine	2 630	40	21	17	21	71	0	6	11	<5	18
P01BA02 hydroxychloroquine	5 211	5 371	5 661	5 897	6 102	82	43	1 663	3 405	991	3 480
P01BA03 primaquine	17	12	<5	0	0	-	0	0	0	0	0
P01BB Biguanides	21 153	19 494	20 468	21 918	23 860	53	1 078	12 694	9 042	1 046	19 905
P01BB01 proguanil	62	22	11	7	<5	100	0	0	<5	0	1
P01BB51 proguanil, combinations	21 096	19 476	20 459	21 913	23 859	53	1 078	12 694	9 041	1 046	19 904
P01BC Methanolquinolines	5 056	5 044	4 802	4 841	4 457	59	469	2 471	1 173	344	1 954
P01BC01 quinine	595	629	569	473	440	65	0	21	197	222	267
P01BC02 mefloquine	4 463	4 415	4 235	4 368	4 018	58	469	2 450	977	122	1 687
P01BD Diaminopyrimidines	<5	5	<5	0	0	-	0	0	0	0	0
P01BD01 pyrimethamine	<5	5	<5	0	0	-	0	0	0	0	0
P01BE Artemisinin and derivatives, plain	0	0	0	0	<5	100	0	<5	0	0	1
P01BE03 artesunate	0	0	0	0	<5	100	0	<5	0	0	1
P01BF Artemisinin and derivatives, combinations	0	0	<5	<5	<5	100	0	0	<5	0	2
P01BF01 artemether and lumefantrine	0	0	<5	<5	<5	100	0	0	<5	0	2

ATC group P

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<5	5-14	15-44	45-69	≥70		<15	15-44	45-69	≥70	
P01C AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS	<5	<5	<5	0	<5	0	0	0	<5	0	10
P01CX Other agents against leishmaniasis and trypanosomiasis	<5	<5	<5	0	<5	0	0	0	<5	0	10
P01CX01 pentamidine isethionate	<5	<5	<5	0	<5	0	0	0	<5	0	10
P02 ANTHELMINTICS	2 008	2 047	2 107	2 224	2 269	57	1 020	811	351	87	1 414
P02B ANTITREMATODALS	16	19	26	41	44	45	5	23	12	<5	115
P02BA Quinoline derivatives and related substances	16	19	26	41	44	45	5	23	12	<5	115
P02BA01 praziquantel	16	19	26	41	44	45	5	23	12	<5	115
P02C ANTINEMATODAL AGENTS	1 985	2 016	2 068	2 171	2 223	57	1 014	785	342	82	1 292
P02CA Benzimidazole derivatives	1 853	1 870	1 900	2 004	2 038	56	955	701	309	73	1 180
P02CA01 mebendazole	1 835	1 847	1 877	1 960	1 974	56	941	666	295	72	376
P02CA03 albendazole	18	24	23	45	70	60	14	38	16	<5	804
P02CF Avermectines	43	47	62	58	77	52	12	38	21	6	94
P02CF01 ivermectin	43	47	62	58	77	52	12	38	21	6	94
P02CX Other antinematodals	103	114	120	119	123	71	49	53	16	5	18
P02CX01 pyrvinium	103	114	120	119	123	71	49	53	16	5	18
P02D ANTICESTODALS	10	18	18	26	12	42	<5	7	<5	<5	7
P02DA Salicylic acid derivatives	10	18	18	26	12	42	<5	7	<5	<5	7
P02DA01 niclosamide	10	18	18	26	12	42	<5	7	<5	<5	7
P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS	1 216	1 157	1 176	1 297	1 354	52	173	835	252	94	530
P03A ECTOPARASITICIDES, INCL. SCABICIDES	1 216	1 157	1 176	1 297	1 354	52	173	835	252	94	530
P03AC Pyrethrines, incl. synthetic compounds	1 126	1 085	1 093	1 222	1 278	51	160	798	233	87	507
P03AC04 permethrin ¹⁾	1 126	1 085	1 093	1 222	1 278	51	160	798	233	87	507
P03AX Other ectoparasiticides, incl. scabicides	97	77	86	82	84	67	14	41	21	8	23
P03AX01 benzyl benzoate ¹⁾	36	18	24	28	21	48	<5	11	<5	<5	6
P03AX03 malathion ¹⁾	61	59	62	54	63	73	10	30	17	6	17

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.16 ATC group R – Respiratory system

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
R RESPIRATORY SYSTEM	1 151 928	1 183 767	1 183 735	1 223 490	1 234 841	56	169 146	451 770	445 061	168 864	1 448 923
R01 NASAL PREPARATIONS	333 006	348 415	353 908	364 669	375 789	57	32 354	176 737	135 634	31 064	113 282
R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	278 007	294 861	297 143	307 141	315 476	55	30 954	143 622	112 782	28 118	107 107
R01AA Sympathomimetics, plain	4 204	3 803	4 017	3 672	3 521	53	1 003	1 334	837	347	258
R01AA05 oxymetazoline ¹⁾	1 734	1 550	1 802	1 781	1 740	54	691	621	331	97	113
R01AA07 xylometazoline ¹⁾	2 483	2 264	2 233	1 899	1 790	51	315	714	510	251	146
R01AB Sympathomimetics, combinations excl. corticosteroids	1 124	514	602	603	466	54	11	187	165	103	86
R01AB06 xylometazoline ¹⁾	1 124	514	602	603	466	54	11	187	165	103	86
R01AC Antiallergic agents, excl. corticosteroids	44 711	44 853	39 407	40 956	39 373	55	10 402	18 752	8 678	1 541	10 628
R01AC01 cromoglicic acid ¹⁾	10 718	10 197	8 772	8 705	7 926	59	1 735	3 731	2 084	376	2 111
R01AC02 levocabastine ¹⁾	34 025	34 686	30 659	32 377	31 513	54	8 733	15 028	6 586	1 166	8 472
R01AC03 azelastine ¹⁾	261	227	198	127	151	55	20	81	41	9	46
R01AD Corticosteroids	234 552	252 559	259 097	267 954	278 023	55	20 701	126 404	104 650	26 268	95 659
R01AD01 beclometasone	2 228	1 943	11	<5	0	-	0	0	0	0	0
R01AD04 flunisolide	4 133	2 634	11	9	10	60	0	0	7	<5	16
R01AD05 budesonide	43 762	39 753	34 996	32 644	31 182	56	1 849	12 163	13 647	3 523	11 314
R01AD08 fluticasone	32 446	27 939	24 352	22 518	21 902	55	975	8 073	10 046	2 808	9 214
R01AD09 mometasone	142 288	143 465	141 114	144 414	150 797	55	9 967	68 048	57 740	15 042	52 700
R01AD11 triamcinolone	13 593	11 025	9 687	8 713	7 886	57	394	3 253	3 371	868	3 174
R01AD12 fluticasone furoate	3 945	38 322	60 417	70 241	77 223	55	8 111	39 800	24 291	5 021	19 241
R01AX Other nasal preparations	459	572	630	728	816	53	56	210	253	297	475
R01AX03 ipratropium bromide	264	302	355	422	467	50	<5	50	164	252	366
R01AX06 mupirocin	195	270	276	306	349	58	55	160	89	45	108
R01B NASAL DECONGESTANTS FOR SYSTEMIC USE	75 926	75 490	81 771	83 161	88 517	67	1 816	48 518	33 865	4 318	6 175
R01BA Sympathomimetics	75 926	75 490	81 771	83 161	88 517	67	1 816	48 518	33 865	4 318	6 175
R01BA01 phenylpropanolamine	75 926	75 490	81 771	83 161	88 517	67	1 816	48 518	33 865	4 318	6 175
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	397 839	419 368	423 205	418 109	418 777	54	87 973	108 738	148 215	73 851	1 094 637
R03A ADRENERGICS, INHALANTS	309 382	328 514	335 492	347 921	353 699	54	59 251	98 941	131 898	63 609	703 188
R03AA Alpha- and beta-adrenoreceptor agonists	185	181	209	246	230	35	200	17	7	6	220
R03AA01 epinephrine	185	181	209	246	230	35	200	17	7	6	220
R03AC Selective beta-2-adrenoreceptor agonists	230 012	244 327	249 080	258 858	263 993	54	56 212	75 627	90 209	41 945	142 844

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group R

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
R03AC02 salbutamol	175 373	190 769	198 277	208 540	215 094	54	54 499	61 549	68 518	30 528	76 681
R03AC03 terbutaline	39 227	38 318	35 556	34 151	32 110	57	1 656	12 091	13 280	5 083	12 333
R03AC04 fenoterol	23	17	17	16	12	42	0	0	11	<5	65
R03AC12 salmeterol	10 847	10 555	10 563	9 699	9 189	55	215	1 017	4 377	3 580	15 951
R03AC13 formoterol	17 310	16 879	16 627	15 456	14 418	55	296	3 039	7 048	4 035	21 468
R03AC18 indacaterol	0	0	713	4 814	7 446	46	0	173	3 959	3 314	16 346
R03AK Adrenergics and other drugs for obstructive airway diseases	155 451	164 536	168 450	175 117	178 056	55	10 285	48 000	79 357	40 414	560 123
R03AK04 salbutamol and other drugs for obstructive airway diseases	<5	<5	<5	0	0	-	0	0	0	0	0
R03AK06 salmeterol and other drugs for obstructive airway diseases	86 941	90 149	90 997	94 190	95 766	55	8 381	23 175	40 755	23 455	323 552
R03AK07 formoterol and other drugs for obstructive airway diseases	71 382	77 502	80 699	84 168	85 605	56	2 006	25 673	40 171	17 755	236 572
R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS	134 223	140 443	146 450	149 797	152 252	51	42 757	21 502	50 901	37 092	258 064
R03BA Glucocorticoids	85 762	88 434	91 633	92 760	93 478	51	42 485	18 589	22 612	9 792	81 339
R03BA01 beclometasone	4 825	4 729	4 380	4 075	4 014	55	807	977	1 533	697	3 388
R03BA02 budesonide	26 377	25 860	25 066	23 194	21 246	57	2 604	5 627	8 566	4 449	27 457
R03BA05 fluticasone	56 192	59 302	62 013	64 095	63 451	47	39 590	10 157	9 874	3 830	43 009
R03BA07 mometasone	<5	<5	<5	0	544	54	50	229	211	54	486
R03BA08 ciclesonide	0	0	1 874	3 476	6 094	58	412	1 951	2 830	901	6 999
R03BB Anticholinergics	53 722	57 032	60 133	62 625	64 392	52	686	3 504	30 783	29 419	176 473
R03BB01 ipratropium bromide	41 832	39 555	38 289	35 884	32 150	56	685	2 945	14 335	14 185	30 527
R03BB04 tiotropium bromide	16 714	22 767	27 429	32 809	39 680	49	<5	685	19 889	19 104	145 947
R03BC Antiallergic agents, excl. corticosteroids	539	521	454	430	383	66	27	139	179	38	252
R03BC01 cromoglicic acid	539	521	454	430	383	66	27	139	179	38	252
R03C ADRENERGICS FOR SYSTEMIC USE	67 040	68 733	63 272	40 582	33 046	49	24 952	3 297	3 489	1 308	4 470
R03CA Alpha- and beta-adrenoreceptor agonists	53 610	55 608	49 364	23 993	17 151	50	12 150	2 161	2 160	680	2 662
R03CA02 ephedrine	53 610	55 608	49 364	23 993	17 151	50	12 150	2 161	2 160	680	2 662
R03CC Selective beta-2-adrenoreceptor agonists	16 509	16 104	16 917	17 886	16 770	48	13 642	1 147	1 352	629	1 808
R03CC02 salbutamol	5 091	4 877	4 731	4 844	4 265	46	3 549	280	309	127	306
R03CC03 terbutaline	11 420	11 149	12 109	12 968	12 440	49	10 233	842	936	429	1 258
R03CC12 bambuterol	227	238	245	210	219	58	0	30	114	75	245

ATC group R

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012 Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	39 324	40 012	41 123	42 178	42 233	56	8 826	10 623	16 153	6 631	128 915
R03DA Xanthines	5 938	5 287	4 785	4 300	3 855	59	5	228	1 900	1 722	2 782
R03DA02 choline theophyllinate	12	8	10	6	8	100	0	<5	7	0	33
R03DA04 theophylline	5 916	5 272	4 768	4 288	3 843	59	5	224	1 892	1 722	2 692
R03DA05 aminophylline	29	26	19	19	14	57	0	<5	10	<5	57
R03DC Leukotriene receptor antagonists	34 436	35 710	37 220	38 267	38 493	56	8 817	10 452	14 415	4 809	102 858
R03DC01 zafirlukast	28	25	22	22	21	62	0	<5	12	7	194
R03DC03 montelukast	34 409	35 686	37 199	38 245	38 473	56	8 817	10 450	14 404	4 802	102 664
R03DX Other systemic drugs for obstructive airway diseases	44	53	145	751	1 058	49	10	105	534	409	23 275
R03DX05 omalizumab	44	53	84	133	175	55	10	97	66	<5	20 507
R03DX07 roflumilast	0	0	61	620	885	47	0	9	469	407	2 767
R05 COUGH AND COLD PREPARATIONS	373 471	385 148	382 371	422 433	412 291	59	31 876	136 634	167 947	75 834	71 178
R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS	126 488	133 512	135 840	147 156	135 543	58	6 848	30 721	57 135	40 839	32 532
R05CA Expectorants	3 135	3 334	3 671	4 351	3 817	55	1 608	873	849	487	274
R05CA10 combinations ¹⁾	3 135	3 334	3 671	4 351	3 817	55	1 608	873	849	487	274
R05CB Mucolytics	123 898	130 752	132 821	143 557	132 373	58	5 318	29 990	56 522	40 543	32 258
R05CB01 acetylcysteine ¹⁾	119 891	126 968	128 953	139 329	128 617	58	3 931	29 241	55 597	39 848	25 155
R05CB02 bromhexine ¹⁾	4 836	4 561	4 658	4 974	4 452	54	1 388	855	1 188	1 021	676
R05CB12 tiopronin	<5	5	5	<5	<5	50	0	0	<5	0	8
R05CB13 dornase alfa (desoxyribonuclease)	110	109	118	128	130	51	42	80	8	0	6 418
R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS	255 435	258 842	254 586	283 928	280 472	60	23 070	102 962	115 180	39 260	33 894
R05DA Opium alkaloids and derivatives	255 434	258 842	254 586	283 928	280 472	60	23 070	102 962	115 180	39 260	33 894
R05DA01 ethylmorphine	246 451	249 476	245 677	274 413	271 143	60	22 669	99 845	110 994	37 635	31 129
R05DA03 hydrocodone	570	581	592	592	543	62	<5	94	297	151	184
R05DA04 codeine	7 660	7 715	7 203	7 752	7 699	64	110	2 816	3 571	1 202	1 671
R05DA07 noscapine ¹⁾	1 561	1 763	1 880	1 952	1 654	60	317	530	538	269	149
R05DA09 dextromethorphan	<5	<5	<5	0	<5	100	0	0	0	<5	0
R05DA20 combinations	2 881	3 036	2 836	2 918	2 978	62	31	867	1 491	589	761
R05DB Other cough suppressants	<5	0	0	0	0	-	0	0	0	0	0
R05DB05 pentoxyverine	<5	0	0	0	0	-	0	0	0	0	0

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group R

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
R05F COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS	37 584	41 525	41 844	48 192	49 132	61	3 395	18 489	20 097	7 151	4 752
R05FA Opium derivatives and expectorants	37 584	41 525	41 844	48 192	49 132	61	3 395	18 489	20 097	7 151	4 752
R05FA02 opium derivatives and expectorants	37 584	41 525	41 844	48 192	49 132	61	3 395	18 489	20 097	7 151	4 752
R06 ANTIHISTAMINES FOR SYSTEMIC USE	514 755	519 116	511 537	529 217	543 430	58	72 424	224 888	191 959	54 159	167 923
R06A ANTIHISTAMINES FOR SYSTEMIC USE	514 755	519 116	511 537	529 217	543 430	58	72 424	224 888	191 959	54 159	167 923
R06AA Aminoalkyl ethers	18	18	15	14	23	52	<5	8	8	6	31
R06AA02 diphenhydramine	<5	<5	<5	0	6	33	0	<5	<5	<5	3
R06AA04 clemastine	14	14	14	14	17	59	<5	6	5	5	28
R06AB Substituted alkylamines	40 313	35 818	25 263	22 719	20 206	67	4 566	7 452	5 534	2 654	5 868
R06AB02 dexchlorpheniramine	40 313	35 818	25 263	22 719	20 206	67	4 566	7 452	5 534	2 654	5 868
R06AD Phenothiazine derivatives	62 532	62 798	64 453	65 875	65 863	62	3 973	23 263	28 737	9 890	35 046
R06AD01 alimemazine	55 908	56 465	57 913	59 728	59 976	62	3 910	21 003	26 163	8 900	32 267
R06AD02 promethazine	7 311	6 991	7 154	6 719	6 447	67	69	2 480	2 849	1 049	2 768
R06AD03 thiethylperazine	8	<5	5	<5	5	80	0	<5	0	<5	11
R06AE Piperazine derivatives	272 062	294 720	285 404	293 955	285 294	58	40 389	113 759	101 056	30 090	57 878
R06AE03 cyclizine ¹⁾	276	655	737	759	726	69	13	221	316	176	278
R06AE05 meclozine ¹⁾	2 094	1 956	2 031	2 165	2 227	88	77	1 640	317	193	202
R06AE07 cetirizine ¹⁾	269 004	291 604	282 294	290 730	282 094	58	40 298	111 811	100 286	29 699	56 880
R06AE09 levocetirizine	1 040	844	703	661	609	62	16	265	263	65	518
R06AX Other antihistamines for systemic use	180 177	164 938	169 564	178 145	206 015	58	27 655	94 797	68 802	14 761	69 100
R06AX02 cyproheptadine	61	59	40	17	23	61	7	8	5	<5	15
R06AX13 loratadine ¹⁾	74 765	92 307	83 864	82 823	71 330	60	4 422	33 534	26 676	6 698	17 651
R06AX17 ketotifen	5	<5	7	10	9	56	0	5	<5	<5	14
R06AX22 ebastine ¹⁾	23 548	11 035	10 315	10 432	9 815	65	166	4 430	4 339	880	8 747
R06AX26 fexofenadine	11 575	24 496	27 017	30 412	29 310	62	794	15 322	10 824	2 370	9 606
R06AX27 desloratadine	81 363	48 971	55 048	60 505	103 310	56	22 750	45 559	29 682	5 319	33 067
R07 OTHER RESPIRATORY SYSTEM PRODUCTS	0	0	0	0	<5	50	0	<5	0	0	1 903
R07A OTHER RESPIRATORY SYSTEM PRODUCTS	0	0	0	0	<5	50	0	<5	0	0	1 903
R07AX Other respiratory system products	0	0	0	0	<5	50	0	<5	0	0	1 903
R07AX02 ivacaftor	0	0	0	0	<5	50	0	<5	0	0	1 903

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.17 ATC group S – Sensory organs

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
S SENSORY ORGANS	596 101	596 290	609 467	617 742	614 238	57	112 776	177 918	192 459	131 085	302 360
S01 OPHTHALMOLOGICALS	525 644	526 629	538 818	549 815	543 836	57	99 861	156 004	166 156	121 815	287 430
S01A ANTIINFECTIVES	262 875	250 367	269 034	266 933	258 814	56	71 421	75 690	74 191	37 512	47 176
S01AA Antibiotics	260 246	247 638	266 185	264 028	255 819	56	71 253	74 615	73 060	36 891	45 738
S01AA01 chloramphenicol	192 708	182 292	197 212	200 731	195 118	55	46 730	59 178	59 547	29 663	38 206
S01AA02 chlortetracycline	<5	<5	<5	<5	<5	67	<5	<5	<5	0	1
S01AA11 gentamicin	2 022	1 763	1 702	1 597	1 242	59	105	419	450	268	145
S01AA12 tobramycin	2 455	2 332	2 302	2 322	2 014	60	277	576	707	454	189
S01AA13 fusidic acid	79 306	75 838	82 810	75 325	70 028	57	29 458	17 227	15 236	8 107	6 332
S01AA26 azithromycin	0	0	0	0	2 738	61	835	830	751	322	272
S01AA30 combinations of different antibiotics	4 917	4 936	5 105	5 269	4 330	59	220	980	1 662	1 468	592
S01AD Antivirals	3 080	3 249	3 266	3 171	3 395	56	122	1 020	1 392	861	836
S01AD01 idoxuridine	0	<5	0	0	0	-	0	0	0	0	0
S01AD02 trifluridine	<5	0	0	0	0	-	0	0	0	0	0
S01AD03 aciclovir	3 079	3 248	3 266	3 171	3 395	56	122	1 020	1 392	861	836
S01AE Fluoroquinolones	1 923	1 982	2 138	2 327	2 459	54	174	964	869	452	583
S01AE03 ciprofloxacin	1 923	1 982	2 138	2 327	2 459	54	174	964	869	452	583
S01AX Other antiinfectives	<5	<5	<5	<5	<5	25	<5	<5	<5	0	18
S01AX15 propamidine	0	0	0	<5	<5	0	0	0	<5	0	2
S01B ANTIINFLAMMATORY AGENTS	42 882	44 119	45 945	46 769	49 765	58	1 675	9 028	18 520	20 542	15 378
S01BA Corticosteroids, plain	30 231	30 111	30 638	31 478	33 466	57	1 618	8 044	13 497	10 307	10 610
S01BA01 dexamethasone	17 332	18 319	18 993	20 148	20 457	55	500	4 547	8 782	6 628	7 184
S01BA04 prednisolone	15 017	12 418	11 840	10 925	13 558	59	1 068	4 069	5 363	3 058	2 192
S01BA07 fluorometholone	15	17	16	12	12	58	0	<5	8	<5	10
S01BA09 clobetasone	22	18	16	13	16	56	<5	<5	9	<5	59
S01BA13 rimexolone	2 151	4 177	4 351	4 414	4 284	57	189	1 127	1 586	1 382	1 164
S01BB Corticosteroids and mydriatics in combination	<5	<5	<5	<5	<5	50	0	<5	0	<5	1
S01BB03 fluorometholone and mydriatics	<5	<5	<5	<5	<5	50	0	<5	0	<5	1
S01BC Antiinflammatory agents, non-steroids	14 254	15 618	17 141	17 568	18 705	58	69	1 311	5 915	11 410	4 767
S01BC03 diclofenac	14 254	15 618	15 814	11 689	7 404	57	54	1 048	2 425	3 877	1 476
S01BC10 nepafenac	0	0	1 528	6 095	10 279	58	11	244	3 155	6 869	2 985
S01BC11 bromfenac	0	0	0	0	1 366	60	5	40	458	863	306

ATC group S

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION	57 374	56 226	56 906	57 674	57 726	58	1 125	8 988	20 689	26 924	10 824
S01CA Corticosteroids and anti-infectives in combination	57 374	56 226	56 906	57 674	57 726	58	1 125	8 988	20 689	26 924	10 824
S01CA01 dexamethasone and anti-infectives	57 374	56 226	56 906	57 674	57 726	58	1 125	8 988	20 689	26 924	10 824
S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS	68 239	68 940	70 039	70 786	71 349	57	187	2 112	21 488	47 562	136 473
S01EA Sympathomimetics in glaucoma therapy¹⁾	3 953	3 992	4 077	4 222	4 439	53	7	170	1 169	3 093	3 991
S01EA01 epinephrine	5	<5	<5	<5	<5	50	0	0	<5	<5	3
S01EA02 dipivefrine	217	122	9	<5	0	-	0	0	0	0	0
S01EA03 apraclonidine	91	97	115	122	145	52	<5	17	56	71	83
S01EA05 brimonidine	3 706	3 838	3 983	4 122	4 344	53	6	159	1 131	3 048	3 905
S01EB Parasympathomimetics	1 498	1 433	1 291	1 254	1 177	60	<5	61	314	800	1 044
S01EB01 pilocarpine	1 496	1 431	1 289	1 253	1 176	60	<5	61	313	800	1 040
S01EB02 carbachol	<5	<5	<5	<5	<5	100	0	0	<5	0	4
S01EC Carbonic anhydrase inhibitors	9 488	9 634	10 040	10 322	10 634	57	103	729	2 770	7 032	12 449
S01EC01 acetazolamide	1 597	1 531	1 699	1 828	1 920	53	50	572	669	629	1 056
S01EC03 dorzolamide	2 783	2 660	2 503	2 393	2 340	58	12	43	542	1 743	2 882
S01EC04 brinzolamide	5 415	5 811	6 195	6 452	6 753	57	46	126	1 660	4 921	8 511
S01EC05 methazolamide	<5	0	0	0	0	-	0	0	0	0	0
S01ED Beta blocking agents¹⁾	47 883	48 377	48 841	49 028	49 427	56	127	1 178	14 898	33 224	72 490
S01ED01 timolol	23 313	22 977	22 326	21 731	21 575	57	99	536	7 287	13 653	22 510
S01ED02 betaxolol	2 233	2 012	1 778	1 587	1 433	65	<5	14	335	1 081	964
S01ED51 timolol, combinations	24 676	25 922	27 060	27 984	28 598	55	32	702	8 025	19 839	49 016
S01EE Prostaglandin analogues¹⁾	35 402	36 048	36 697	37 171	37 030	58	14	652	10 412	25 952	46 500
S01EE01 latanoprost	29 658	28 946	27 890	26 156	24 215	58	5	352	6 328	17 530	20 507
S01EE03 bimatoprost	1 814	1 807	1 867	1 871	2 055	58	<5	61	612	1 381	3 220
S01EE04 travoprost	4 469	4 844	5 035	6 464	7 190	55	<5	123	2 127	4 938	10 849
S01EE05 tafluprost	0	1 654	3 068	4 029	4 997	63	7	137	1 805	3 048	11 924
S01F MYDRIATICS AND CYCLOPLEGICS	4 744	4 899	5 066	5 041	5 301	46	477	1 270	2 354	1 200	995
S01FA Anticholinergics	4 737	4 891	5 062	5 038	5 295	46	477	1 267	2 352	1 199	989
S01FA01 atropine	2 750	2 670	2 549	2 323	2 318	47	416	477	935	490	476
S01FA04 cyclopentolate	2 034	2 277	2 546	2 746	3 057	45	57	823	1 453	724	485
S01FA06 tropicamide	164	157	189	164	140	56	10	51	63	16	29

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group S

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
S01FB Sympathomimetics excl. antiglaucoma preparations	48	39	29	35	33	39	0	15	15	<5	5
S01FB01 phenylephrine	48	39	29	35	33	39	0	15	15	<5	5
S01G DECONGESTANTS AND ANTIALLERGICS	164 724	172 049	158 625	167 530	163 297	58	29 102	73 198	48 775	12 222	47 041
S01GA Sympathomimetics used as decongestants	23 730	23 098	20 728	21 288	20 269	60	2 415	9 165	6 902	1 787	6 023
S01GA51 naphazoline, combinations	11	11	<5	6	<5	67	<5	0	<5	<5	1
S01GA52 tetrazoline, combinations	23 719	23 089	20 725	21 283	20 266	60	2 414	9 165	6 901	1 786	6 022
S01GX Other antiallergics	144 671	152 775	141 091	149 662	146 376	58	27 320	65 543	42 870	10 643	41 018
S01GX01 cromoglicic acid ¹⁾	24 839	25 305	22 551	23 401	22 526	61	3 348	9 764	7 549	1 865	5 698
S01GX02 levocabastine ¹⁾	73 171	77 301	70 567	75 499	73 730	57	14 686	33 142	20 955	4 947	18 750
S01GX04 nedocromil	1 982	2 018	1 777	1 702	1 442	58	171	731	449	91	291
S01GX05 lodoxamide ¹⁾	339	35	0	0	0	-	0	0	0	0	0
S01GX06 emedastine	546	490	379	384	374	63	67	129	135	43	128
S01GX07 azelastine	755	691	580	553	528	56	74	231	162	61	151
S01GX08 ketotifen ¹⁾	16 912	17 926	16 305	17 279	16 678	59	2 970	7 422	4 961	1 325	6 367
S01GX09 olopatadine	30 752	34 046	32 856	35 349	35 400	57	7 051	15 768	9 927	2 654	9 633
S01X OTHER OPHTHALMOLOGICALS	6 859	18 266	26 371	34 504	40 527	76	305	3 967	17 429	18 826	29 519
S01XA Other ophthalmologicals	6 859	18 266	26 371	34 504	40 527	76	305	3 967	17 429	18 826	29 519
S01XA03 sodium chloride, hypertonic	16	20	15	17	10	30	0	<5	<5	6	32
S01XA18 ciclosporin	27	41	70	112	252	61	10	72	131	39	2 635
S01XA20 artificial tears and other indifferent preparations ¹⁾	6 823	18 234	26 329	34 451	40 435	76	296	3 942	17 386	18 811	26 853
S02 OTOLOGICALS	13 048	14 496	14 933	20 226	18 667	54	3 446	4 974	7 220	3 027	3 578
S02A ANTIINFECTIVES	7 097	7 037	7 346	10 565	9 559	48	3 241	2 722	2 623	973	1 711
S02AA Antiinfectives	7 097	7 037	7 346	10 565	9 559	48	3 241	2 722	2 623	973	1 711
S02AA01 chloramphenicol	202	123	75	75	17	41	<5	5	<5	<5	19
S02AA15 ciprofloxacin	6 923	6 937	7 290	10 501	9 545	48	3 238	2 718	2 620	969	1 691
S02B CORTICOSTEROIDS	6 139	7 724	7 847	10 185	9 535	60	233	2 424	4 787	2 091	1 851
S02BA Corticosteroids	6 139	7 724	7 847	10 185	9 535	60	233	2 424	4 787	2 091	1 851
S02BA07 betamethasone	6 139	7 724	7 847	10 185	9 535	60	233	2 424	4 787	2 091	1 851
S02C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	58	70	66	104	91	49	<5	20	42	26	16
S02CA Corticosteroids and anti-infectives in combination	58	70	66	104	91	49	<5	20	42	26	16
S02CA02 flumetasone and antiinfectives	58	70	66	104	91	49	<5	20	42	26	16

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group S

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
S03 OPTHALMOLOGICAL AND OTOTOLOGICAL PREPARATIONS	78 318	75 322	77 041	68 909	73 148	54	13 607	21 755	26 744	11 042	11 352
S03C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	78 318	75 322	77 041	68 909	73 148	54	13 607	21 755	26 744	11 042	11 352
S03CA Corticosteroids and antiinfectives in combination	78 318	75 322	77 041	68 909	73 148	54	13 607	21 755	26 744	11 042	11 352
S03CA01 dexamethasone and antiinfectives	18 919	15 356	14 416	24 937	11 210	55	1 109	3 071	4 868	2 162	1 390
S03CA04 hydrocortisone and antiinfectives	62 532	62 503	65 038	47 812	64 324	54	12 714	19 350	22 909	9 351	9 962

2.18 ATC group V – Various

ATC level	2008	2009	2010	2011	2012	Share of women (%)	2012				2012
	Number of individuals						Number of individuals per age group				Sales in 1000 NOK
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
V VARIOUS	11 571	13 317	15 898	18 600	21 769	50	3 026	7 406	7 228	4 109	77 662
V01 ALLERGENS	4 962	6 170	7 289	8 273	8 880	46	1 691	5 582	1 573	34	41 735
V01A ALLERGENS	4 962	6 170	7 289	8 273	8 880	46	1 691	5 582	1 573	34	41 735
V01AA Allergen extracts	4 962	6 170	7 289	8 273	8 880	46	1 691	5 582	1 573	34	41 735
V01AA02 grass pollen	3 056	4 021	5 033	5 758	6 295	44	1 065	4 278	939	13	23 719
V01AA03 house dust mites	284	301	349	426	487	47	121	292	72	<5	2 785
V01AA05 tree pollen	3 104	3 705	4 150	4 670	4 839	49	933	2 970	917	19	11 218
V01AA07 insects	206	185	183	181	156	53	20	50	78	8	660
V01AA10 flowers	54	90	108	141	149	63	10	91	48	0	715
V01AA11 animals	201	217	288	382	421	52	103	227	91	0	2 638

Noen forkortelser og definisjoner / Some abbreviations and definitions

ATC	Anatomisk Terapeutisk Kjemisk (klassifikasjonssystem for legemidler)	Anatomical Therapeutical Chemical (classification system for medicines)
DDD	Definert døgndose	Defined Daily Doses
EEA		European Economic Association
EØS	Europeisk økonomisk samarbeid	
FHI	Folkehelseinstituttet	
GP		General Practitioner
ICD -10		International Classification of Diseases version 10
ICPC		International Classification of Primary Care
MA	Markedsføringstillatelse	Marketing Authorisation
NIPH		Norwegian Institute of Public Health
NMD	Norsk Medisinaldepot	Norwegian Medicinal Depot (wholesaler)
NOK	Norske kroner	Norwegian kroner
NorPD	Reseptregisteret	Norwegian Prescription Database
NSAID	Ikke-steroid antiinflammatorisk legemiddel	Non Steroidal Anti-Inflammatory Drug
OTC	Reseptfritt	Over The Counter, non prescription drugs
SPC		Summary of Product Characteristics
SSB	Statistisk sentralbyrå	Statistics Norway
WHO	Verdens helseorganisasjon	World Health Organization

Definisjoner

Prevalens

Brukere (individer) defineres som personer som har hentet minst én resept på apotek i perioden. Prevalens er definert som antall brukere per 100 innbyggere (%) i det definerte befolkningsutvalget.

Insidens (nye brukere)

Insidens er antall brukere av et bestemt legemiddel eller en legemiddelgruppe i en definert tidsperiode som ikke var brukere i en tidligere, definert periode. Insidens kan også uttrykkes som andel (%) i forhold til antallet potensielle nye brukere i det definerte befolkningsutvalget.

Definitions

Prevalence

Users (individuals) are defined as persons who had at least one prescription dispensed at pharmacies in the period. Prevalence is defined as the number of users per 100 inhabitants (%) in the defined population sample.

Incidence (new users)

Incidence is the number of users of a particular drug or drug group in a defined time period who were not users in a previous, defined time period. Incidence can be expressed as a percentage relative to the number of potential users in the defined population sample.

Folkemengde i Norge 2008–2012 (per 1. juli)/ Population in Norway 2008–2012 (as of 1st July)

Year	2008	2009	2010	2011	2012
Population	4 768 077	4 829 800	4 888 946	4 953 217	5 018 415

Folkemengde etter alder i 2012 (per 1. juli)/ Population by age in 2012 (as of 1st July)

Age groups	<15	15–44	45–69	≥70
Population	893 338	2 036 569	1 545 456	543 052

Kilde: Statistisk sentralbyrå / Source: Statistics Norway

Liste over publikasjoner basert på data fra Reseptregisteret per mars 2013 / List of publications based on data from the Norwegian Prescription Database (NorPD) as of March 2013

2013:

Bakken MS, Engeland A, Engesaeter LB, Ranhoff AH, Hunskaar S, Ruths S. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. *Age Ageing* 2013; [Epub ahead of print]. doi: 10.1093/ageing/af009

Berge LI, Riise T, Fasmer OB, Hundal O, Oedegaard KJ, Midthjell K, et al. Does diabetes have a protective effect on migraine? *Epidemiology* 2013;24:129-34.

Brelin S, Loge JH, Skurtveit S, Johannesen TB, Aass N, Ottesen S, et al. Antidepressants to cancer patients during the last year of life – a population-based study. *Psychooncology* 2013;22:506-14.

Engeland A, Bjørge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, et al. Effects of preconceptional paternal drug exposure on birth outcomes: Cohort study of 340000 pregnancies using Norwegian population-based databases. *British Journal of Clinical Pharmacology* 2013;75:1134-41.

Fossum GH, Lindbaek M, Gjelstad S, Dalen I, Kvaerner KJ. Are children carrying the burden of broad-spectrum antibiotics in general practice? Prescription pattern for paediatric outpatients with respiratory tract infections in Norway. *BMJ Open* 2013;3:e002285.

Grytli HH, Fagerland MW, Fosså SD, Taskén KA. Association Between Use of b-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease. *European Urology* 2013; [In press]. doi: 10.1016/j.eururo.2013.01.007

Klovstad H, Natas O, Tverdal A, Aavitsland P. Systematic screening with information and home sampling for genital Chlamydia trachomatis infections in young men and women in Norway: a randomized controlled trial. *BMC Infectious Diseases* 2013;13:Article number 30.

Kravdal O. The poorer cancer survival among the unmarried in Norway: Is much explained by comorbidities? *Social Science and Medicine* 2013;81:42-52.

Log T, Skurtveit S, Selmer R, Tverdal A, Furu K, Hartz I. The association between prescribed opioid use for mothers and children: a record-linkage study. *Eur J Clin Pharmacol* 2013;69:111-8.

Lund IO, Skurtveit S, Engeland A, Furu K, Ravndal E, Handal M. Prescription drug use among pregnant women in opioid Maintenance Treatment. *Addiction* 2013;108:367-76.

Nordeng H, Lupattelli A, Romøren M, Koren G. Neonatal outcomes after gestational exposure to nitrofurantoin. *Obstetrics and Gynecology* 2013;121:306-13.

Nordfjærn T, Bjerkeset O, Bratberg G, Møyilan S, Berk M, Grawe R. Socio-demographic, lifestyle and psychological predictors of benzodiazepine and z-hypnotic use patterns. *Nord J Psychiatry* 2013; [Epub ahead of print]. doi:10.3109/08039488.2013.775342

Persheim MS, Helland A, Spigset O, Slordal L. Potensielt vanedannende legemidler på blåresept ved kroniske sterke smerter. [Potentially addictive drugs on reimbursable prescription for chronic severe pain]. *Tidsskrift for den Norske Laegeforening* 2013;133:150-4. In Norwegian.

Skollerud LM, Fredheim OM, Svendsen K, Skurtveit S, Borchgrevink PC. Laxative prescriptions to cancer outpatients receiving opioids: A study from the Norwegian prescription database. *Supportive Care in Cancer* 2013;21:67-73.

Stene LE, Jacobsen GW, Dyb G, Tverdal A, Schei B. Intimate partner violence and cardiovascular risk in women: A population-based cohort study. *Journal of Women's Health* 2013;22:250-8.

Stephansson O, Kieler H, Haglund B, Artama M, Engeland A, Furu K, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. *JAMA* 2013;309:48-54.

Welle-Strand GK, Skurtveit S, Jones HE, Waal H, Bakstad B, Bjarkø L, et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: A National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009. *Drug and Alcohol Dependence* 2013;127:200-6.

2012:

Berge LI, Riise T, Fasmer OB, Lund A, Oedegaard KJ, Hundal O. Risk of depression in diabetes is highest for young persons using oral anti-diabetic agents. *Diabet Med*. 2012;29:509-14.

Blix HS, Hjellvik V. Økt bruk av antibiotika blant 19-åringer i mai. [Increased use of antibiotics among nineteen-year-olds in May]. *Tidsskr Nor Laegeforen*. 2012 ;132:1084-8. In Norwegian.

Blix HS, Landmark K, Selmer R, Reikvam Å. Forskrivning av antihypertensive legemidler 1975-2010. [Patterns in the prescription of antihypertensive drugs in Norway, 1975 – 2010] *Tidsskr Nor Laegeforen* 2012;132:1224-8. In Norwegian.

Bramness JG, Furu K, Skurtveit S, Engeland A. Effect of withdrawal of carisoprodol on use of other prescribed drugs with abuse potential. *Clin Pharmacol Therap* 2012;91:438-41.

Bramness JG, Skurtveit S, Mørland J, Engeland A. An increased risk of motor vehicle accidents after prescription of methadone. *Addiction*. 2012;107:967-72.

Devold H, Furu K, Skurtveit S, Tverdal A, Falck JA, Søgård AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. *Pharmacoepidemiol Drug Saf*. 2012;21:297-304.

Devold HM, Søgård AJ, Tverdal A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. *Osteoporosis International* 2012;24:1225-33.

Fasmer OB, Riise T, Lund A, Dilsaver SC, Hundal O, Ødegaard KJ. Comorbidity of migraine with ADHD. *J Attend Disord* 2012;16:339-45.

Fredheim OMS, Moksnes K, Borchgrevink PC, Skurtveit S. Opioid switching to methadone: A pharmacoepidemiological study from a national prescription database. *Palliative Medicine* 2012;26:804-12.

Fredheim OM, Moksnes K, Borchgrevink PC, Skurtveit S. Opioid switching to methadone: a pharmacoepidemiological study from a national prescription database. *Palliat Med* 2012;26:804-812.

Gedde-Dahl A, Devold HM, Molden E. Statin medication in patients treated with antiepileptic drugs in Norway. *Pharmacoepidemiology and Drug Safety* 2012;21:881-5.

Gjelsvik B, Heyerdahl F, Hawton K. Prescribed medication availability and deliberate self-poisoning: a longitudinal study. *J Clin Psychiatry*. 2012;73:e548-54.

Handal M, Skurtveit S, Mørland JG. Samtidig bruk av ulike benzodiazepiner. [Co-medication with benzodiazepines]. *Tidsskr Nor Laegeforen*. 2012;132:526-30. In Norwegian.

Hartz I, Furu K, Bratlid T, Handal M, Skurtveit S. Hypnotic drug use among 0-17 year olds during 2004-2011: A nationwide prescription database study. *Scandinavian Journal of Public Health* 2012;40:704-11.

Hjellvik V, Mahic M, Tverdal A. Utdanning og legemiddelbruk. [Education and use of drugs in Norway]. *Tidsskr Nor Laegeforen* 2012;132:2166-70. In Norwegian.

Karlstad O, Nafstad P, Tverdal A, Skurtveit S, Furu K. Comorbidities in an asthma population 8-29 years old: A study from the Norwegian Prescription Database. *Pharmacoepidemiology and Drug Safety* 2012;21:1045-52.

Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nørgaard M, Nielsen RB, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B. Selective serotonin-reuptake inhibitors during pregnancy and risks of persistent pulmonary hypertension of the newborn: population based cohort study from the five Nordic countries *BMJ*. 2012 Jan 12;344:d8012. doi: 10.1136/bmj.d8012.

Kjome RL, Roraas T, Granas AG, Sandberg S. Regional differences in sales of glucometer strips and antidiabetics. *Tidsskr Nor Laegeforen* 2012;132:1453-7.

Kjosavik SR, Ruths S, Hunskaar S. Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. *Eur J Clin Pharmacol* 2012;68: 311-9.

Kvaale MK, Grave K, Kristoffersen AB, Norström M. The prescription rate of antibacterial agents in dogs in Norway – geographical patterns and trends during the period 2004-2008. *Journal of Veterinary Pharmacology and Therapeutics* 2012; [In press]. doi: 10.1111/j.1365-2885.2012.01425.x

Langhammer A, Krokstad S, Romundstad P, Heggland J, Holmen J. The HUNT study: Participation is associated with survival and depends on socioeconomic status, diseases and symptoms. *BMC Medical Research Methodology* 2012;12:Article number 143.

Lillemoen PKS, Kjosavik SR, Hunskaar S, Ruths S. Prescriptions for ADHD medication, 2004 – 08. *Tidsskr Nor Laegeforen* 2012;132:1856-60.

Mellbye A, Svendsen K, Borchgrevink PC, Skurtveit S, Fredheim OMS. Concomitant medication among persistent opioid users with chronic non-malignant pain. *Acta Anaesthesiologica Scandinavica* 2012;56:1267-76.

Neutel CI, Skurtveit S, Berg C. What is the point of guidelines? Benzodiazepine and z-hypnotic use by an elderly population. *Sleep Medicine* 2012;13:893-7.

Neutel I, Skurtveit S, Berg C. Polypharmacy of potentially addictive medication in the older persons – quantifying usage. *Pharmacoepidemiol Drug Saf* 2012;21:199-206.

Neutel CI, Skurtveit S, Berg C. Benzodiazepine and z-hypnotic use in Norwegian elderly, aged 65-79. *Norsk Epidemiologi* 2012;22:203-8.

Nordbø A, Skurtveit S, Borchgrevink PC, Kaasa S, Fredheim OM. Low-dose transdermal buprenorphine – long-term use and co-medication with other potentially addictive drugs. *Acta Anaesthesiol Scand*. 2012;56:88-94.

Nordfjærn T. A population-based cohort study of anxiety, depression, sleep and alcohol outcomes among benzodiazepine and z-hypnotic users. *Addictive Behaviors* 2012;37:1151-7.

Nyborg G, Straand J, Brekke M. Inappropriate prescribing for the elderly – A modern epidemic? *European Journal of Clinical Pharmacology* 2012;68:1085-94.

Pedersen L, Hansen AB, Svendsen K, Skurtveit S, Borchgrevink PC, Fredheim OMS. Reimbursement of analgesics for chronic pain. *Tidsskr Nor Laegeforen* 2012;132:2489-93.

Romoren M, Lindbaek M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin – a population-based register study from Norway. *British Journal of Clinical Pharmacology* 2012;74:1053-62.

Rønning PA, Helseth E, Meling TR, Johannesen TB. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. *Neuro-Oncology* 2012;14:1178-84.

Selmer R, Blix HS, Landmark K, Reikvam Å. Choice of initial antihypertensive drugs and persistence of drug use—a 4-year follow-up of 78,453 incident users. *Eur J Clin Pharmacol* 2012;68:1435-42.

Skjeldestad FE. Prescribing contraception for young women. *Tidsskr Nor Laegeforen*. 2012;132:292-4.

Steffenak AKM, Wilde-Larsson B, Skurtveit S, Furu K, Nordström G, Hartz I. Mental distress and subsequent use of psychotropic drugs among adolescents – a prospective register linkage study. *J Adolescent Health* 2012;50:578-87.

Steffenak AKM, Wilde-Larsson B, Nordstr+Åm G, Skurtveit S, Hartz I. Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: A nationwide prescription database study. *Clinical Epidemiology* 2012;4:225-31.

Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study. *BMJ Open*. 2012 Apr 5;2(2):e000614.

Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co-prescription of medication for bipolar disorder and diabetes mellitus: A nationwide population-based study with focus on gender differences. *BMC Medicine* 2012;10:Article number 148.

Svendsen K, Skurtveit S, Romundstad P, Borchgrevink PC, Fredheim OM. Differential patterns of opioid use: defining persistent opioid use in a prescription database. *Eur J Pain* 2012;16:359-69.

Viktil KK, Engeland A, Furu K. Outcomes after antirheumatic drug use before and during pregnancy – a cohort study among 150 000 pregnant women and expectant fathers. *Scand J Rheum* 2012;41:196-201.

Von Soest T, Bramness JG, Pedersen W, Wichstrøm L. The relationship between socio-economic status and antidepressant prescription: A longitudinal survey and register study of young adults. *Epidemiology and Psychiatric Sciences* 2012;21:87-95.

Åsvold BO, Vatten LJ, Midthjell K, Bjørø T. Serum TSH within the reference range as a predictor of future hypothyroidism and hyperthyroidism: 11-year follow-up of the HUNT Study in Norway. *J Clin Endocrinol Metab*. 2012;97:93-9.

2011:

Berg C, Sakshaug S, Handal M, Skurtveit S. Z-hypnotika – Sovemidlene som dominerer markedet i Norge. *Norsk Farmaceutisk Tidsskrift* 2011;4:20-23.

Blix H, Hjellvik V, Litleskare I, Rønning M, Tverdal A. Cigarette smoking and risk of subsequent use of antibacterials: a follow-up of 365 117 men and women. *J Antimicrob Chemother* 2011;66:2159-67.

Bramness JG, Sexton JA. The basic pharmacoepidemiology of benzodiazepine use in Norway 2004-9. *Norsk Epidemiologi* 2011; 21: 35-42.

Brekke M, Straand J. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observation study. *BMC Public Health*. 2011;11:144.

Dalen DM, Furu K, Locatelli M, Strøm S. Generic substitution: micro evidence from register data in Norway. *Eur J Health Econ* 2011;12:49-59.

Engeland A, Bjørge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, Furu K. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230.000 women in Norway. *Eur J Epidemiol* 2011;26:157-63.

Espnes MG, Bjørge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. *Pharmacoepidemiol Drug Saf* 2011;20:243-8.

Fasmer OB, Riise T, Eagan TM, Lund A, Dilsaver SC, Hundal Ø, Ødegaard KJ. Comorbidity of asthma with ADHD. *J Atten Disord* 2011;15:564-71.

Fredheim OM, Borchgrevink P, Nordstrand B, Clausen T, Skurtveit S. Prescription of analgesics to patients in opioid maintenance therapy: A pharmacoepidemiological study. *Drug Alcohol Depend* 2011;116:158-62.

Furu K, Karlstad Ø, Skurtveit S, Håberg SE, Nafstad P, London SJ, Nystad W. High validity of mother-reported use of antiasthmatics among children: a comparison with a population-based prescription database. *J Clin Epidemiol* 2011;64:878-84.

Furu K, Skurtveit S. Legemidler forskrevet til barn og ungdom i alderen 0-17 år i Norge. En studie basert på data fra Reseptregisteret. *Norsk Farmaceutisk Tidsskrift* 2011;119:14-7. In Norwegian.

Ghaderi S, Nordbø SA, Bakken IJ. Chlamydiainfeksjon i Sør-Trøndelag – behandling og oppfølging. [Chlamydia infections in South Trøndelag – treatment and follow-up]. *Tidsskr Nor Laegeforen* 2011;131:461-3. In Norwegian.

Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. *Expert Rev Pharmacoecon Outcomes Res*. 2011;11:121-9.

Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba M, Laius O, Lonsdale J, Malmström R, Martikainen J, Samaluk V, Sermet C, Schwabe U, Teixeira I, Tilson L, Tulunay F, Vlahovic-Palcevski V, Wendykowska K, Wettermark B, Zara Corinne Gustafsson L. Policies to enhance prescribing efficiency in Europe: findings and future implications. *Frontiers in Pharmacology* 2011.

Gjelstad S, Straand J, Dalen I, Fetveit A, Strøm H, Lindbæk M. Do general practitioners' consultation rates influence their prescribing patterns of antibiotics for acute respiratory tract infections? *J Antimicrob Chemother* 2011;66:2425-33.

Hancock D, Håberg SE, Furu K, Whitworth KV, Nafstad P, Nystad W, London SJ. Oral contraceptive pill use before pregnancy and respiratory outcomes in early childhood. *Pediatr Allergy Immunol* 2011;22:528-36.

Handal M, Engeland A, Rønning M, Skurtveit S, Furu K. Use of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during and after pregnancy. A population based cohort study. *Eur J Clin Pharmacol* 2011;67:953-60.

Harman C, Reid M, Thomas KV. In situ calibration of a passive sampling device for selected illicit drugs and their metabolites in wastewater, and subsequent year-long assessment of community drug usage. *Environ Sci Technol*. 2011;45:5676-82.

Hartz I, Bramness JG, Skurtveit S. Prescription of antidepressants to patients on opioid maintenance therapy – a pharmacoepidemiological study *Norsk Epidemiologi* 2011;21:77-83.

Hartz I, Tverdal, Aa, Skurtveit S. Langtidsbruk av benzodiazepiner i kombinasjon med opioider og z-hypnotika blant uføretrygdede i Norge. *Norsk Farmaceutisk Tidsskrift* 2011; 119, 24-28.

Hjellvik V, Tverdal A, Strøm H. Boiled coffee intake and subsequent risk for Type 2 Diabetes. *Epidemiology* 2011;22:418-21.

Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S. Breast cancer incidence trends in Norway – explained by hormone therapy or mammographic screening? *International Journal of Cancer* 2011;95:51-9.

Karlstad Ø, Tverdal A, Skurtveit S, Nafstad P, Furu K. A prospective study of asthma and subsequent use of hypnotics in young adults. *Pharmacoepidemiol Drug Saf* 2011;20:370-7.

Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial prescription of antipsychotics and antidepressants in general practice and specialist care in Norway. *Acta Psychiatr Scand* 2011;123:459-65.

Kvaale MK, Grave K, Bangen M, Norström M. Forskrivning av antibakterielle midler til hund og katt i Norge i perioden 2005-2008. *Norsk Veterinærtidsskrift* 2011;123:76-79. In Norwegian.

Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. *Epilepsy Res*. 2011;95:51-9.

Landmark CJ, Larsson PG, Rytter E, Johannessen SI. Oppklarende om pregabalin og Reseptregisteret [Clarification about pregabalin and the Norwegian Prescription Database]. *Tidsskr Nor Laegeforen*. 2011;131:800-1. In Norwegian.

Langballe EM, Engdahl B, Selbaek G, Nordeng H. Concomitant use of anti-dementia drugs with psychotropic drugs in Norway—a population-based study. *Pharmacoepidemiol Drug Saf*. 2011;20:1319-26.

Log T, Hartz I, Handal M, Tverdal A, Furu K, Skurtveit S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults – a population-based cohort study. *Pharmacoepidemiol Drug Saf* 2011;20:90-8.

Log T, Hartz I, Tverdal A, Furu K, Skurtveit S. Dispensing of prescribed analgesics in Norway among young people with foreign- or Norwegian-born parents. *Scand J Pain* 2011;2:36-44.

Mahic M, Skurtveit S, Selmer R, Rønning M, Furu K. Prevalence, incidence and persistence of etanercept and adalimumab in Norway 2005-2009. *Pharmacoepidemiol Drug Saf*. 2011;20:457-63.

Neubert A, Hsia Y, de Jong-van den Berg LT, Janhsen K, Glaeske G, Furu K, Kieler H, Nørgaard M, Clavenna A, Wong IC. Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries. *Br J Clin Pharmacol*. 2011;72:969-77.

Skurtveit S, Furu K, Handal M, Borchgrevink P, Fredheim O. To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? *Pain* 2011;152:1555-61.

Zoega H, Furu K, Halldórsson M, Thomsen PH, Sourander A, Martikainen JE. Use of ADHD drugs in the Nordic countries: A population-based comparison study. *Acta Psychiatr Scand* 2011;123:360-7.

Ødegaard KJ, Dilsaver SC, Hundal O, Riise T, Lund A, Akiskal HS, Fasmer OB. Are migraine and bipolar disorders comorbid phenomena?: findings from a pharmacoepidemiological study using the Norwegian Prescription Database. *J Clin Psychopharmacol*. 2011;31:734-9.

Ødegaard KJ, Riise T, Dilsaver S, Lund A, Akiskal H, Fasmer OB, Hundal Ø. A pharmaco-epidemiological study of migraine and antidepressant medications: Complete one year data from the Norwegian population. *J Affective Disorders* 2011;129:198-204.

2010:

Amundsen MO, Engdahl B, Berg C, Nordeng H. Cardiovascular co-medication among users of antiobesity drugs: a population-based study. *Pharm World Sci*. 2010;32:752-8.

Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs – a population based study. *Pharmacoepidemiol Drug Saf* 2010;19:273-9.

Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. *Eur J Neurol* 2010;17:1445-50.

Berg A, Furu K, Einen, M, Spigseth O: Bør barn behandles med efedrin mikstur? [Should children be treated with ephedrine mixture?]. *Tidsskr Nor Lægeforen* 2010;24: 2474-5. In Norwegian.

Berge HM, Gjelstad S, Furu K, Straand J. Glukosaminbruk reduserer ikke behovet for analgetika [Use of glucosamine does not reduce the need for other pain-relieving drugs]. *Tidsskr Nor Lægeforen* 2010;130:1463-6. In Norwegian.

Bramness JG, Rossow I. Can the total consumption of a medicinal drug be used as an indicator of excessive use? The case of carisoprodol. *Drugs: Education, Prevention, and Policy* 2010;17:168-80

Bramness J, Sandvik P, Engeland A, Skurtveit S. Does pregabalin (Lyrica) help patients reduce their use of benzodiazepines? A comparison with gabapentin using the Norwegian Prescription Database. *Basic Clin Pharmacol Toxicol* 2010;107:883-6

Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sjøgaard AJ. Prescription of anti-osteoporosis drugs during 2004–2007 – a nationwide register study in Norway. *Eur J Clin Pharmacol* 2010;66:299-306.

Fredheim OM, Skurtveit S, Breivik H, Borchgrevink P. Increasing use of opioids from 2004 to 2007 – Pharmacoepidemiological data from a complete national prescription database in Norway. *Eur J Pain* 2010;14:289-294.

Fredheim OM, Log T, Olsen W, Skurtveit S, Sagen Ø, Borchgrevink P. Prescription of opioids to children and adolescents; a study from a national prescription database in Norway. *Pediatric Anesthesia* 2010;20:537-544.

Furu K, Skurtveit S, Strøm H, Rønning M. Reseptregisteret 2004–2009 – en kilde til informasjon. *Norsk Farmaceutisk Tidsskrift* 2010;12:29-31.

Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic Countries as a cohort for pharmacoepidemiological research. *Basic Clin Pharmacol Toxicol* 2010;106:86-94.

Gjerden P, Slørdal L, Bramness JG. Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up. *Eur J Clin Pharmacol* 2010;66:911-7.

Hartz I, Tverdal A, Skille E, Skurtveit S. Disability pension as a predictor of later use of benzodiazepines among benzodiazepines users. *Soc Sci Med* 2010;70:921-5.

Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of anxiolytic drugs – a prospective population-based cohort study of 16 000 individuals. *Scand J Public Health* 2010;38:465-73.

Hjellvik V, Tverdal A, Furu K. Body mass index as predictor for asthma: a cohort study of 118 723 males and females. *Eur Resp J* 2010;35:1235-42.

Hunnskaar S, Welle-Nilsen LK. The market lifecycle of duloxetine for urinary incontinence in Norway. *Acta Obstet Gynecol Scand*. 2010;89:217-22

Kann IC, Bjørn E, Lurås H. Competition in general practice: prescriptions to the elderly in a list patient system. *J Health Econ*. 2010;29:751-64

Karlstad Ø, Nafstad P, Tverdal A, Skurtveit S, Furu K. Prevalence, incidence and persistence of anti-asthma medication use in 2- to 29-year-olds: a nationwide prescription study. *Eur J Clin Pharmacol* 2010;66:399-406.

Karouni M, Arulthas S, Larsson PG, Rytter E, Johannessen SI, Landmark CJ. Psychiatric comorbidity in patients with epilepsy: a population-based study. *Eur J Clin Pharmacol* 2010;66:1151-60.

Kjome RL, Granås AG, Nerhus K, Roraas TH, Sandberg S. The prevalence of self-monitoring of blood glucose and costs of glucometer strips in a nationwide cohort. *Diabetes Technol Ther* 2010;12:701-5.

Kornør H, Pedersen W, von Soest T, Rossow I, Bramness JG. Bruk av benzodiazepiner og cannabis blant unge voksne [Use of benzodiazepines and cannabis in young adults]. *Tidsskr Nor Lægeforen* 2010 ;130:928-31. In Norwegian.

Skurtveit S, Furu K, Bramness J, Selmer R, Tverdal A. Benzodiazepines predict use of opioids– a follow-up study of 17 074 men and women. *Pain Med* 2010;11:805-14.

Skurtveit S, Furu K, Selmer R, Handal M, Tverdal A. Nicotine dependence predicts repeated use of prescribed opioids. Prospective population-based cohort study. *Ann Epidemiol* 2010;20:890-7.

Vandraas K, Spigset O, Mahic M, Slørdal S. Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. *Eur J Clin Pharmacol* 2010;66:823-9.

2009:

Bachs LC, Engeland A, Mørland JG, Skurtveit S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or tramadol. *Clin Pharmacol Ther* 2009;85:596-9.

Bramness JG. Bruk av litium i Oslo og i Sogn og Fjordane [Use of lithium in the Norwegian counties Oslo and Sogn og Fjordane]. *Tidsskr Nor Lægeforen* 2009;129:855-7. In Norwegian.

Bramness JG. Ungdom og dagliglivets smerter. [Adolescents and everyday life pains]. *Tidsskr Nor Lægeforen* 2009; 129:1444. In Norwegian.

Bramness JG, Grøholt B, Engeland A, Furu K. The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004-2007 – a prescription database study. *J Affect Disord* 2009; 117:208-11.

Bramness JG, Skurtveit S, Neutel I, Mørland J, Engeland A. An increased risk of road traffic accidents after prescriptions of lithium or valproate? *Pharmacoepidemiol Drug Saf* 2009;18:492-6.

Bramness JG, Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. *J Affect Disord* 2009;118:224-8.

Devold H, Molden E, Skurtveit S, Furu K. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. *Brit J Clin Pharmacol* 2009;67:234-41.

Engeland A, Bjørge T, Daltveit AK, Vollset SE, Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. *Acta Obstet Gynecol Scand* 2009;88:1083-9.

Fredheim OM, Skurtveit S, Moroz A, Breivik H, Borchgrevink P. Prescription pattern of codeine for non-malignant pain in Norway- a pharmacoepidemiological study from The Norwegian Prescription Database. *Acta Anaesthesiol Scand* 2009;53:627-33.

Gjerden P, Bramness JG, Slørdal L. The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study. *Br J Clin Pharmacol* 2009;67:228-33.

Gjerden P, Slørdal L, Bramness JG. Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. *Eur J Clin Pharmacol* 2009;65:1229-35.

Gjerden P, Slørdal L, Bramness JG. The use of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal of orphenadrine. *Br J Clin Pharmacol* 2009;68:238-42.

Hartz I, Lundesgaard E, Tverdal A, Skurtveit S. Disability pension is associated with the use of benzodiazepines 20 years later: A prospective study. *Scand J Public Health* 2009;37:320-6.

Hartz I, Tverdal A, Skurtveit S. A comparison of self-reported data on disability pension status with data from a nationwide administrative register. *Nor J Epidemiol* 2009;19:169-172.

Hartz I, Tverdal A, Skurtveit S. Social inequalities in use of potentially addictive drugs in Norway – use among disability pensioners. *Nor J Epidemiol* 2009;19:209-218.

Hauge S, Blix HS, Borgen K, Hungnes O, Dudman SG, Aavitsland P. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. *Virology* 2009;6:54.

Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. *Eur J Clin Pharmacol* 2009;65:295-301.

Håkonsen GD, Pettersen MH, Skurtveit S, Giverhaug T. Samtidig bruk av warfarin, analgetika og antiinflammatoriske midler. *Tidsskr Nor Laegeforen* 2009;129:1217-20. In Norwegian.

Kjosavik SR, Ruths S, Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database *Pharmacoepidemiol Drug Saf* 2009;18:572-8.

Landmark CJ, Larsson P, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders – a population-based study of prescriptions. *Epilepsy Res* 2009; 87: 31-9.

Selmer R, Sakshaug S, Skurtveit S, Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. *Brit J Clin Pharmacol* 2009;67:355-62.

Skurtveit S, Furu K, Kaasa S, Borchgrevink P. Introduction of low dose transdermal buprenorphine – did it influence use of potentially addictive drugs in chronic non-malignant pain patients? *Eur J Pain* 2009;13:949-53.

Skurtveit S, Strøm H, Skriverhaug T, Mørland J, Bramness J, Engeland A. Road traffic accident risk in patients with diabetes mellitus, receiving blood glucose-lowering drugs. Prospective follow-up study. *Diabet Med* 2009; 26:404-08.

Viktil K, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy – a population-based cohort study *Pharmacoepidemiol Drug Saf* 2009;18:737-42.

Winther RB, Bramness JG. Legemiddelshopping av vanedannende medikamenter i Norge [Prescription shopping of addictive drugs in Norway]. *Tidsskr Nor Laegeforen* 2009;129:517-20. In Norwegian.

2008:

Bachs LC, Bramness JG, Engeland A, Skurtveit S. Repeated dispensing of codeine is associated with high consumption of benzodiazepines. *Nor J Epidemiol* 2008;18:185-90.

Berg A, Furu K, Spigset O. Slimhinneavsvellende nesedråper og nesepåse hos barn [Nasal decongestants and nasal sprays in children]. *Tidsskr Nor Laegeforen* 2008;128:2582-3. In Norwegian.

Bramness JG, Buajordet I, Skurtveit S. The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril®) in Europe. *Nor J Epidemiol* 2008;18:167-72.

Bramness JG, Skurtveit S. Carisoprodol should be taken off the market. *South Med J* 2008;101:1074-5.

Bramness JG, Skurtveit S, Neutel CI, Mørland J, Engeland A. Minor increase in risk of road traffic accidents after prescriptions of antidepressants. *J Clin Psych* 2008; 69:1099-1103.

Brekke M, Rogstad, Straand J, Furu K, Gjelstad S, Bjørner T, Dalen I. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study. *Scand J Prim Health Care* 2008;26:80-5.

Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-06. *Br J Clin Pharmacol* 2008;65:653-60.

Engeland A, Bramness JG, Mørland J, Skurtveit S. Veitrafikkulykker knyttet til forskrivning av legemidler: en registerbasert kohortstudie. [Traffic accident risks associated with the prescription of medicinal drugs: a registry-based cohort study] *Nor J Epidemiol* 2008;18: 159-66.

Fetveit A, Straand J, Bjorvatn B. Sleep disturbances in an arctic population: the Tromsø Study. *BMC Health Serv Res* 2008;8:117.

Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) – New opportunities for research in pharmacoepidemiology in Norway. *Nor J Epidemiol* 2008; 18:129-36.

Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel CI, Mørland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. *Sleep Med* 2008;9:818-22.

Hagen K, Stovner LJ, Skorpén F, Pettersen E, Swart JA. COMT genotypes and use of antipsychotic medication: linking population-based prescription database to the HUNT study. *Pharmacoepidemiol Drug Saf* 2008;17:372-7.

Litleskare I, Blix H, Rønning M. Antibiotikaforbruk i Norge [Antibiotic use in Norway]. *Tidsskr Nor Laegeforen* 2008;128:2324-9. In Norwegian.

Olsen AS, Ottesen S. Varierende forskrivning av opioider til norske kreftpasienter [Variable prescription of opioids to cancer patients in Norway]. *Tidsskr Nor Laegeforen* 2008;128:1271-4. In Norwegian.

Skurtveit S, Furu K, Bramness JG, Tverdal A. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20 years later – a follow-up study of 13 390 men and women aged 40-42 years. *Pharmacoepidemiol Drug Saf* 2008;17:926-933.

Skurtveit S, Selmer R, Tverdal A, Furu K. The validity of self-reported prescription medication use among adolescents varied by therapeutic class. *J Clin Epidemiol* 2008;61:714-17.

Strøm H, Sakshaug S, Skurtveit S. Use of statins in patients receiving oral blood glucose-lowering drugs. *Nor J Epidemiol* 2008;18:191-94.

2007:

Al-Haroni M, Skaug N. Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption. *J Antimicrob Chemother* 2007;59:1161-6.

Blix HS, Engeland A, Litleskare I, Rønning M. Age- and gender-specific antibacterial prescribing in Norway. *J Antimicrob Chemother* 2007;59:971-6.

Bramness JG, Engeland A, Furu K. Antidepressiver hos barn og ungdom – førte advarsler til færre forskrivninger? [The use of antidepressants amongst children and adolescents – did the warnings lead to fewer prescriptions?] *Tidsskr Nor Laegeforen* 2007;127:2653-5. In Norwegian.

Bramness JG, Furu K, Engeland A, Skurtveit S. Carisoprodol use and abuse in Norway. A pharmacoepidemiological study. *Br J Clin Pharmacol* 2007;64: 210-8.

Bramness JG, Kornør H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. *Drug Alcohol Depend* 2007;90:203-9.

Bramness JG, Skurtveit S, Mørland J, Engeland A. The risk of road traffic accidents after prescriptions of carisoprodol. *Accid Anal Prev* 2007;39:1050-5.

Engeland A, Skurtveit S, Mørland J. Risk of road traffic accidents associated with the prescription of medicinal drugs: a registry-based cohort study. *Ann Epidemiol* 2007;17:597-602.

Furu K, Skurtveit S, Langhammer A, Nafstad P. Use of anti-asthmatic medications as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription database analysis. *Eur J Clin Pharmacol* 2007;63:693-8.

Hartz I, Sakshaug S, Furu K, Engeland A, Eggen AE, Njølstad I, Skurtveit S. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption – an individual-level prescription database study. *BMC Clin Pharmacol* 2007;7:14.

Sakshaug S, Furu K, Karlstad Ø, Rønning M, Skurtveit S. Switching statins in Norway after new reimbursement policy – a nationwide prescription study. *Br J Clin Pharmacol* 2007;64:476-81.

Torkildsen O, Grytten N, Myhr KM. Immunomodulatory treatment of multiple sclerosis in Norway. *Acta Neurol Scand Suppl* 2007;187:46-50.

Åsheim H, Nilsen KB, Johansen K, Furu K. Forskrivning av sentralstimulerende legemidler ved ADHD i Nordland. [Prescribing of stimulants for ADHD in Nordland county] *Tidsskr Nor Laegeforen* 2007;127:2360-2. In Norwegian.

2006:

Bramness JG, Skurtveit S, Furu K, Engeland A, Sakshaug S, Rønning M. Endringer i salg og bruk av flunitrazepam etter 1999. [Changes in the sale and use of flunitrazepam in Norway, 1999 – 2004]. *Tidsskr Nor Laegeforen* 2006;126:589-90. In Norwegian.

Gjelstad S, Fetveit A, Straand J, Dalen I, Rognstad S, Lindback M. Can antibiotic prescriptions in respiratory tract infections be improved? A cluster-randomized educational intervention in general practice--the Prescription Peer Academic Detailing (Rx-PAD) Study [NCT00272155]. *BMC Health Serv Res* 2006;6:75.

Mellingsæter T, Bramness JG, Slørdal L. Benzodiazepinlignende z-hypnotika: bedre og tryggere søvnmidler? [Are z-hypnotics better and safer sleeping pills than benzodiazepines?] *Tidsskr Nor Laegeforen* 2006; 126: 2954-6. In Norwegian.

Nygard K, Schimmer B, Sobstad O, Walde A, Tveit I, Langeland N, Hausken T, Aavitsland P. A large community outbreak of waterborne giardiasis--delayed detection in a non-endemic urban area. *BMC Public Health* 2006;6:141.

Straand J, Fetveit A, Rognstad S, Gjelstad S, Brekke M, Dalen I. A cluster-randomized educational intervention to reduce inappropriate prescription patterns for elderly patients in general practice--The Prescription Peer Academic Detailing (Rx-PAD) study [NCT00281450]. *BMC Health Serv Res* 2006;6:72.

Strøm H, Engeland A, Eriksen E, Sakshaug S, Rønning M. Hvor mange og hvem behandles medikamentelt for diabetes mellitus? [How many and who are receiving medication for diabetes mellitus?] *Tidsskr Nor Laegeforen* 2006;126:768-70. In Norwegian.

2005:

Bramness JG, Hausken AM, Sakshaug S, Skurtveit S, Rønning M. Forskrivning av selektive serotoninreopptakshemmere 1990 – 2004. [Prescription of selective serotonin reuptake inhibitors 1990-2004]. *Tidsskr Nor Laegeforen* 2005;125:2470-3. In Norwegian.

2004:

Strøm H. Reseptbasert legemiddelregister: Et viktig verktøy for å oppnå detaljert legemiddelstatistikk [The Norwegian Prescription Database: An important tool for detailed information on drug use]. *Nor J Epidemiol* 2004;14:53-56.

2001:

Furu K. Drug utilisation in a public health perspective: Establishing a national prescription register in Norway. *Nor J Epidemiol* 2001;11:55-60.

